

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 August 2004 (12.08.2004)

PCT

(10) International Publication Number
WO 2004/067706 A2

(51) International Patent Classification⁷: C12N

70810 (US). **FIORETTI, William, C.** [US/US]; 2225 Lakeridge Road Drive, Grapevine, TX 76051 (US). **CADD, Gary, G.** [US/US]; 501 Turner Road, Apartment 1111, Grapevine, TX 76051 (US).

(21) International Application Number:
PCT/US2003/041261

(22) International Filing Date:
24 December 2003 (24.12.2003)

(74) Agent: **PRATT, John, S.**; Kilpatrick Stockton, LLC, Suite 2800, 1100 Peachtree Street, Atlanta, GA 30309 (US).

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(30) Priority Data:

60/441,377	21 January 2003 (21.01.2003)	US
60/441,381	21 January 2003 (21.01.2003)	US
60/441,392	21 January 2003 (21.01.2003)	US
60/441,405	21 January 2003 (21.01.2003)	US
60/441,447	21 January 2003 (21.01.2003)	US
60/441,502	21 January 2003 (21.01.2003)	US
10/609,019	26 June 2003 (26.06.2003)	US

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (*for all designated States except US*): **TRANS-GENRX, INC.** [US/US]; 1750 Valley View Lane, Suite 110, Dallas, TX 75243 (US). **THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE** [US/US]; P.O. BOX 25055, Baton Rouge, LA 70894 (US).

Published:

— without international search report and to be republished upon receipt of that report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **COOPER, Richard, K.** [US/US]; 111 Pecan Meadow Drive, Baton Rouge, LA

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PRODUCTION OF MULTIMERIC PROTEINS

Prom	prepro	Gene of Interest	pro	Gene of interest	polyA
------	--------	------------------	-----	------------------	-------

(57) Abstract: The present invention provides a new, effective and efficient method of producing multimeric proteins in an individual. Multimeric proteins include associated multimeric proteins (two or more associated polypeptides) and multivalent multimeric proteins (a single polypeptide encoded by more than one gene of interest). Expression and/or formation of the multimeric protein in the individual is achieved by administering a polynucleotide cassette containing genes of interest that encode portions of the multimeric protein to the individual. The polynucleotide cassette may additionally contain one or more pro sequences, prepro sequences, cecropin prepro sequences, and/or cleavage site sequences.



WO 2004/067706 A2

5

10 **PRODUCTION OF MULTIMERIC PROTEINS**

The U.S. Government has certain rights in this invention. The development of this invention was partially funded by the United States Government under a HATCH grant from the United States Department of Agriculture, partially funded by the United States Government with Formula 1433 funds from the United States Department of Agriculture and partially funded by the United States Government under contract DAAD 19-02016 awarded by the Army.

20

FIELD OF THE INVENTION

The present invention relates generally to production of multimeric proteins in a transgenic individual, wherein genes encoding the multimeric proteins are operably linked to signal sequences, or portions of signal sequences.

25

BACKGROUND OF THE INVENTION

Methods for producing multimeric proteins in transgenic animals are desirable for a variety of reasons, including the transgenic animal's potential as biological factories to produce multimeric proteins for pharmaceutical, diagnostic and industrial uses. This potential is attractive to the industry due to the inadequate capacity in facilities used for recombinant production of multimeric proteins and the increasing demand by the pharmaceutical industry for use of these facilities. Numerous attempts to produce transgenic animals have met several problems, including low rates of gene incorporation and unstable gene incorporation. Accordingly, improved gene technologies are needed for the development of transgenic animals for the production of multimeric proteins .

35

Several of the prior art gene delivery technologies employed viruses that are associated with potentially undesirable side effects and safety concerns. The majority

of current gene-delivery technologies useful for gene therapy rely on virus-based delivery vectors, such as adeno and adeno-associated viruses, retroviruses, and other viruses, which have been attenuated to no longer replicate. (Kay, M.A., et al. 2001. Nature Medicine 7:33-40).

5 There are multiple problems associated with the use of viral vectors. Firstly, they are not tissue-specific. In fact, a gene therapy trial using adenovirus was recently halted because the vector was present in the patient's sperm (Gene trial to proceed despite fears that therapy could change child's genetic makeup. The New York Times, December 23, 2001). Secondly, viral vectors are likely to be transiently
10 incorporated, which necessitates re-treating a patient at specified time intervals. (Kay, M.A., et al. 2001. Nature Medicine 7:33-40). Thirdly, there is a concern that a viral-based vector could revert to its virulent form and cause disease. Fourthly, viral-based vectors require a dividing cell for stable integration. Fifthly, viral-based vectors indiscriminately integrate into various cells, which can result in undesirable germline
15 integration. Sixthly, the required high titers needed to achieve the desired effect have resulted in the death of one patient and they are believed to be responsible for induction of cancer in a separate study. (Science, News of the Week, October 4, 2002).

 Accordingly, what is needed is a new method to produce multimeric proteins
20 in transgenic animals and humans, in which the vector containing those genes does not cause disease or other unwanted side effects. There is also a need for DNA constructs that would be stably incorporated into the tissues and cells of animals and humans, including cells in the resting state that are not replicating. There is a further recognized need in the art for DNA constructs capable of delivering genes to specific
25 tissues and cells of animals and humans and for producing multimeric proteins in those animals and humans.

SUMMARY OF THE INVENTION

 The present invention provides a new, effective and efficient method of
30 producing multimeric proteins in an individual. Multimeric proteins include associated multimeric proteins (two or more associated polypeptides) and multivalent multimeric proteins (a single polypeptide encoded by more than one gene of interest). Expression and/or formation of the multimeric protein in the individual is achieved by administering a polynucleotide cassette containing the genes of interest to the
35 individual. The polynucleotide cassette may additionally contain one or more pro sequences, prepro sequences, cecropin prepro sequences, and/or cleavage site sequences.

This invention provides polynucleotide cassettes containing two or more genes of interest and two or more pro polynucleotide sequences, wherein each gene of interest is operably-linked to a pro nucleotide sequence. Each of the genes of interest encodes a polypeptide that forms a part of the multimeric protein. One discovery of the present invention is the use of pro portions of prepro signal sequences to facilitate appropriate processing, expression, and/or formation of multimeric proteins in an individual. Several examples of prepro polynucleotides from which a pro polynucleotide can be derived or be a part of are a cecropin prepro, lysozyme prepro, ovomucin prepro, ovotransferrin prepro, a signal peptide for tumor necrosis factor receptor (SEQ ID NO:6), a signal peptide encoded by a polynucleotide sequence provided in one of SEQ ID NOs:7-54 and a signal peptide provide in SEQ ID NO:55. The prepro or pro polynucleotide can be a cecropin prepro or pro polynucleotide selected from the group consisting of cecropin A1, cecropin A2, cecropin B, cecropin C, cecropin D, cecropin E and cecropin F. In a preferred embodiment, the pro polynucleotide is a cecropin B pro polynucleotide having a sequence shown in SEQ ID NO:1 or SEQ ID NO:2. A preferred prepro polynucleotide is a cecropin B polynucleotide having a sequence shown in SEQ ID NO:3 or SEQ ID NO:4.

Another discovery of the present invention is that cecropin prepro sequences facilitate appropriate processing, expression, and/or formation of proteins, including multimeric proteins, in an individual. Accordingly, the present invention includes polynucleotide cassettes containing one or more genes of interest operably-linked to a cecropin prepro sequence. In one embodiment, the polynucleotide cassette contains two or more genes of interest operably-linked to a cecropin prepro sequence. Preferred cecropin prepro polynucleotides are provided in SEQ ID NO:3 and SEQ ID NO:4. The present invention also includes polynucleotide cassettes containing two or more genes of interest operably linked to a cecropin prepro polynucleotide, wherein pro sequences are located between the genes of interest.

These polynucleotide cassettes are administered to an individual for expression of polypeptide sequences and the formation of a protein, and more preferably, a multimeric protein. Preferably, the individual is an animal from which the protein can be harvested. Preferred animals are egg-laying or milk-producing animals.

In one embodiment, the egg-laying transgenic animal is an avian. The method of the present invention may be used in avians including Ratites, Psittaciformes, Falconiformes, Piciformes, Strigiformes, Passeriformes, Coraciformes, Ralliformes, Cuculiformes, Columbiformes, Galliformes, Anseriformes, and Herodiones.

5 Preferably, the egg-laying transgenic animal is a poultry bird. More preferably, the bird is a chicken, turkey, duck, goose or quail. Another preferred bird is a ratite, such as, an emu, an ostrich, a rhea, or a cassowary. Other preferred birds are partridge, pheasant, kiwi, parrot, parakeet, macaw, falcon, eagle, hawk, pigeon, cockatoo, song birds, jay bird, blackbird, finch, warbler, canary, toucan, mynah, or sparrow.

10 In some embodiments, the polynucleotide cassettes are located within transposon-based vectors that allow for incorporation of the cassettes into the DNA of the individual. The transposon-based vectors of the present invention include a transposase, operably-linked to a first promoter, and a coding sequence for a protein or peptide of interest operably-linked to a second promoter, wherein the coding
15 sequence for the protein or peptide of interest and its operably-linked promoter are flanked by transposase insertion sequences recognized by the transposase. The transposon-based vector also includes the following characteristics: a) one or more modified Kozak sequences comprising ACCATG (SEQ ID NO:5) at the 3' end of the first promoter to enhance expression of the transposase; b) modifications of the
20 codons for the first several N-terminal amino acids of the transposase, wherein the nucleotide at the third base position of each codon is changed to an A or a T without changing the corresponding amino acid; c) addition of one or more stop codons to enhance the termination of transposase synthesis; and/or, d) addition of an effective polyA sequence operably-linked to the transposase to further enhance expression of
25 the transposase gene. In some embodiments, the effective polyA sequence is an avian optimized polyA sequence.

In one embodiment, the transposon-based vector comprises an avian optimized polyA sequence and does not comprise a modified Kozak sequence comprising ACCATG (SEQ ID NO:5). One example of such a transposon-based vector is the
30 pTnMCS vector (SEQ ID NO:56). In another embodiment the transposon-based vector comprises a) one or more modified Kozak sequences comprising ACCATG (SEQ ID NO:5) at the 3' end of the first promoter to enhance expression of the transposase; b) modifications of the codons for the first several N-terminal amino

acids of the transposase, wherein the third base of each codon was changed to an A or a T without changing the corresponding amino acid; c) addition of one or more stop codons to enhance the termination of transposase synthesis; and, d) addition of an effective polyA sequence operably-linked to the transposase to further enhance expression of the transposase gene. One example of such a transposon-based vector is the pTnMod vector (SEQ ID NO:57).

Accordingly, it is an object of the present invention to provide improved methods for the production of multimeric proteins in an individual.

It is another object of the present invention to provide improved methods for the production of multimeric proteins in an egg-laying animal or a milk-producing animal.

It is yet another object of the present invention to provide improved methods for the production of multimeric proteins in a chicken or quail.

Another object of the present invention is to provide a method to produce an egg or milk containing a multimeric protein.

An advantage of the present invention is that multimeric proteins are produced by transgenic animals much more efficiently and economically than prior art methods, thereby providing a means for large scale production of multimeric proteins.

These and other objects, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiments and claims.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 depicts schematically a polynucleotide cassette containing two genes of interest operably-linked to two pro polynucleotides, wherein the first pro polynucleotide is a part of a prepro polynucleotide. "Prom" indicates promoter.

Figure 2 depicts schematically a polynucleotide cassette containing polynucleotides encoding for a heavy chain and a light chain of an antibody. "Oval prom" indicates an ovalbumin promoter. The polynucleotide cassette contains pro and prepro sequences and is flanked by insertion sequences (IS) recognized by a transposase.

Figure 3 depicts schematically a polynucleotide cassette containing a cecropin prepro sequence operably-linked to two genes of interest. Between the genes of interest resides a cleavage site indicated by "CS."

5 Figure 4 depicts schematically a polynucleotide cassette containing two genes of interest, a promoter (prom), a signal sequence (SS) and a cleavage site (CS). The polynucleotide cassette is flanked by insertion sequences (IS) recognized by a transposase.

10 Figure 5 is a picture of a gel showing partially purified egg white derived from a transgenic avian run under reducing and non-reducing conditions.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a new, effective and efficient method of
15 producing multimeric proteins in an individual. Multimeric proteins include associated multimeric proteins (two or more associated polypeptides) and multivalent multimeric proteins (a single polypeptide encoded by more than one gene of interest). Expression and/or formation of the multimeric protein in the individual is achieved by administering a polynucleotide cassette containing the genes of interest to the
20 individual. The polynucleotide cassette may additionally contain one or more pro sequences, prepro sequences, cecropin prepro sequences, and/or cleavage site sequences.

This invention provides polynucleotide cassettes containing two or more genes of interest and two or more pro polynucleotide sequences, wherein each gene of
25 interest is operably-linked to a pro nucleotide sequence. Each of the genes of interest encodes a polypeptide that forms a part of the multimeric protein. These polynucleotide cassettes are administered to an individual for expression of the polypeptide sequences and expression and/or formation of the multimeric protein. Preferably, the individual is an animal from which the multimeric protein can be
30 harvested. Preferred animals are egg-laying or milk-producing animals. In some embodiments, the polynucleotide cassettes are located within transposon-based vectors that allow for incorporation of the cassettes into the DNA of the individual.

The pro polynucleotide sequences operably-linked to the genes of interest include pro portions of prepro polynucleotide sequences commonly associated with

polynucleotides encoding proteins secreted from a cell in nature. It may be that the pre polynucleotide sequence functions to direct the resultant protein into the endoplasmic reticulum and the pro sequence is cleaved within the endoplasmic reticulum or Golgi complex of a cell containing the protein. While prepro

5 polynucleotide sequences are associated with secreted polypeptides in nature, one discovery of the present invention is the use of pro portions of the prepro signal sequences to facilitate appropriate processing, expression, and/or formation of multimeric proteins, and more particularly, associated multimeric proteins. In the present invention, each gene of interest is operably-linked with a pro polynucleotide

10 sequence. Figure 1 shows schematically one polynucleotide cassette containing two genes of interest, wherein each gene of interest is operably-linked to a pro polynucleotide sequence. The first gene of interest is operably-linked to a pro polynucleotide sequence that is part of a prepro polynucleotide sequence, while the second gene of interest is operably-linked to a pro polynucleotide sequence that is not

15 part of a prepro polynucleotide sequence, but may have been derived from a prepro polynucleotide sequence. Accordingly, the term "pro sequence" encompasses a pro sequence that is part of a prepro sequence and a pro sequence that is not part of a prepro sequence, but may have been derived from a prepro sequence. In preferred embodiments, the most 5' pro polynucleotide sequence in the polynucleotide cassette

20 is a part of a prepro polynucleotide sequence.

Several examples of prepro polynucleotides from which a pro polynucleotide can be derived or be a part of are a cecropin prepro, lysozyme prepro, ovomucin prepro, ovotransferrin prepro, a signal peptide for tumor necrosis factor receptor (SEQ ID NO:6), a signal peptide encoded by a polynucleotide sequence provided in one of

25 SEQ ID NOs:7-54 and a signal peptide provide in SEQ ID NO:55. The prepro or pro polynucleotide can be a cecropin prepro or pro polynucleotide selected from the group consisting of cecropin A1, cecropin A2, cecropin B, cecropin C, cecropin D, cecropin E and cecropin F. In a preferred embodiment, the pro polynucleotide is a cecropin B pro polynucleotide having a sequence shown in SEQ ID NO:1 or SEQ ID NO:2. A

30 preferred prepro polynucleotide is a cecropin B polynucleotide having a sequence shown in SEQ ID NO:3 or SEQ ID NO:4.

Figure 1 provides one embodiment of the invention wherein the polynucleotide cassette includes two genes of interest and two pro polynucleotide

sequences arranged in the following order: a prepro polynucleotide, a first gene of interest, a pro polynucleotide, and a second gene of interest. Preferably, the sequences are arranged in the aforementioned order beginning at a 5' end of the polynucleotide cassette. Figure 2 provides a more specific embodiment of the present invention wherein the first and second genes of interest are polynucleotides encoding antibody heavy and light chains. However, the invention includes polynucleotide cassettes containing at least two genes of interest. Each of the genes of interest is operably-linked to a pro polynucleotide. Each of these pro polynucleotides can be the same, or each can be different. In one embodiment, all of the pro polynucleotides in the polynucleotide cassette are the same and are cecropin pro polynucleotides. The most 5' cecropin pro polynucleotide is preferably a part of a cecropin prepro polynucleotide sequence as shown in Figure 3.

The polynucleotide cassettes of the present invention may be administered to an individual for production of a multimeric protein in that individual. Accordingly, the present invention includes a method of producing a multimeric protein in an individual comprising administering to the individual a polynucleotide cassette comprising at least two genes of interest, each encoding a part of the multimeric protein, wherein each gene of interest is operably-linked to a pro polynucleotide sequence. The present invention also includes a method of producing a multimeric protein in an individual comprising administering to the individual a polynucleotide cassette comprising a cecropin prepro sequence operably-linked to two or more genes of interest, each gene of interest encoding a part of the multimeric protein. This second method does not require the linking of pro polynucleotides to each gene of interest since the use of a cecropin prepro sequence itself in a polynucleotide cassette facilitates processing, expression, and/or formation of multimeric proteins. Polynucleotide cassettes containing the cecropin prepro polynucleotide can contain at least two genes of interest. Preferably, the cecropin prepro polynucleotide is located 5' of the genes of interest in the polynucleotide cassette. One exemplary polynucleotide cassette is shown in Figure 3. In a preferred embodiment, the prepro sequence comprises a sequence shown in SEQ ID NO:3 or SEQ ID NO:4. As shown in Figure 3, the polynucleotide cassettes containing a cecropin prepro polynucleotide preferably contain a cleavage site between each of two genes of interest. Such cleavage site(s) may be nucleotides encoding any cleavage sites including, but not

limited to, an enzymatic cleavage site, a pro polynucleotide, and a photolabile cleavage site, a chemical cleavage site, and a self-splicing cleavage site (i.e., intein). Cleavage sites are discussed in more detail below.

The polynucleotide cassettes of the present invention are particularly suited for
5 production of multimeric proteins in an individual. Individuals include both humans and animals. Preferred animals are egg-laying animals and milk-producing animals. As used herein, the term "egg-laying animal" includes all amniotes such as birds, turtles, lizards and monotremes. Monotremes are egg-laying mammals and include the platypus and echidna. The term "bird" or "fowl," as used herein, is defined as a
10 member of the Aves class of animals which are characterized as warm-blooded, egg-laying vertebrates primarily adapted for flying. Avians include, without limitation, Ratites, Psittaciformes, Falconiformes, Piciformes, Strigiformes, Passeriformes, Coraciiformes, Ralliformes, Cuculiformes, Columbiformes, Galliformes, Anseriformes, and Herodiones. The term "Ratite," as used herein, is defined as a
15 group of flightless, mostly large, running birds comprising several orders and including the emus, ostriches, kiwis, and cassowaries. The term "Psittaciformes", as used herein, includes parrots and refers to a monofamilial order of birds that exhibit zygodactylism and have a strong hooked bill. A "parrot" is defined as any member of the avian family Psittacidae (the single family of the Psittaciformes), distinguished by
20 the short, stout, strongly hooked beak. Preferred avians are poultry birds including chickens, quail, turkeys, geese and ducks. The term "chicken" as used herein denotes chickens used for table egg production, such as egg-type chickens, chickens reared for public meat consumption, or broilers, and chickens reared for both egg and meat production ("dual-purpose" chickens). The term "chicken" also denotes chickens
25 produced by primary breeder companies, or chickens that are the parents, grandparents, great-grandparents, etc. of those chickens reared for public table egg, meat, or table egg and meat consumption.

When the polynucleotide cassettes of the present invention are administered to an egg-laying or milk-producing animal, a transgenic animal containing a
30 polynucleotide cassette is created and the animal produces a transgenic multimeric protein. It is preferred that the resultant multimeric protein is deposited in the egg or in the milk. Various different signal sequences and promoters may be used to achieve deposition of the multimeric protein in the egg or in the milk and these are described

in more detail below. In order to achieve a transgenic animal containing a polynucleotide cassette of the present invention, the polynucleotide cassettes can be administered to the individual with, or contained in, any vector, as naked DNA, or in any delivery construct or solution. A preferred vector for incorporation of the polynucleotide cassettes into an individual is a transposon-based vector described below.

Definitions

It is to be understood that as used in the specification and in the claims, "a" or "an" can mean one or more, depending upon the context in which it is used. Thus, for example, reference to "a cell" can mean that at least one cell can be utilized.

The term "antibody" is used interchangeably with the term "immunoglobulin" and is defined herein as a protein synthesized by an animal or a cell of the immune system in response to the presence of a foreign substance commonly referred to as an "antigen" or an "immunogen". The term antibody includes fragments of antibodies. Antibodies are characterized by specific affinity to a site on the antigen, wherein the site is referred to an "antigenic determinant" or an "epitope". Antigens can be naturally occurring or artificially engineered. Artificially engineered antigens include but are not limited to small molecules, such as small peptides, attached to haptens such as macromolecules, for example proteins, nucleic acids, or polysaccharides. Artificially designed or engineered variants of naturally occurring antibodies and artificially designed or engineered antibodies not occurring in nature are all included in the current definition. Such variants include conservatively substituted amino acids and other forms of substitution as described in the section concerning proteins and polypeptides.

The term "egg" is defined herein as including a large female sex cell enclosed in a porous, calcarous or leathery shell, produced by birds and reptiles. The term "ovum" is defined as a female gamete, and is also known as an egg. Therefore, egg production in all animals other than birds and reptiles, as used herein, is defined as the production and discharge of an ovum from an ovary, or "ovulation". Accordingly, it is to be understood that the term "egg" as used herein is defined as a large female sex cell enclosed in a porous, calcarous or leathery shell, when a bird or reptile produces it, or it is an ovum when it is produced by all other animals.

The term “gene” is defined herein to include a polynucleotide that includes a coding region for a protein, peptide or polypeptide, with or without intervening sequences such as introns.

5 The term “multimeric protein” is defined herein to include one or more polypeptides that are associated, or joined, by any means including disulfide bonds. An example of this type of multimeric protein is an antibody that contains both heavy and light chains that are associated by disulfide bonds. These multimeric proteins are referred to herein as “associated multimeric proteins.” The term “multimeric protein” also includes a polypeptide that is encoded by more than one gene of interest. An
10 example of this type of multimeric protein is a single polypeptide containing a heavy chain polypeptide (first polypeptide of interest) and a light chain polypeptide (second polypeptide of interest). In these embodiments, the different polypeptides of interest may be separated by other polypeptide sequences such as spacer polypeptides and cleavage site polypeptides. These types of multimeric proteins are referred to herein
15 as “multivalent multimeric proteins.”

The term “milk-producing animal” refers herein to mammals including, but not limited to, bovine, ovine, porcine, equine, and primate animals. Milk-producing animals include but are not limited to cows, llamas, camels, goats, reindeer, zebu, water buffalo, yak, horses, pigs, rabbits, non-human primates, and humans.

20 The term “transgenic animal” refers to an animal having at least a portion of the transposon-based vector DNA is incorporated into its DNA. While a transgenic animal includes an animal wherein the transposon-based vector DNA is incorporated into the germline DNA, a transgenic animal also includes an animal having DNA in one or more somatic cells that contain a portion of the transposon-based vector DNA
25 for any period of time. In a preferred embodiment, a portion of the transposon-based vector comprises a gene of interest. More preferably, the gene of interest is incorporated into the animal’s DNA for a period of at least five days, more preferably the laying life of the animal, and most preferably the life of the animal. In a further preferred embodiment, the animal is an avian.

30 The term “vector” is used interchangeably with the terms “construct”, “DNA construct” and “genetic construct” to denote synthetic nucleotide sequences used for manipulation of genetic material, including but not limited to cloning, subcloning, sequencing, or introduction of exogenous genetic material into cells, tissues or

organisms, such as birds. It is understood by one skilled in the art that vectors may contain synthetic DNA sequences, naturally occurring DNA sequences, or both. The vectors of the present invention are transposon-based vectors as described herein.

When referring to two nucleotide sequences, one being a regulatory sequence, the term “operably-linked” is defined herein to mean that the two sequences are associated in a manner that allows the regulatory sequence to affect expression of the other nucleotide sequence. It is not required that the operably-linked sequences be directly adjacent to one another with no intervening sequence(s).

The term “regulatory sequence” is defined herein as including promoters, enhancers and other expression control elements such as polyadenylation sequences, matrix attachment sites, insulator regions for expression of multiple genes on a single construct, ribosome entry/attachment sites, introns that are able to enhance expression, and silencers.

Transposon-Based Vectors

While not wanting to be bound by the following statement, it is believed that the nature of the DNA construct is an important factor in successfully producing transgenic animals. The “standard” types of plasmid and viral vectors that have previously been almost universally used for transgenic work in all species, especially avians, have low efficiencies and may constitute a major reason for the low rates of transformation previously observed. The DNA (or RNA) constructs previously used often do not integrate into the host DNA, or integrate only at low frequencies. Other factors may have also played a part, such as poor entry of the vector into target cells. The present invention provides transposon-based vectors that can be administered to an animal that overcome the prior art problems relating to low transgene integration frequencies. Two preferred transposon-based vectors of the present invention in which a transposase, gene of interest and other polynucleotide sequences may be introduced are termed pTnMCS (SEQ ID NO:56) and pTnMod (SEQ ID NO:57).

The transposon-based vectors of the present invention produce integration frequencies an order of magnitude greater than has been achieved with previous vectors. More specifically, intratesticular injections performed with a prior art transposon-based vector (described in U.S. Patent No. 5,719,055) resulted in 41% sperm positive roosters whereas intratesticular injections performed with the novel transposon-based vectors of the present invention resulted in 77% sperm positive

roosters. Actual frequencies of integration were estimated by either or both comparative strength of the PCR signal from the sperm and histological evaluation of the testes and sperm by quantitative PCR.

The transposon-based vectors of the present invention include a transposase
5 gene operably-linked to a first promoter, and a coding sequence for a desired protein or peptide operably-linked to a second promoter, wherein the coding sequence for the desired protein or peptide and its operably-linked promoter are flanked by transposase insertion sequences recognized by the transposase. The transposon-based vector also includes one or more of the following characteristics: a) one or more modified Kozak
10 sequences comprising ACCATG (SEQ ID NO:5) at the 3' end of the first promoter to enhance expression of the transposase; b) modifications of one or more of the codons for the first several N-terminal amino acids of the transposase, wherein the third base of each codon was changed to an A or a T without changing the corresponding amino acid; c) addition of one or more stop codons to enhance the termination of transposase
15 synthesis; and/or, d) addition of an effective polyA sequence operably-linked to the transposase to further enhance expression of the transposase gene. In one embodiment, the transposon-based vector comprises an avian optimized polyA sequence and does not comprise a modified Kozak sequence comprising ACCATG (SEQ ID NO:5). One example of such a transposon-based vector is the pTnMCS
20 vector (SEQ ID NO:56). In another embodiment the transposon-based vector comprises a) one or more modified Kozak sequences comprising ACCATG (SEQ ID NO:5) at the 3' end of the first promoter to enhance expression of the transposase; b) modifications of the codons for the first several N-terminal amino acids of the transposase, wherein the third base of each codon was changed to an A or a T without
25 changing the corresponding amino acid; c) addition of one or more stop codons to enhance the termination of transposase synthesis; and, d) addition of an effective polyA sequence operably-linked to the transposase to further enhance expression of the transposase gene. One example of such a transposon-based vector is the pTnMod vector (SEQ ID NO:57). The transposon-based vector may additionally or
30 alternatively include one or more of the following Kozak sequences at the 3' end of any promoter, including the promoter operably-linked to the transposase: ACCATGG (SEQ ID NO:58), AAGATGT (SEQ ID NO:59), ACGATGA (SEQ ID NO:60),

AAGATGG (SEQ ID NO:61), GACATGA (SEQ ID NO:62), ACCATGA (SEQ ID NO:63), and ACCATGA (SEQ ID NO:64), ACCATGT (SEQ ID NO:65).

Transposases and Insertion Sequences

In a further embodiment of the present invention, the transposase found in the transposase-based vector is an altered target site (ATS) transposase and the insertion sequences are those recognized by the ATS transposase. However, the transposase located in the transposase-based vectors is not limited to a modified ATS transposase and can be derived from any transposase. Transposases known in the prior art include those found in AC7, Tn5SEQ1, Tn916, Tn951, Tn1721, Tn 2410, Tn1681, Tn1, Tn2, Tn3, Tn4, Tn5, Tn6, Tn9, Tn10, Tn30, Tn101, Tn903, Tn501, Tn1000 ($\gamma\delta$), Tn1681, Tn2901, AC transposons, Mp transposons, Spm transposons, En transposons, Dotted transposons, Mu transposons, Ds transposons, dSpm transposons and I transposons. According to the present invention, these transposases and their regulatory sequences are modified for improved functioning as follows: a) the addition one or more modified Kozak sequences comprising ACCATG (SEQ ID NO:5) at the 3' end of the promoter operably-linked to the transposase; b) a change of one or more of the codons for the first several amino acids of the transposase, wherein the third base of each codon was changed to an A or a T without changing the corresponding amino acid; c) the addition of one or more stop codons to enhance the termination of transposase synthesis; and/or, d) the addition of an effective polyA sequence operably-linked to the transposase to further enhance expression of the transposase gene.

Although not wanting to be bound by the following statement, it is believed that the modifications of the first several N-terminal codons of the transposase gene facilitate transcription of the transposase gene, in part, by increasing strand dissociation during transcription. It is preferable that one or more of between approximately the first 1 to 20, more preferably 3 to 15, and most preferably between 4 to 12 N-terminal codons of the transposase are modified such that the third base of each codon is changed to an A or a T without changing the encoded amino acid. In one embodiment, the first ten N-terminal codons of the transposase gene are modified in this manner. It is also preferred that the transposase contain mutations that make it less specific for preferred insertion sites and thus increases the rate of transgene insertion as discussed in U.S. Patent No. 5,719,055.

In some embodiments, the transposon-based vectors are optimized for expression in a particular host by changing the methylation patterns of the vector DNA. For example, prokaryotic methylation may be reduced by using a methylation deficient organism for production of the transposon-based vector. The transposon-based vectors may also be methylated to resemble eukaryotic DNA for expression in a eukaryotic host.

Transposases and insertion sequences from other analogous eukaryotic transposon-based vectors that can also be modified and used are, for example, the *Drosophila* P element derived vectors disclosed in U.S. Patent No. 6,291,243; the *Drosophila* mariner element described in Sherman et al. (1998); or the sleeping beauty transposon. See also Hackett et al. (1999); D. Lampe et al., 1999. Proc. Natl. Acad. Sci. USA, 96:11428-11433; S. Fischer et al., 2001. Proc. Natl. Acad. Sci. USA, 98:6759-6764; L. Zagoraiou et al., 2001. Proc. Natl. Acad. Sci. USA, 98:11474-11478; and D. Berg et al. (Eds.), Mobile DNA, Amer. Soc. Microbiol. (Washington, D.C., 1989). However, it should be noted that bacterial transposon-based elements are preferred, as there is less likelihood that a eukaryotic transposase in the recipient species will recognize prokaryotic insertion sequences bracketing the transgene.

Many transposases recognize different insertion sequences, and therefore, it is to be understood that a transposase-based vector will contain insertion sequences recognized by the particular transposase also found in the transposase-based vector. In a preferred embodiment of the invention, the insertion sequences have been shortened to about 70 base pairs in length as compared to those found in wild-type transposons that typically contain insertion sequences of well over 100 base pairs.

While the examples provided below incorporate a "cut and insert" Tn10 based vector that is destroyed following the insertion event, the present invention also encompasses the use of a "rolling replication" type transposon-based vector. Use of a rolling replication type transposon allows multiple copies of the transposon/transgene to be made from a single transgene construct and the copies inserted. This type of transposon-based system thereby provides for insertion of multiple copies of a transgene into a single genome. A rolling replication type transposon-based vector may be preferred when the promoter operably-linked to gene of interest is endogenous to the host cell and present in a high copy number or highly expressed. However, use of a rolling replication system may require tight control to limit the insertion events to

non-lethal levels. Tn1, Tn2, Tn3, Tn4, Tn5, Tn9, Tn21, Tn501, Tn551, Tn951, Tn1721, Tn2410 and Tn2603 are examples of a rolling replication type transposon, although Tn5 could be both a rolling replication and a cut and insert type transposon.

Stop Codons and PolyA Sequences

5 In one embodiment, the transposon-based vector contains two stop codons operably-linked to the transposase and/or to the gene of interest. In an alternate embodiment, one stop codon of UAA or UGA is operably linked to the transposase and/or to the gene of interest. While not wanting to be bound by the following statement, it is thought that the stop codon UAG is less effective in translation
10 termination and is therefore less desirable in the constructs described herein.

As used herein an "effective polyA sequence" refers to either a synthetic or non-synthetic sequence that contains multiple and sequential nucleotides containing an adenine base (an A polynucleotide string) and that increases expression of the gene to which it is operably-linked. A polyA sequence may be operably-linked to any gene
15 in the transposon-based vector including, but not limited to, a transposase gene and a gene of interest. A preferred polyA sequence is optimized for use in the host animal or human. In one embodiment, the polyA sequence is optimized for use in an avian species and more specifically, a chicken. An avian optimized polyA sequence generally contains a minimum of 40 base pairs, preferably between approximately 40
20 and several hundred base pairs, and more preferably approximately 75 base pairs that precede the A polynucleotide string and thereby separate the stop codon from the A polynucleotide string. In one embodiment of the present invention, the polyA sequence comprises a conalbumin polyA sequence as provided in SEQ ID NO:66 and as taken from GenBank accession # Y00407, base pairs 10651-11058. In another
25 embodiment, the polyA sequence comprises a synthetic polynucleotide sequence shown in SEQ ID NO:67. In yet another embodiment, the polyA sequence comprises an avian optimized polyA sequence provided in SEQ ID NO:68. A chicken optimized polyA sequence may also have a reduced amount of CT repeats as compared to a synthetic polyA sequence.

30 It is a surprising discovery of the present invention that such an avian optimized poly A sequence increases expression of a polynucleotide to which it is operably-linked in an avian as compared to a non-avian optimized polyA sequence. Accordingly, the present invention includes methods of or increasing incorporation of

a gene of interest wherein the gene of interest resides in a transposon-based vector containing a transposase gene and wherein the transposase gene is operably linked to an avian optimized polyA sequence. The present invention also includes methods of increasing expression of a gene of interest in an avian that includes administering a gene of interest to the avian, wherein the gene of interest is operably-linked to an avian optimized polyA sequence. An avian optimized polyA nucleotide string is defined herein as a polynucleotide containing an A polynucleotide string and a minimum of 40 base pairs, preferably between approximately 40 and several hundred base pairs, and more preferably approximately 75 base pairs that precede the A polynucleotide string. The present invention further provides transposon-based vectors containing a gene of interest or transposase gene operably linked to an avian optimized polyA sequence.

Promoters and Enhancers

The first promoter operably-linked to the transposase gene and the second promoter operably-linked to the gene of interest can be a constitutive promoter or an inducible promoter. Constitutive promoters include, but are not limited to, immediate early cytomegalovirus (CMV) promoter, herpes simplex virus 1 (HSV1) immediate early promoter, SV40 promoter, lysozyme promoter, early and late CMV promoters, early and late HSV promoters, β -actin promoter, tubulin promoter, Rous-Sarcoma virus (RSV) promoter, and heat-shock protein (HSP) promoter. Inducible promoters include tissue-specific promoters, developmentally-regulated promoters and chemically inducible promoters. Examples of tissue-specific promoters include the glucose 6 phosphate (G6P) promoter, vitellogenin promoter, ovalbumin promoter, ovomucoid promoter, conalbumin promoter, ovotransferrin promoter, prolactin promoter, kidney uromodulin promoter, and placental lactogen promoter. In one embodiment, the vitellogenin promoter includes a polynucleotide sequence of SEQ ID NO:69. The G6P promoter sequence may be deduced from a rat G6P gene untranslated upstream region provided in GenBank accession number U57552.1. Examples of developmentally-regulated promoters include the homeobox promoters and several hormone induced promoters. Examples of chemically inducible promoters include reproductive hormone induced promoters and antibiotic inducible promoters such as the tetracycline inducible promoter and the zinc-inducible metallothioneine promoter.

Other inducible promoter systems include the Lac operator repressor system inducible by IPTG (isopropyl beta-D-thiogalactoside) (Cronin, A. et al. 2001. *Genes and Development*, v. 15), ecdysone-based inducible systems (Hoppe, U. C. et al. 2000. *Mol. Ther.* 1:159-164); estrogen-based inducible systems (Braselmann, S. et al. 5 1993. *Proc. Natl. Acad. Sci.* 90:1657-1661); progesterone-based inducible systems using a chimeric regulator, GLVP, which is a hybrid protein consisting of the GAL4 binding domain and the herpes simplex virus transcriptional activation domain, VP16, and a truncated form of the human progesterone receptor that retains the ability to bind ligand and can be turned on by RU486 (Wang, et al. 1994. *Proc. Natl. Acad. Sci.* 10 91:8180-8184); CID-based inducible systems using chemical inducers of dimerization (CIDs) to regulate gene expression, such as a system wherein rapamycin induces dimerization of the cellular proteins FKBP12 and FRAP (Belshaw, P. J. et al. 1996. *J. Chem. Biol.* 3:731-738; Fan, L. et al. 1999. *Hum. Gene Ther.* 10:2273-2285; Shariat, S.F. et al. 2001. *Cancer Res.* 61:2562-2571; Spencer, D.M. 1996. *Curr. Biol.* 6:839- 15 847). Chemical substances that activate the chemically inducible promoters can be administered to the animal containing the transgene of interest via any method known to those of skill in the art.

Other examples of cell or tissue-specific and constitutive promoters include but are not limited to smooth-muscle SM22 promoter, including chimeric 20 SM22alpha/telokin promoters (Hoggatt A.M. et al., 2002. *Circ Res.* 91(12):1151-9); ubiquitin C promoter (*Biochim Biophys Acta*, 2003. Jan. 3;1625(1):52-63); Hsf2 promoter; murine COMP (cartilage oligomeric matrix protein) promoter; early B cell-specific mb-1 promoter (Sigvardsson M., et al., 2002. *Mol. Cell Biol.* 22(24):8539-51); prostate specific antigen (PSA) promoter (Yoshimura I. et al., 2002, *J. Urol.* 25 168(6):2659-64); exorh promoter and pineal expression-promoting element (Asaoka Y., et al., 2002. *Proc. Natl. Acad. Sci.* 99(24):15456-61); neural and liver ceramidase gene promoters (Okino N. et al., 2002. *Biochem. Biophys. Res. Commun.* 299(1):160-6); PSP94 gene promoter/enhancer (Gabril M.Y. et al., 2002. *Gene Ther.* 9(23):1589-99); promoter of the human FAT/CD36 gene (Kuriki C., et al., 2002. *Biol.* 30 *Pharm. Bull.* 25(11):1476-8); VL30 promoter (Staplin W.R. et al., 2002. *Blood* October 24, 2002); and IL-10 promoter (Brenner S., et al., 2002. *J. Biol. Chem.* December 18, 2002).

Examples of avian promoters include, but are not limited to, promoters controlling expression of egg white proteins, such as ovalbumin, ovotransferrin (conalbumin), ovomucoid, lysozyme, ovomucin, g2 ovoglobulin, g3 ovoglobulin, ovoflavoprotein, ovostatin (ovomacroglobin), cystatin, avidin, thiamine-binding protein, glutamyl aminopeptidase minor glycoprotein 1, minor glycoprotein 2; and promoters controlling expression of egg-yolk proteins, such as vitellogenin, very low-density lipoproteins, low density lipoprotein, cobalamin-binding protein, riboflavin-binding protein, biotin-binding protein (Awade, 1996. Z. Lebensm. Unters. Forsch. 202:1-14). An advantage of using the vitellogenin promoter is that it is active during the egg-laying stage of an animal's life-cycle, which allows for the production of the protein of interest to be temporally connected to the import of the protein of interest into the egg yolk when the protein of interest is equipped with an appropriate targeting sequence. In some embodiments, the avian promoter is an oviduct-specific promoter. As used herein, the term "oviduct-specific promoter" includes, but is not limited to, ovalbumin, ovotransferrin (conalbumin), ovomucoid, lysozyme, ovomucin, g2 ovoglobulin, g3 ovoglobulin, ovoflavoprotein, and ovostatin (ovomacroglobin) promoters.

Liver-specific promoters of the present invention include, but are not limited to, the following promoters, vitellogenin promoter, G6P promoter, cholesterol-7-alpha-hydroxylase (CYP7A) promoter, phenylalanine hydroxylase (PAH) promoter, protein C gene promoter, insulin-like growth factor I (IGF-I) promoter, bilirubin UDP-glucuronosyltransferase promoter, aldolase B promoter, furin promoter, metallothioneine promoter, albumin promoter, and insulin promoter.

Also included in the present invention are promoters that can be used to target expression of a protein of interest into the milk of a milk-producing animal including, but not limited to, β lactoglobulin promoter, whey acidic protein promoter, lactalbumin promoter and casein promoter.

Promoters associated with cells of the immune system may also be used. Acute phase promoters such as interleukin (IL)-1 and IL-2 may be employed. Promoters for heavy and light chain Ig may also be employed. The promoters of the T cell receptor components CD4 and CD8, B cell promoters and the promoters of CR2 (complement receptor type 2) may also be employed. Immune system promoters are preferably used when the desired protein is an antibody protein.

Also included in this invention are modified promoters/enhancers wherein elements of a single promoter are duplicated, modified, or otherwise changed. In one embodiment, a steroid hormone-binding domain of the ovalbumin promoter is moved from about -6.5 kb to within approximately the first 1000 base pairs of the gene of interest. Modifying an existing promoter with promoter/enhancer elements not found naturally in the promoter, as well as building an entirely synthetic promoter, or drawing promoter/enhancer elements from various genes together on a non-natural backbone, are all encompassed by the current invention.

Accordingly, it is to be understood that the promoters contained within the transposon-based vectors of the present invention may be entire promoter sequences or fragments of promoter sequences. For example, in one embodiment, the promoter operably linked to a gene of interest is an approximately 900 base pair fragment of a chicken ovalbumin promoter (SEQ ID NO:70). The constitutive and inducible promoters contained within the transposon-based vectors may also be modified by the addition of one or more modified Kozak sequences of ACCATG (SEQ ID NO:5).

As indicated above, the present invention includes transposon-based vectors containing one or more enhancers. These enhancers may or may not be operably-linked to their native promoter and may be located at any distance from their operably-linked promoter. A promoter operably-linked to an enhancer is referred to herein as an "enhanced promoter." The enhancers contained within the transposon-based vectors are preferably enhancers found in birds, and more preferably, an ovalbumin enhancer, but are not limited to these types of enhancers. In one embodiment, an approximately 675 base pair enhancer element of an ovalbumin promoter is cloned upstream of an ovalbumin promoter with 300 base pairs of spacer DNA separating the enhancer and promoter. In one embodiment, the enhancer used as a part of the present invention comprises base pairs 1-675 of a Chicken Ovalbumin enhancer from GenBank accession #S82527.1. The polynucleotide sequence of this enhancer is provided in SEQ ID NO:71.

Also included in some of the transposon-based vectors of the present invention are cap sites and fragments of cap sites. In one embodiment, approximately 50 base pairs of a 5' untranslated region wherein the capsite resides are added on the 3' end of an enhanced promoter or promoter. An exemplary 5' untranslated region is provided

in SEQ ID NO:72. A putative cap-site residing in this 5' untranslated region preferably comprises the polynucleotide sequence provided in SEQ ID NO:73.

In one embodiment of the present invention, the first promoter operably-linked to the transposase gene is a constitutive promoter and the second promoter operably-linked to the gene of interest is a tissue-specific promoter. In the second embodiment, use of the first constitutive promoter allows for constitutive activation of the transposase gene and incorporation of the gene of interest into virtually all cell types, including the germline of the recipient animal. Although the gene of interest is incorporated into the germline generally, the gene of interest is only expressed in a tissue-specific manner. A transposon-based vector having a constitutive promoter operably-linked to the transposase gene can be administered by any route, and in one embodiment, the vector is administered to an ovary or to an artery leading to the ovary. In another embodiment, the vector is administered into the lumen of the oviduct or into an artery supplying the oviduct.

It should be noted that cell- or tissue-specific expression as described herein does not require a complete absence of expression in cells or tissues other than the preferred cell or tissue. Instead, "cell-specific" or "tissue-specific" expression refers to a majority of the expression of a particular gene of interest in the preferred cell or tissue, respectively.

When incorporation of the gene of interest into the germline is not preferred, the first promoter operably-linked to the transposase gene can be a tissue-specific promoter. For example, transfection of a transposon-based vector containing a transposase gene operably-linked to an oviduct specific promoter such as the ovalbumin promoter provides for activation of the transposase gene and incorporation of the gene of interest in the cells of the oviduct but not into the germline and other cells generally. In this embodiment, the second promoter operably-linked to the gene of interest can be a constitutive promoter or an inducible promoter. In a preferred embodiment, both the first promoter and the second promoter are an ovalbumin promoter. In embodiments wherein tissue-specific expression or incorporation is desired, it is preferred that the transposon-based vector is administered directly to the tissue of interest or to an artery leading to the tissue of interest. In a preferred embodiment, the tissue of interest is the oviduct and administration is achieved by direct injection into the lumen of the oviduct or an artery leading to the oviduct. In a

further preferred embodiment, administration is achieved by direct injection into the lumen of the magnum or the infundibulum of the oviduct.

Accordingly, cell specific promoters may be used to enhance transcription in selected tissues. In birds, for example, promoters that are found in cells of the fallopian tube, such as ovalbumin, conalbumin, ovomucoid and/or lysozyme, are used in the vectors to ensure transcription of the gene of interest in the epithelial cells and tubular gland cells of the fallopian tube, leading to synthesis of the desired protein encoded by the gene and deposition into the egg white. In mammals, promoters specific for the epithelial cells of the alveoli of the mammary gland, such as prolactin, insulin, beta lactoglobulin, whey acidic protein, lactalbumin, casein, and/or placental lactogen, are used in the design of vectors used for transfection of these cells for the production of desired proteins for deposition into the milk. In liver cells, the G6P promoter may be employed to drive transcription of the gene of interest for protein production. Proteins made in the liver of birds may be delivered to the egg yolk.

In order to achieve higher or more efficient expression of the transposase gene, the promoter and other regulatory sequences operably-linked to the transposase gene may be those derived from the host. These host specific regulatory sequences can be tissue specific as described above or can be of a constitutive nature. For example, an avian actin promoter and its associated polyA sequence can be operably-linked to a transposase in a transposase-based vector for transfection into an avian. Examples of other host specific promoters that could be operably-linked to the transposase include the myosin and DNA or RNA polymerase promoters.

Directing Sequences

In some embodiments of the present invention, the gene of interest is operably-linked to a directing sequence or a sequence that provides proper conformation to the desired protein encoded by the gene of interest. As used herein, the term "directing sequence" refers to both signal sequences and targeting sequences. An egg directing sequence includes, but is not limited to, an ovomucoid signal sequence, an ovalbumin signal sequence, a cecropin prepro sequence, and a vitellogenin targeting sequence. The term "signal sequence" refers to an amino acid sequence, or the polynucleotide sequence that encodes the amino acid sequence, a portion or the entirety of which directs the protein to which it is linked to the endoplasmic reticulum in a eukaryote, and more preferably the translocational pores

in the endoplasmic reticulum, or the plasma membrane in a prokaryote, or mitochondria, such as for the purpose of gene therapy for mitochondrial diseases. Signal and targeting sequences can be used to direct a desired protein into, for example, the milk, when the transposon-based vectors are administered to a milk-producing animal.

Signal sequences can also be used to direct a desired protein into, for example, a secretory pathway for incorporation into the egg yolk or the egg white, when the transposon-based vectors are administered to a bird or other egg-laying animal. The present invention also includes a gene of interest operably-linked to a second gene containing a signal sequence. An example of such an embodiment is wherein the gene of interest is operably-linked to the ovalbumin gene that contains an ovalbumin signal sequence. Other signal sequences that can be included in the transposon-based vectors include, but are not limited to the ovotransferrin and lysozyme signal sequences. In one embodiment, the signal sequence is an ovalbumin signal sequence including a sequence shown in SEQ ID NO:74. In another embodiment, the signal sequence is a shortened ovalbumin signal sequence including a sequence shown in SEQ ID NO:75 or SEQ ID NO:76.

As also used herein, the term "targeting sequence" refers to an amino acid sequence, or the polynucleotide sequence encoding the amino acid sequence, which amino acid sequence is recognized by a receptor located on the exterior of a cell. Binding of the receptor to the targeting sequence results in uptake of the protein or peptide operably-linked to the targeting sequence by the cell. One example of a targeting sequence is a vitellogenin targeting sequence that is recognized by a vitellogenin receptor (or the low density lipoprotein receptor) on the exterior of an oocyte. In one embodiment, the vitellogenin targeting sequence includes the polynucleotide sequence of SEQ ID NO:77. In another embodiment, the vitellogenin targeting sequence includes all or part of the vitellogenin gene. Other targeting sequences include VLDL and Apo E, which are also capable of binding the vitellogenin receptor. Since the ApoE protein is not endogenously expressed in birds, its presence may be used advantageously to identify birds carrying the transposon-based vectors of the present invention.

Genes of Interest

The genes of interest in the polynucleotide cassette can be any gene, and preferably are genes that encode portions of multimeric proteins. A gene of interest may contain modifications of the codons for the first several N-terminal amino acids of the gene of interest, wherein the third base of each codon is changed to an A or a T without changing the corresponding amino acid. In one embodiment, the genes of interest are antibody genes or portions of antibody genes. Figure 2 shows a schematic drawing of a polynucleotide cassette containing an antibody heavy chain and an antibody light chain as two genes of interest. Antibodies used in or encoded by the polynucleotide cassettes of the present invention include, but are not limited to, IgG, IgM, IgA, IgD, IgE, IgY, lambda chains, kappa chains, bi-specific antibodies, and fragments thereof; scFv fragments, Fc fragments, and Fab fragments as well as dimeric, trimeric and oligomeric forms of antibody fragments. Desired antibodies include, but are not limited to, naturally occurring antibodies, human antibodies, humanized antibodies, autoantibodies and hybrid antibodies. Genes encoding modified versions of naturally occurring antibodies or fragments thereof and genes encoding artificially designed antibodies or fragments thereof may be incorporated into the transposon-based vectors of the present invention. Desired antibodies also include antibodies with the ability to bind specific ligands, for example, antibodies against proteins associated with cancer-related molecules, such as anti-her 2, or anti-CA125. Accordingly, the present invention encompasses a polynucleotide cassette as described herein containing one or more genes encoding a heavy immunoglobulin (Ig) chain and a light Ig chain.

Antibodies that may be produced using the present invention include, but are not limited to, antibodies for use in cancer immunotherapy against specific antigens, or for providing passive immunity to an animal or a human against an infectious disease or a toxic agent. The antibodies prepared using the methods of the present invention may also be designed to possess specific labels that may be detected through means known to one of ordinary skill in the art. For example, antibodies may be labeled with a fluorescent label attached that may be detected following exposure to specific wavelengths. Such labeled antibodies may be primary antibodies directed to a specific antigen, for example, rhodamine-labeled rabbit anti-growth hormone, or may be labeled secondary antibodies, such as fluorescein-labeled goat-anti chicken

IgG. Such labeled antibodies are known to one of ordinary skill in the art. The antibodies may also be designed to possess specific sequences useful for purification through means known to one of ordinary skill in the art. Labels useful for attachment to antibodies are also known to one of ordinary skill in the art. Some of these labels are described in the "Handbook of Fluorescent Probes and Research Products", ninth edition, Richard P. Haugland (ed) Molecular Probes, Inc. Eugene, OR), which is incorporated herein in its entirety. Antibodies produced with the present invention may be used as laboratory reagents for numerous applications including radioimmunoassay, western blots, dot blots, ELISA, immunoaffinity columns and other procedures requiring antibodies as known to one of ordinary skill in the art. Such antibodies include primary antibodies, secondary antibodies and tertiary antibodies, which may be labeled or unlabeled.

Additional antibodies that may be made with the practice of the present invention include, but are not limited to, primary antibodies, secondary antibodies, designer antibodies, anti-protein antibodies, anti-peptide antibodies, anti-DNA antibodies, anti-RNA antibodies, anti-hormone antibodies, anti-hypophysiotropic peptides, antibodies against non-natural antigens, anti-anterior pituitary hormone antibodies, anti-posterior pituitary hormone antibodies, anti-venom antibodies, anti-tumor marker antibodies, antibodies directed against epitopes associated with infectious disease, including, anti-viral, anti-bacterial, anti-protozoal, anti-fungal, anti-parasitic, anti-receptor, anti-lipid, anti-phospholipid, anti-growth factor, anti-cytokine, anti-monokine, anti-idiotypic, and anti-accessory (presentation) protein antibodies. Antibodies made with the present invention, as well as light chains or heavy chains, may also be used to inhibit enzyme activity.

Antibodies that may be produced using the present invention include, but are not limited to, antibodies made against the following proteins: Bovine γ -Globulin, Serum; Bovine IgG, Plasma; Chicken γ -Globulin, Serum; Human γ -Globulin, Serum; Human IgA, Plasma; Human IgA₁, Myeloma; Human IgA₂, Myeloma; Human IgA₂, Plasma; Human IgD, Plasma; Human IgE, Myeloma; Human IgG, Plasma; Human IgG, Fab Fragment, Plasma; Human IgG, F(ab')₂ Fragment, Plasma; Human IgG, Fc Fragment, Plasma; Human IgG₁, Myeloma; Human IgG₂, Myeloma; Human IgG₃, Myeloma; Human IgG₄, Myeloma; Human IgM, Myeloma; Human IgM, Plasma; Human Immunoglobulin, Light Chain κ , Urine; Human Immunoglobulin, Light

Chains κ and λ , Plasma; Mouse γ -Globulin, Serum; Mouse IgG, Serum; Mouse IgM, Myeloma; Rabbit γ -Globulin, Serum; Rabbit IgG, Plasma; and Rat γ -Globulin, Serum. In one embodiment, the transposon-based vector comprises the coding sequence of light and heavy chains of a murine monoclonal antibody that shows
 5 specificity for human seminoprotein (GenBank Accession numbers AY129006 and AY129304 for the light and heavy chains, respectively).

A further non-limiting list of antibodies that recognize other antibodies and that may be produced using the present invention is as follows: Anti-Chicken IgG, heavy (H) & light (L) Chain Specific (Sheep); Anti-Goat γ -Globulin (Donkey); Anti-
 10 Goat IgG, Fc Fragment Specific (Rabbit); Anti-Guinea Pig γ -Globulin (Goat); Anti-Human Ig, Light Chain, Type κ Specific; Anti-Human Ig, Light Chain, Type λ Specific; Anti-Human IgA, α -Chain Specific (Goat); Anti-Human IgA, Fab Fragment Specific; Anti-Human IgA, Fc Fragment Specific; Anti-Human IgA, Secretory; Anti-Human IgE, ϵ -Chain Specific (Goat); Anti-Human IgE, Fc Fragment Specific; Anti-
 15 Human IgG, Fc Fragment Specific (Goat); Anti-Human IgG, γ -Chain Specific (Goat); Anti-Human IgG, Fc Fragment Specific; Anti-Human IgG, Fd Fragment Specific; Anti-Human IgG, H & L Chain Specific (Goat); Anti-Human IgG₁, Fc Fragment Specific; Anti-Human IgG₂, Fc Fragment Specific; Anti-Human IgG₂, Fd Fragment Specific; Anti-Human IgG₃, Hinge Specific; Anti-Human IgG₄, Fc Fragment Specific;
 20 Anti-Human IgM, Fc Fragment Specific; Anti-Human IgM, μ -Chain Specific; Anti-Mouse IgE, ϵ -Chain Specific; Anti-Mouse γ -Globulin (Goat); Anti-Mouse IgG, γ -Chain Specific (Goat); Anti-Mouse IgG, γ -Chain Specific (Goat) F(ab')₂ Fragment; Anti-Mouse IgG, H & L Chain Specific (Goat); Anti-Mouse IgM, μ -Chain Specific (Goat); Anti-Mouse IgM, H & L Chain Specific (Goat); Anti-Rabbit γ -Globulin
 25 (Goat); Anti-Rabbit IgG, Fc Fragment Specific (Goat); Anti-Rabbit IgG, H & L Chain Specific (Goat); Anti-Rat γ -Globulin (Goat); Anti-Rat IgG, H & L Chain Specific; Anti-Rhesus Monkey γ -Globulin (Goat); and, Anti-Sheep IgG, H & L Chain Specific.

Antibodies that bind a particular ligand may also be produced. Exemplary ligands are as follows: adrenomedulin, amylin, calcitonin, amyloid, calcitonin gene-
 30 related peptide, cholecystokinin, gastrin, gastric inhibitory peptide, gastrin releasing peptide, interleukin, interferon, cortistatin, somatostatin, endothelin, sarafotoxin, glucagon, glucagon-like peptide, insulin, atrial natriuretic peptide, BNP, CNP, neurokinin, substance P, leptin, neuropeptide Y, melanin concentrating hormone,

melanocyte stimulating hormone, orphanin, endorphin, dynorphin, enkephalin, enkephalin, leumorphin, peptide F, PACAP, PACAP-related peptide, parathyroid hormone, urocortin, corticotrophin releasing hormone, PHM, PHI, vasoactive intestinal polypeptide, secretin, ACTH, angiotensin, angiostatin, bombesin, endostatin, bradykinin, FMRF amide, galanin, gonadotropin releasing hormone (GnRH) associated peptide, GnRH, growth hormone releasing hormone, inhibin, granulocyte-macrophage colony stimulating factor (GM-CSF), motilin, neurotensin, oxytocin, vasopressin, osteocalcin, pancreastatin, pancreatic polypeptide, peptide YY, proopiomelanocortin, transforming growth factor, vascular endothelial growth factor, vesicular monoamine transporter, vesicular acetylcholine transporter, ghrelin, NPW, NPB, C3d, prokineticin, thyroid stimulating hormone, luteinizing hormone, follicle stimulating hormone, prolactin, growth hormone, beta-lipotropin, melatonin, kallikriens, kinins, prostaglandins, erythropoietin, p146 (SEQ ID NO:78 amino acid sequence, SEQ ID NO:79, nucleotide sequence), estrogen, testosterone, corticosteroids, mineralocorticoids, thyroid hormone, thymic hormones, connective tissue proteins, nuclear proteins, actin, avidin, activin, agrin, albumin, and prohormones, propeptides, splice variants, fragments and analogs thereof.

The following is yet another non-limiting of antibodies that can be produced by the methods of present invention: abciximab (ReoPro), abciximab anti-platelet aggregation monoclonal antibody, anti-CD11a (hu1124), anti-CD18 antibody, anti-CD20 antibody, anti-cytomegalovirus (CMV) antibody, anti-digoxin antibody, anti-hepatitis B antibody, anti-HER-2 antibody, anti-idiotypic antibody to GD3 glycolipid, anti-IgE antibody, anti-IL-2R antibody, antimetastatic cancer antibody (mAb 17-1A), anti-rabies antibody, anti-respiratory syncytial virus (RSV) antibody, anti-Rh antibody, anti-TCR, anti-TNF antibody, anti-VEGF antibody and Fab fragment thereof, rattlesnake venom antibody, black widow spider venom antibody, coral snake venom antibody, antibody against very late antigen-4 (VLA-4), C225 humanized antibody to EGF receptor, chimeric (human & mouse) antibody against TNF α , antibody directed against GPIIb/IIIa receptor on human platelets, gamma globulin, anti-hepatitis B immunoglobulin, human anti-D immunoglobulin, human antibodies against *S aureus*, human tetanus immunoglobulin, humanized antibody against the epidermal growth receptor-2, humanized antibody against the α subunit of the interleukin-2 receptor, humanized antibody CTLA4IG, humanized antibody to the

IL-2 R α -chain, humanized anti-CD40-ligand monoclonal antibody (5c8), humanized mAb against the epidermal growth receptor-2, humanized mAb to rous sarcoma virus, humanized recombinant antibody (IgG1k) against respiratory syncytial virus (RSV), lymphocyte immunoglobulin (anti-thymocyte antibody), lymphocyte
5 immunoglobulin, mAb against factor VII, MDX-210 bi-specific antibody against HER-2, MDX-22, MDX-220 bi-specific antibody against TAG-72 on tumors, MDX-33 antibody to Fc γ R1 receptor, MDX-447 bi-specific antibody against EGF receptor, MDX-447 bispecific humanized antibody to EGF receptor, MDX-RA immunotoxin (ricin A linked) antibody, Medi-507 antibody (humanized form of BTI-322) against
10 CD2 receptor on T-cells, monoclonal antibody LDP-02, muromonab-CD3(OKT3) antibody, OKT3 ("muromomab-CD3") antibody, PRO 542 antibody, ReoPro ("abciximab") antibody, and TNF-IgG fusion protein.

Another non-limiting list of the antibodies that may be produced using the present invention is provided in product catalogs of companies such as Phoenix
15 Pharmaceuticals, Inc. (www.phoenixpeptide.com; 530 Harbor Boulevard, Belmont, CA), Peninsula Labs San Carlos CA, SIGMA, St.Louis, MO www.sigma-aldrich.com, Cappel ICN, Irvine, California, www.icnbiomed.com, and Calbiochem, La Jolla, California, www.calbiochem.com, which are all incorporated herein by reference in their entirety. The polynucleotide sequences encoding these antibodies
20 may be obtained from the scientific literature, from patents, and from databases such as GenBank. Alternatively, one of ordinary skill in the art may design the antibody polynucleotide sequence by choosing the codons that encode for each amino acid in the desired antibody.

Genes encoding protein and peptide hormones are a preferred class of genes of
25 interest in the present invention. Such protein and peptide hormones are synthesized throughout the endocrine system and include, but are not limited to, hypothalamic hormones and hypophysiotropic hormones, anterior, intermediate and posterior pituitary hormones, pancreatic islet hormones, hormones made in the gastrointestinal system, renal hormones, thymic hormones, parathyroid hormones, adrenal cortical
30 and medullary hormones. Specifically, hormones that can be produced using the present invention include, but are not limited to, chorionic gonadotropin, corticotropin, erythropoietin, glucagons, IGF-1, oxytocin, platelet-derived growth factor, calcitonin, follicle-stimulating hormone, luteinizing hormone, thyroid-

stimulating hormone, insulin, gonadotropin-releasing hormone and its analogs, vasopressin, octreotide, somatostatin, prolactin, adrenocorticotrophic hormone, antidiuretic hormone, thyrotropin-releasing hormone (TRH), growth hormone-releasing hormone (GHRH), dopamine, melatonin, thyroxin (T₄), parathyroid hormone (PTH), glucocorticoids such as cortisol, mineralocorticoids such as aldosterone, androgens such as testosterone, adrenaline (epinephrine), noradrenaline (norepinephrine), estrogens such as estradiol, progesterone, glucagons, calcitriol, calciferol, atrial-natriuretic peptide, gastrin, secretin, cholecystokinin (CCK), neuropeptide Y, ghrelin, PYY₃₋₃₆, angiotensinogen, thrombopoietin, and leptin. By using appropriate polynucleotide sequences, species-specific hormones may be made by transgenic animals.

In one embodiment of the present invention, the gene of interest is a proinsulin gene and the desired molecule is insulin. Proinsulin consists of three parts: a C-peptide and two strands of amino acids (the alpha and beta chains) that later become linked together to form the insulin molecule. In these embodiments, proinsulin is expressed in the oviduct tubular gland cells and then deposited in the egg white. One example of a proinsulin polynucleotide sequence is shown in SEQ ID NO:80, wherein the C-peptide cleavage site spans from Arg at position 31 to Arg at position 65.

Further included in the present invention are genes of interest that encode proteins and peptides synthesized by the immune system including those synthesized by the thymus, lymph nodes, spleen, and the gastrointestinal associated lymph tissues (GALT) system. The immune system proteins and peptides that can be made in transgenic animals using the polynucleotide cassettes of the present invention include, but are not limited to, alpha-interferon, beta-interferon, gamma-interferon, alpha-interferon A, alpha-interferon 1, G-CSF, GM-CSF, interleukin-1 (IL-1), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, TNF- α , and TNF- β . Other cytokines included in the present invention include cardiotrophin, stromal cell derived factor, macrophage derived chemokine (MDC), melanoma growth stimulatory activity (MGSA), macrophage inflammatory proteins 1 alpha (MIP-1 alpha), 2, 3 alpha, 3 beta, 4 and 5.

Genes encoding lytic peptides such as p146 are also included in the genes of interest of the present invention. In one embodiment, the p146 peptide comprises an amino acid sequence of SEQ ID NO:78. The present invention also encompasses a

polynucleotide cassette comprising a p146 nucleic acid having a sequence of SEQ ID NO:79.

Enzymes are another class of proteins that may be encoded by the polynucleotide cassettes of the present invention. Such enzymes include but are not
5 limited to adenosine deaminase, alpha-galactosidase, cellulase, collagenase, dnaseI, hyaluronidase, lactase, L-asparaginase, pancreatin, papain, streptokinase B, subtilisin, superoxide dismutase, thrombin, trypsin, urokinase, fibrinolysin, glucocerebrosidase and plasminogen activator. In some embodiments wherein the enzyme could have deleterious effects, additional amino acids and a protease cleavage site are added to
10 the carboxy end of the enzyme of interest in order to prevent expression of a functional enzyme. Subsequent digestion of the enzyme with a protease results in activation of the enzyme.

Extracellular matrix proteins are one class of desired proteins that may be encoded by the polynucleotide cassettes of the present invention. Examples include
15 but are not limited to collagen, fibrin, elastin, laminin, and fibronectin and subtypes thereof. Intracellular proteins and structural proteins are other classes of desired proteins in the present invention.

Growth factors are another desired class of proteins that may be encoded by the polynucleotide cassettes of the present invention and include, but are not limited
20 to, transforming growth factor- α ("TGF- α "), transforming growth factor- β (TGF- β), platelet-derived growth factors (PDGF), fibroblast growth factors (FGF), including FGF acidic isoforms 1 and 2, FGF basic form 2 and FGF 4, 8, 9 and 10, nerve growth factors (NGF) including NGF 2.5s, NGF 7.0s and beta NGF and neurotrophins, brain derived neurotrophic factor, cartilage derived factor, growth factors for stimulation of
25 the production of red blood cells, growth factors for stimulation of the production of white blood cells, bone growth factors (BGF), basic fibroblast growth factor, vascular endothelial growth factor (VEGF), granulocyte colony stimulating factor (G-CSF), insulin like growth factor (IGF) I and II, hepatocyte growth factor, glial neurotrophic growth factor (GDNF), stem cell factor (SCF), keratinocyte growth factor (KGF),
30 transforming growth factors (TGF), including TGFs alpha, beta, beta1, beta2, beta3, skeletal growth factor, bone matrix derived growth factors, bone derived growth factors, erythropoietin (EPO) and mixtures thereof.

Another desired class of proteins that may be encoded by the polynucleotide cassettes of the present invention include, but are not limited to, leptin, leukemia inhibitory factor (LIF), tumor necrosis factor alpha and beta, ENBREL, angiostatin, endostatin, thrombospondin, osteogenic protein-1, bone morphogenetic proteins 2 and 7, osteonectin, somatomedin-like peptide, and osteocalcin.

Yet another desired class of proteins encoded by the genes of interest are blood proteins or clotting cascade protein including albumin, Prekallikrein, High molecular weight kininogen (HMWK) (contact activation cofactor; Fitzgerald, Flaubeac Williams factor), Factor I (Fibrinogen), Factor II (prothrombin), Factor III (Tissue Factor), Factor IV (calcium), Factor V (proaccelerin, labile factor, accelerator (Ac-) globulin), Factor VI (Va) (accelerin), Factor VII (proconvertin), serum prothrombin conversion accelerator (SPCA), cothromboplastin), Factor VIII (antihemophilic factor A, antihemophilic globulin (AHG)), Factor IX (Christmas Factor, antihemophilic factor B, plasma thromboplastin component (PTC)), Factor X (Stuart-Prower Factor), Factor XI (Plasma thromboplastin antecedent (PTA)), Factor XII (Hageman Factor), Factor XIII (fibrin stabilizing factor (FSF), fibrinolytic factor), von Willebrand factor, Protein C, Protein S, Thrombomodulin, Antithrombin III.

A non-limiting list of the peptides and proteins that may be encoded by the polynucleotide cassettes of the present invention is provided in product catalogs of companies such as Phoenix Pharmaceuticals, Inc. (www.phoenixpeptide.com; 530 Harbor Boulevard, Belmont, CA), Peninsula Labs (San Carlos CA), SIGMA, (St. Louis, MO www.sigma-aldrich.com), Cappel ICN (Irvine, California, www.icnbiomed.com), and Calbiochem (La Jolla, California, www.calbiochem.com). The polynucleotide sequences encoding these proteins and peptides of interest may be obtained from the scientific literature, from patents, and from databases such as GenBank. Alternatively, one of ordinary skill in the art may design the polynucleotide sequence to be incorporated into the genome by choosing the codons that encode for each amino acid in the desired protein or peptide.

Some of these desired proteins or peptides that may be encoded by the polynucleotide cassettes of the present invention include but are not limited to the following: adrenomedullin, amylin, calcitonin, amyloid, calcitonin gene-related peptide, cholecystokinin, gastrin, gastric inhibitory peptide, gastrin releasing peptide,

interleukin, interferon, cortistatin, somatostatin, endothelin, sarafotoxin, glucagon, glucagon-like peptide, insulin, atrial natriuretic peptide, BNP, CNP, neurokinin, substance P, leptin, neuropeptide Y, melanin concentrating hormone, melanocyte stimulating hormone, orphanin, endorphin, dynorphin, enkephalin, leumorphin, peptide F, PACAP, PACAP-related peptide, parathyroid hormone, urocortin, corticotrophin releasing hormone, PHM, PHI, vasoactive intestinal polypeptide, secretin, ACTH, angiotensin, angiostatin, bombesin, endostatin, bradykinin, FMRF amide, galanin, gonadotropin releasing hormone (GnRH) associated peptide, GnRH, growth hormone releasing hormone, inhibin, granulocyte-macrophage colony stimulating factor (GM-CSF), motilin, neurotensin, oxytocin, vasopressin, osteocalcin, pancreastatin, pancreatic polypeptide, peptide YY, proopiomelanocortin, transforming growth factor, vascular endothelial growth factor, vesicular monoamine transporter, vesicular acetylcholine transporter, ghrelin, NPW, NPB, C3d, prokineticin, thyroid stimulating hormone, luteinizing hormone, follicle stimulating hormone, prolactin, growth hormone, beta-lipotropin, melatonin, kallikriens, kinins, prostaglandins, erythropoietin, p146 (SEQ ID NO:78, amino acid sequence, SEQ ID NO:79, nucleotide sequence), thymic hormones, connective tissue proteins, nuclear proteins, actin, avidin, activin, agrin, albumin, apolipoproteins, apolipoprotein A, apolipoprotein B, and prohormones, propeptides, splice variants, fragments and analogs thereof.

Other desired proteins that may be encoded by the polynucleotide cassettes of the present invention include bacitracin, polymixin b, vancomycin, cyclosporine, anti-RSV antibody, alpha-1 antitrypsin (AAT), anti-cytomegalovirus antibody, anti-hepatitis antibody, anti-inhibitor coagulant complex, anti-rabies antibody, anti-Rh(D) antibody, adenosine deaminase, anti-digoxin antibody, antivenin crotalidae (rattlesnake venom antibody), antivenin latrodectus (black widow spider venom antibody), antivenin micrurus (coral snake venom antibody), aprotinin, corticotropin (ACTH), diphtheria antitoxin, lymphocyte immune globulin (anti-thymocyte antibody), protamine, thyrotropin, capreomycin, α -galactosidase, gramicidin, streptokinase, tetanus toxoid, tyrothricin, IGF-1, proteins of varicella vaccine, anti-TNF antibody, anti-IL-2r antibody, anti-HER-2 antibody, OKT3 ("muromonab-CD3") antibody, TNF-IgG fusion protein, ReoPro ("abciximab") antibody, ACTH fragment 1-24, desmopressin, gonadotropin-releasing hormone, histrelin, leuprolide,

lypressin, nafarelin, peptide that binds GPIIb/GPIIIa on platelets (integrilin), goserelin, capreomycin, colistin, anti-respiratory syncytial virus, lymphocyte immune globulin (Thymoglovin, Atgam), panorex, alpha-antitrypsin, botulinin, lung surfactant protein, tumor necrosis receptor-IgG fusion protein (enbrel), gonadorelin, proteins of

5 influenza vaccine, proteins of rotavirus vaccine, proteins of haemophilus b conjugate vaccine, proteins of poliovirus vaccine, proteins of pneumococcal conjugate vaccine, proteins of meningococcal C vaccine, proteins of influenza vaccine, megakaryocyte growth and development factor (MGDF), neuroimmunophilin ligand-A (NIL-A), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor

10 (GDNF), leptin (native), leptin B, leptin C, IL-1RA (interleukin-1RA), R-568, novel erythropoiesis-stimulating protein (NESP), humanized mAb to rous sarcoma virus (MEDI-493), glutamyl-tryptophan dipeptide IM862, LFA-3TIP immunosuppressive, humanized anti-CD40-ligand monoclonal antibody (5c8), gelsonin enzyme, tissue factor pathway inhibitor (TFPI), proteins of meningitis B vaccine, antimetastatic

15 cancer antibody (mAb 17-1A), chimeric (human & mouse) mAb against TNF α , mAb against factor VII, relaxin, capreomycin, glycopeptide (LY333328), recombinant human activated protein C (rhAPC), humanized mAb against the epidermal growth receptor-2, altepase, anti-CD20 antigen, C2B8 antibody, insulin-like growth factor-1, atrial natriuretic peptide (anaritide), tenectapase, anti-CD11a antibody (hu 1124),

20 anti-CD18 antibody, mAb LDP-02, anti-VEGF antibody, Fab fragment of anti-VEGF Ab, APO2 ligand (tumor necrosis factor-related apoptosis-inducing ligand), rTGF- β (transforming growth factor- β), alpha-antitrypsin, ananain (a pineapple enzyme), humanized mAb CTLA4IG, PRO 542 (mAb), D2E7 (mAb), calf intestine alkaline phosphatase, α -L-iduronidase, α -L-galactosidase (humanglutamic acid decarboxylase,

25 acid sphingomyelinase, bone morphogenetic protein-2 (rhBMP-2), proteins of HIV vaccine, T cell receptor (TCR) peptide vaccine, TCR peptides, V beta 3 and V beta 13.1. (IR502), (IR501), BI 1050/1272 mAb against very late antigen-4 (VLA-4), C225 humanized mAb to EGF receptor, anti-idiotypic antibody to GD3 glycolipid, antibacterial peptide against *H. pylori*, MDX-447 bispecific humanized mAb to EGF

30 receptor, anti-cytomegalovirus (CMV), Medi-491 B19 parvovirus vaccine, humanized recombinant mAb (IgG1k) against respiratory syncytial virus (RSV), urinary tract infection vaccine (against "pili" on *Escherichia coli* strains), proteins of lyme disease vaccine against *B. burgdorferi* protein (DbpA), proteins of Medi-501 human

papilloma virus-11 vaccine (HPV), *Streptococcus pneumoniae* vaccine, Medi-507 mAb (humanized form of BTI-322) against CD2 receptor on T-cells, MDX-33 mAb to Fc γ R1 receptor, MDX-RA immunotoxin (ricin A linked) mAb, MDX-210 bi-specific mAb against HER-2, MDX-447 bi-specific mAb against EGF receptor, 5 MDX-22, MDX-220 bi-specific mAb against TAG-72 on tumors, colony-stimulating factor (CSF) (molgramostim), humanized mAb to the IL-2 R α -chain (basiliximab), mAb to IgE (IGE 025A), myelin basic protein-altered peptide (MSP771A), humanized mAb against the epidermal growth receptor-2, humanized mAb against the α subunit of the interleukin-2 receptor, low molecular weight heparin, anti- 10 hemophilic factor, and bactericidal/permeability-increasing protein (r-BPI).

Other multimeric proteins that may be produced using the present invention are as follows: factors involved in the synthesis or replication of DNA, such as DNA polymerase alpha and DNA polymerase delta; proteins involved in the production of mRNA, such as TFIID and TFIIF; cell, nuclear and other membrane-associated 15 proteins, such as hormone and other signal transduction receptors, active transport proteins and ion channels, multimeric proteins in the blood, including hemoglobin, fibrinogen and von Willabrand's Factor; proteins that form structures within the cell, such as actin, myosin, and tubulin and other cytoskeletal proteins; proteins that form structures in the extra cellular environment, such as collagen, elastin and fibronectin; 20 proteins involved in intra- and extra-cellular transport, such as kinesin and dynein, the SNARE family of proteins (soluble NSF attachment protein receptor) and clathrin; proteins that help regulate chromatin structure, such as histones and protamines, Swi3p, Rsc8p and moira; multimeric transcription factors such as Fos, Jun and CBTF (CCAAT box transcription factor); multimeric enzymes such as acetylcholinesterase 25 and alcohol dehydrogenase; chaperone proteins such as GroE, Gro EL (chaperonin 60) and Gro ES(chaperonin 10); anti-toxins, such as snake venom, botulism toxin, *Streptococcus* super antigens; lysins (enzymes from bacteriophage and viruses); as well as most allosteric proteins.

The multimeric proteins made using the present invention may be labeled 30 using labels and techniques known to one of ordinary skill in the art. Some of these labels are described in the "Handbook of Fluorescent Probes and Research Products", ninth edition, Richard P. Haugland (ed) Molecular Probes, Inc. Eugene, OR), which is incorporated herein in its entirety. Some of these labels may be genetically

engineered into the polynucleotide sequence for the expression of the selected multimeric protein. The peptides and proteins may also have label-incorporation "handles" incorporated to allow labeling of an otherwise difficult or impossible to label multimeric protein.

5 It is to be understood that the various classes of desired peptides and proteins, as well as specific peptides and proteins described in this section may be modified as described below by inserting selected codons for desired amino acid substitutions into the gene incorporated into the transgenic animal.

10 The present invention may also be used to produce desired molecules other than proteins and peptides including, but not limited to, lipoproteins such as high density lipoprotein (HDL), HDL-Milano, and low density lipoprotein, lipids, carbohydrates, siRNA and ribozymes. In these embodiments, a gene of interest encodes a nucleic acid molecule or a protein that directs production of the desired molecule.

15 The present invention further encompasses the use of inhibitory molecules to inhibit endogenous (i.e., non-vector) protein production. These inhibitory molecules include antisense nucleic acids, siRNA and inhibitory proteins. In a preferred embodiment, the endogenous protein whose expression is inhibited is an egg white protein including, but not limited to ovalbumin, ovotransferrin, and ovomucin
20 ovomucoid, ovoinhibitor, cystatin, ovostatin, lysozyme, ovoglobulin G2, ovoglobulin G3, avidin, and thiamin binding protein. In one embodiment, a polynucleotide cassette containing an ovalbumin DNA sequence, that upon transcription forms a double stranded RNA molecule, is transfected into an animal such as a bird and the bird's production of endogenous ovalbumin protein is reduced by the interference
25 RNA mechanism (RNAi). In other embodiments, a polynucleotide cassette encodes an inhibitory RNA molecule that inhibits the expression of more than one egg white protein. Additionally, inducible knockouts or knockdowns of the endogenous protein may be created to achieve a reduction or inhibition of endogenous protein production. Endogenous egg white production can be inhibited in an avian at any time, but is
30 preferably inhibited preceding, or immediately preceding, the harvest of eggs.

Modified Desired Proteins and Peptides

 The present invention may be used for the production of multimeric proteins. "Proteins", "peptides", "polypeptides" and "oligopeptides" are chains of amino acids

(typically L-amino acids) whose alpha carbons are linked through peptide bonds formed by a condensation reaction between the carboxyl group of the alpha carbon of one amino acid and the amino group of the alpha carbon of another amino acid. The terminal amino acid at one end of the chain (i.e., the amino terminal) has a free amino group, while the terminal amino acid at the other end of the chain (i.e., the carboxy terminal) has a free carboxyl group. As such, the term "amino terminus" (abbreviated N-terminus) refers to the free alpha-amino group on the amino acid at the amino terminal of the protein, or to the alpha-amino group (imino group when participating in a peptide bond) of an amino acid at any other location within the protein. Similarly, the term "carboxy terminus" (abbreviated C-terminus) refers to the free carboxyl group on the amino acid at the carboxy terminus of a protein, or to the carboxyl group of an amino acid at any other location within the protein.

Typically, the amino acids making up a protein are numbered in order, starting at the amino terminal and increasing in the direction toward the carboxy terminal of the protein. Thus, when one amino acid is said to "follow" another, that amino acid is positioned closer to the carboxy terminal of the protein than the preceding amino acid.

The term "residue" is used herein to refer to an amino acid (D or L) or an amino acid mimetic that is incorporated into a protein by an amide bond. As such, the amino acid may be a naturally occurring amino acid or, unless otherwise limited, may encompass known analogs of natural amino acids that function in a manner similar to the naturally occurring amino acids (i.e., amino acid mimetics). Moreover, an amide bond mimetic includes peptide backbone modifications well known to those skilled in the art.

Furthermore, one of skill will recognize that, as mentioned above, individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids (typically less than about 5%, more typically less than about 1%) in an encoded sequence are conservatively modified variations where the alterations result in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. The following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Serine (S), Threonine (T);
- 2) Aspartic acid (D), Glutamic acid (E);

- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

5 A conservative substitution is a substitution in which the substituting amino acid (naturally occurring or modified) is structurally related to the amino acid being substituted, i.e., has about the same size and electronic properties as the amino acid being substituted. Thus, the substituting amino acid would have the same or a similar functional group in the side chain as the original amino acid. A “conservative
10 substitution” also refers to utilizing a substituting amino acid which is identical to the amino acid being substituted except that a functional group in the side chain is protected with a suitable protecting group.

 Suitable protecting groups are described in Green and Wuts, “Protecting Groups in Organic Synthesis”, John Wiley and Sons, Chapters 5 and 7, 1991, the
15 teachings of which are incorporated herein by reference. Preferred protecting groups are those which facilitate transport of the peptide through membranes, for example, by reducing the hydrophilicity and increasing the lipophilicity of the peptide, and which can be cleaved, either by hydrolysis or enzymatically (Ditter et al., 1968. J. Pharm. Sci. 57:783; Ditter et al., 1968. J. Pharm. Sci. 57:828; Ditter et al., 1969. J. Pharm.
20 Sci. 58:557; King et al., 1987. Biochemistry 26:2294; Lindberg et al., 1989. Drug Metabolism and Disposition 17:311; Tunek et al., 1988. Biochem. Pharm. 37:3867; Anderson et al., 1985 Arch. Biochem. Biophys. 239:538; and Singhal et al., 1987. FASEB J. 1:220). Suitable hydroxyl protecting groups include ester, carbonate and carbamate protecting groups. Suitable amine protecting groups include acyl groups
25 and alkoxy or aryloxy carbonyl groups, as described above for N-terminal protecting groups. Suitable carboxylic acid protecting groups include aliphatic, benzyl and aryl esters, as described below for C-terminal protecting groups. In one embodiment, the carboxylic acid group in the side chain of one or more glutamic acid or aspartic acid residues in a peptide of the present invention is protected, preferably as a methyl,
30 ethyl, benzyl or substituted benzyl ester, more preferably as a benzyl ester.

 Provided below are groups of naturally occurring and modified amino acids in which each amino acid in a group has similar electronic and steric properties. Thus, a conservative substitution can be made by substituting an amino acid with another

amino acid from the same group. It is to be understood that these groups are non-limiting, i.e. that there are additional modified amino acids which could be included in each group.

5 Group I includes leucine, isoleucine, valine, methionine and modified amino acids having the following side chains: ethyl, n-propyl n-butyl. Preferably, Group I includes leucine, isoleucine, valine and methionine.

Group II includes glycine, alanine, valine and a modified amino acid having an ethyl side chain. Preferably, Group II includes glycine and alanine.

10 Group III includes phenylalanine, phenylglycine, tyrosine, tryptophan, cyclohexylmethyl glycine, and modified amino residues having substituted benzyl or phenyl side chains. Preferred substituents include one or more of the following: halogen, methyl, ethyl, nitro, —NH_2 , methoxy, ethoxy and —CN . Preferably, Group III includes phenylalanine, tyrosine and tryptophan.

15 Group IV includes glutamic acid, aspartic acid, a substituted or unsubstituted aliphatic, aromatic or benzylic ester of glutamic or aspartic acid (e.g., methyl, ethyl, n-propyl iso-propyl, cyclohexyl, benzyl or substituted benzyl), glutamine, asparagine, —CO—NH— alkylated glutamine or asparagines (e.g., methyl, ethyl, n-propyl and iso-propyl) and modified amino acids having the side chain $\text{—(CH}_2\text{)}_3\text{—COOH}$, an ester thereof (substituted or unsubstituted
20 aliphatic, aromatic or benzylic ester), an amide thereof and a substituted or unsubstituted N-alkylated amide thereof. Preferably, Group IV includes glutamic acid, aspartic acid, methyl aspartate, ethyl aspartate, benzyl aspartate and methyl glutamate, ethyl glutamate and benzyl glutamate, glutamine and asparagine.

25 Group V includes histidine, lysine, ornithine, arginine, N-nitroarginine, β -cycloarginine, γ -hydroxyarginine, N-amidinocitruline and 2-amino-4-guanidinobutanoic acid, homologs of lysine, homologs of arginine and homologs of ornithine. Preferably, Group V includes histidine, lysine, arginine and ornithine. A homolog of an amino acid includes from 1 to about
30 3 additional or subtracted methylene units in the side chain.

Group VI includes serine, threonine, cysteine and modified amino acids having C1-C5 straight or branched alkyl side chains substituted with —OH or —SH , for

example, $-\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$ or $-\text{CH}_2\text{CH}_2\text{OHCH}_3$. Preferably, Group VI includes serine, cysteine or threonine.

In another aspect, suitable substitutions for amino acid residues include “severe” substitutions. A “severe substitution” is a substitution in which the substituting amino acid (naturally occurring or modified) has significantly different size and/or electronic properties compared with the amino acid being substituted. Thus, the side chain of the substituting amino acid can be significantly larger (or smaller) than the side chain of the amino acid being substituted and/or can have functional groups with significantly different electronic properties than the amino acid being substituted. Examples of severe substitutions of this type include the substitution of phenylalanine or cyclohexylmethyl glycine for alanine, isoleucine for glycine, a D amino acid for the corresponding L amino acid, or $-\text{NH}-\text{CH}[(\text{CH}_2)_5-\text{COOH}]-\text{CO}-$ for aspartic acid. Alternatively, a functional group may be added to the side chain, deleted from the side chain or exchanged with another functional group. Examples of severe substitutions of this type include adding of valine, leucine or isoleucine, exchanging the carboxylic acid in the side chain of aspartic acid or glutamic acid with an amine, or deleting the amine group in the side chain of lysine or ornithine. In yet another alternative, the side chain of the substituting amino acid can have significantly different steric and electronic properties that the functional group of the amino acid being substituted. Examples of such modifications include tryptophan for glycine, lysine for aspartic acid and $-(\text{CH}_2)_4\text{COOH}$ for the side chain of serine. These examples are not meant to be limiting.

In another embodiment, for example in the synthesis of a peptide 26 amino acids in length, the individual amino acids may be substituted according in the following manner:

- AA₁ is serine, glycine, alanine, cysteine or threonine;
- AA₂ is alanine, threonine, glycine, cysteine or serine;
- AA₃ is valine, arginine, leucine, isoleucine, methionine, ornithine, lysine, N-nitroarginine, β-cycloarginine, γ-hydroxyarginine, N-amidinocitruline or 2-amino-4-guanidinobutanoic acid;
- AA₄ is proline, leucine, valine, isoleucine or methionine;
- AA₅ is tryptophan, alanine, phenylalanine, tyrosine or glycine;

- AA₆ is serine, glycine, alanine, cysteine or threonine;
AA₇ is proline, leucine, valine, isoleucine or methionine;
AA₈ is alanine, threonine, glycine, cysteine or serine;
AA₉ is alanine, threonine, glycine, cysteine or serine;
- 5 AA₁₀ is leucine, isoleucine, methionine or valine;
AA₁₁ is serine, glycine, alanine, cysteine or threonine;
AA₁₂ is leucine, isoleucine, methionine or valine;
AA₁₃ is leucine, isoleucine, methionine or valine;
AA₁₄ is glutamine, glutamic acid, aspartic acid, asparagine, or a substituted or
10 unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid;
AA₁₅ is arginine, N-nitroarginine, β-cycloarginine, γ-hydroxy-arginine, N-amidinocitruline or 2-amino-4-guanidino-butanoic acid
AA₁₆ is proline, leucine, valine, isoleucine or methionine;
AA₁₇ is serine, glycine, alanine, cysteine or threonine;
- 15 AA₁₈ is glutamic acid, aspartic acid, asparagine, glutamine or a substituted or unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid;
AA₁₉ is aspartic acid, asparagine, glutamic acid, glutamine, leucine, valine, isoleucine, methionine or a substituted or unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid;
- 20 AA₂₀ is valine, arginine, leucine, isoleucine, methionine, ornithine, lysine, N-nitroarginine, β-cycloarginine, γ-hydroxyarginine, N-amidinocitruline or 2-amino-4-guanidinobutanoic acid;
AA₂₁ is alanine, threonine, glycine, cysteine or serine;
AA₂₂ is alanine, threonine, glycine, cysteine or serine;
- 25 AA₂₃ is histidine, serine, threonine, cysteine, lysine or ornithine;
AA₂₄ is threonine, aspartic acid, serine, glutamic acid or a substituted or unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid;
AA₂₅ is asparagine, aspartic acid,, glutamic acid, glutamine, leucine, valine, isoleucine, methionine or a substituted or unsubstituted aliphatic or aryl ester of
30 glutamic acid or aspartic acid; and
AA₂₆ is cysteine, histidine, serine, threonine, lysine or ornithine.

It is to be understood that these amino acid substitutions may be made for longer or shorter peptides than the 26 mer in the preceding example above, and for proteins.

In one embodiment of the present invention, codons for the first several N-terminal amino acids of the transposase are modified such that the third base of each
5 codon is changed to an A or a T without changing the corresponding amino acid. It is preferable that between approximately 1 and 20, more preferably 3 and 15, and most preferably between 4 and 12 of the first N-terminal codons of the gene of interest are modified such that the third base of each codon is changed to an A or a T without
10 changing the corresponding amino acid. In one embodiment, the first ten N-terminal codons of the gene of interest are modified in this manner.

When several desired proteins, protein fragments or peptides are encoded in the gene of interest to be incorporated into the genome, as with the multivalent multimeric proteins, one of skill in the art will appreciate that the proteins, protein
15 fragments or peptides may be separated by a spacer molecule such as, for example, a peptide, consisting of one or more amino acids. Generally, the spacer will have no specific biological activity other than to join the desired proteins, protein fragments or peptides together, or to preserve some minimum distance or other spatial relationship between them. However, the constituent amino acids of the spacer may be selected to
20 influence some property of the molecule such as the folding, net charge, or hydrophobicity. The spacer may also be contained within a nucleotide sequence with a purification handle or be flanked by proteolytic cleavage sites.

Such polypeptide spacers may have from about 1 to about 100 amino acids, preferably 3 to 20 amino acids, and more preferably 4-15 amino acids. The spacers in
25 a polypeptide are independently chosen, but are preferably all the same. The spacers should allow for flexibility of movement in space and are therefore typically rich in small amino acids, for example, glycine, serine, proline or alanine. Preferably, peptide spacers contain at least 60%, more preferably at least 80% glycine or alanine. In addition, peptide spacers generally have little or no biological and antigenic
30 activity. Preferred spacers are (Gly-Pro-Gly-Gly)_x (SEQ ID NO:81) and (Gly₄-Ser)_y, wherein x is an integer from about 3 to about 9 and y is an integer from about 1 to about 8. Specific examples of suitable spacers include

(Gly-Pro-Gly-Gly)₃

SEQ ID NO:82 Gly Pro Gly Gly Gly Pro Gly Gly Gly Pro Gly Gly

(Gly₄-Ser)₃

SEQ ID NO:83 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

5 or (Gly₄-Ser)₄

SEQ ID NO:84 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser.

One example of a multivalent multimeric protein containin a spacer is
leutinizing hormone (LH), normally made as separate alpha and beta chains, made as
10 a single polypeptide as described in Galet et. al., Mol. Cell Endocrinology, 2001, 174
(1-2):31-40. Production of a multimeric protein may thus be simplified using a spacer
sequence that may or may not contain cleavage sites. In the case of an
immunoglobulin, for example, a heavy and light chain may be synthesized as a single
polypeptide using a spacer sequence with protease sites native to the transgenic
15 animal so as to make, upon processing, a heavy and light chain combination in close
association, facilitating the addition of a similar heavy and light chain to produce the
native immunoglobulin. In this model, the removal of the spacer sequence may or
may not be required. Other multimeric proteins may be made in bioengineered
organisms in a similar fashion.

20 Nucleotide sequences encoding for the production of residues which may be
useful in purification of the expressed recombinant protein may also be built into the
vector. Such sequences are known in the art and include the glutathione binding
domain from glutathione S-transferase, polylysine, hexa-histidine or other cationic
amino acids, thioredoxin, hemagglutinin antigen and maltose binding protein.

25 Additionally, nucleotide sequences may be inserted into the gene of interest to
be incorporated so that the protein or peptide can also include from one to about six
amino acids that create signals for proteolytic cleavage. In this manner, if a gene is
designed to make one or more peptides or proteins of interest in the transgenic animal,
specific nucleotide sequences encoding for amino acids recognized by enzymes may
30 be incorporated into the gene to facilitate cleavage of the large protein or peptide
sequence into desired peptides or proteins or both. For example, nucleotides encoding
a proteolytic cleavage site can be introduced into the gene of interest so that a signal
sequence can be cleaved from a protein or peptide encoded by the gene of interest.

Nucleotide sequences encoding other amino acid sequences which display pH sensitivity, chemical sensitivity or photolability may also be added to the vector to facilitate separation of the signal sequence from the peptide or protein of interest.

Proteolytic cleavage sites include cleavage sites recognized by exopeptidases
5 such as carboxypeptidase A, carboxypeptidase B, aminopeptidase I, and
dipeptidylaminopeptidase; endopeptidases such as trypsin, V8-protease, enterokinase,
factor Xa, collagenase, endoproteinase, subtilisin, and thrombin; and proteases such as
Protease 3C IgA protease (Igase) Rhinovirus 3C(preScission)protease. Chemical
cleavage sites are also included in the definition of cleavage site as used herein.
10 Chemical cleavage sites include, but are not limited to, site cleaved by cyanogen
bromide, hydroxylamine, formic acid, and acetic acid. Self-splicing cleavage sites
such as inteins are also included in the present invention.

In some embodiments, one or more cleavage sites are incorporated into a
polynucleotide cassette containing multiple genes of interest. Figure 4 depicts one
15 example of a polynucleotide cassette containing two genes of interest containing a
cleavage site between them. The genes of interest may encode different proteins or
peptides, the same protein or peptide, or modified versions of the same protein or
peptide. While Figure 4 shows a polynucleotide cassette containing two genes of
interest, the present invention encompasses a polynucleotide cassette containing any
20 number of genes of interest. The cleavage site located between the genes of interest
can encode any amino acid sequence that is cleaved by any means. As mentioned
above, the cleavage site can encode an amino acid sequence cleaved by a protease, a
chemical reaction, can be a photolabile site. can be a pro polynucleotide


The present invention includes a polynucleotide cassette that encodes a
25 repetitive polypeptide chain in which two or more peptides, polypeptides or proteins,
designated as P in the structural formulae presented below, are each separated by a
peptide spacer or cleavage site designated as B. A polypeptide multivalent ligand,
also called a multivalent protein, is a form of a multimeric protein encoded by the
polynucleotide cassettes of the present invention, and is represented by structural
30 formulae (I, II and III). Each peptide or protein is connected to another peptide or
protein through a peptide bond, to a linker group, to a spacer, or to a cleavage site.
Each peptide, polypeptide or protein may be the same or different and each linker,
spacer, cleavage site or covalent bond is independently chosen.

A "polypeptide multivalent protein" is a multiple repeat polypeptide chain in which two or more peptides P are each separated by a peptide linker group, a spacer or a cleavage site. A polypeptide multivalent ligand is represented by structural formulae II and III.



wherein B is a peptide spacer or cleavage site, n is an integer from 2 to about 20, each L is a covalent bond, a linking group or cleavage site which may be present or absent, and each P is a peptide having from about 4 to about 200 amino acid residues.

10





wherein m is an integer from 0 to about 20.



wherein n is an integer from 1 to 20, preferably 2 to 10, more preferably 3 to 7, further wherein a is 1.

Other examples of multivalent proteins include the following:

20



In the preceding structural formulae IV and V of polypeptide multivalent ligands encoded by a polynucleotide cassette of the present invention, each P is a peptide having from about 4 to about 200 amino acid residues, y is 1, x is an integer from 1 to 3, and n is an integer from 1 to 20, preferably 2 to 10, more preferably 3 to 7. Each B is a peptide spacer or cleavage site comprised of at least 2 amino acids or a cleavage site. Each peptide P and each B are independently chosen and may be the same or different.

Suitable linkers (L) are groups that can connect peptides and proteins to each other. In one example, the linker is an oligopeptide of from about 1 to about 10 amino acids consisting of amino acids with inert side chains. Suitable oligopeptides include polyglycine, polyserine, polyproline, polyalanine and oligopeptides consisting of alanyl and/or serinyl and/or prolinyl and/or glycyl amino acid residues. m in structural formula II is an integer from 0 to about 20.

The peptides, polypeptides and proteins in a multivalent protein can be connected to each other by covalent bonds, linker groups, spacers, cleavage groups or a combination thereof. The linking groups can be the same or different.

A polypeptide spacer shown in structural formula (II) is a peptide having from about 5 to about 40 amino acid residues. The spacers in a polypeptide multivalent ligand are independently chosen, and may be the same or different. The spacers should allow for flexibility of movement in space for the flanking peptides, polypeptides and proteins P, and are therefore typically rich in small amino acids, for example, glycine, serine, proline or alanine. Preferably, peptide spacers contain at least 60%, more preferably at least 80% glycine or alanine. In addition, peptide spacers generally have little or no biological and antigenic activity. Preferred spacers are (Gly-Pro-Gly-Gly)_x (SEQ ID NO:81) and (Gly₄-Ser)_y, wherein x is an integer from about 3 to about 9 and y is an integer from about 1 to about 8. Specific examples of suitable spacers include (Gly₄-Ser)₃ (SEQ ID NO:82). Spacers can also include from one to about four amino acids that create a signal for proteolytic cleavage.

In another embodiment of the present invention, a TAG sequence is linked to a gene of interest. The TAG sequence serves three purposes: 1) it allows free rotation of the peptide or protein to be isolated so there is no interference from the native protein or signal sequence, i.e. vitellogenin, 2) it provides a "purification handle" to

isolate the protein using affinity purification, and 3) it includes a cleavage site to remove the desired protein from the signal and purification sequences. Accordingly, as used herein, a TAG sequence includes a spacer sequence, a purification handle and a cleavage site. The spacer sequences in the TAG proteins contain one or more repeats shown in SEQ ID NO:85. A preferred spacer sequence comprises the sequence provided in SEQ ID NO:86. One example of a purification handle is the gp41 hairpin loop from HIV I. Exemplary gp41 polynucleotide and polypeptide sequences are provided in SEQ ID NO:87 and SEQ ID NO:88, respectively. However, it should be understood that any antigenic region, or otherwise associative regions such as avidin/biotin, may be used as a purification handle, including any antigenic region of gp41. Preferred purification handles are those that elicit highly specific antibodies. Additionally, the cleavage site can be any protein cleavage site known to one of ordinary skill in the art and includes an enterokinase cleavage site comprising the Asp Asp Asp Asp Lys sequence (SEQ ID NO:89) and a furin cleavage site. In one embodiment of the present invention, the TAG sequence comprises a polynucleotide sequence of SEQ ID NO:90.

Methods of Administering Polynucleotide Cassettes

In addition to the polynucleotide cassettes described above, the present invention also includes methods of administering the polynucleotide cassettes to an animal, methods of producing a transgenic animal wherein a gene of interest is incorporated into the germline of the animal and methods of producing a transgenic animal wherein a gene of interest is incorporated into cells other than the germline cells of the animal. The polynucleotide cassettes may reside in any vector or delivery solution when administered or may be naked DNA. In one embodiment, a transposon-based vector containing the polynucleotide cassette between two insertion sequences recognized by a transposase is administered to an animal. The polynucleotide cassettes of the present invention may be administered to an animal via any method known to those of skill in the art, including, but not limited to, intraembryonic, intratesticular, intraoviduct, intraovarian, into the duct system of the mammary gland, intraperitoneal, intraarterial, intravenous, topical, oral, nasal, and pronuclear injection methods of administration, or any combination thereof. The polynucleotide cassettes may also be administered within the lumen of an organ, into an organ, into a body cavity, into the cerebrospinal fluid, through the urinary system,

through the genitourinary system, through the reproductive system, or through any route to reach the desired cells.

The polynucleotide cassettes may be delivered through the vascular system to be distributed to the cells supplied by that vessel. For example, the compositions may be placed in the artery supplying the ovary or supplying the fallopian tube to transfect cells in those tissues. In this manner, follicles could be transfected to create a germline transgenic animal. Alternatively, supplying the compositions through the artery leading to the oviduct would preferably transfect the tubular gland and epithelial cells. Such transfected cells could manufacture a desired protein or peptide for deposition in the egg white. Administration of the compositions through the portal vein would target uptake and transformation of hepatic cells. Administration through the urethra and into the bladder would target the transitional epithelium of the bladder. Administration through the vagina and cervix would target the lining of the uterus and the epithelial cells of the fallopian tube. Administration through the internal mammary artery or through the duct system of the mammary gland would transfect secretory cells of the lactating mammary gland to perform a desired function, such as to synthesize and secrete a desired protein or peptide into the milk.

The polynucleotide cassettes may be administered in a single administration, multiple administrations, continuously, or intermittently. The polynucleotide cassettes may be administered by injection, via a catheter, an osmotic mini-pump or any other method. In some embodiments, a polynucleotide cassette is administered to an animal in multiple administrations, each administration containing the polynucleotide cassette and a different transfecting reagent.

In a preferred embodiment, the animal is an egg-laying animal, and more preferably, an avian. In one embodiment, between approximately 1 and 150 μg , 1 and 100 μg , 1 and 50 μg , preferably between 1 and 20 μg , and more preferably between 5 and 10 μg of a transposon-based vector containing the polynucleotide cassette is administered to the oviduct of a bird. In a chicken, it is preferred that between approximately 1 and 100 μg , or 5 and 50 μg are administered. In a quail, it is preferred that between approximately 5 and 10 μg are administered. Optimal ranges depending upon the type of bird and the bird's stage of sexual maturity. Intraoviduct administration of the transposon-based vectors of the present invention result in a PCR positive signal in the oviduct tissue, whereas intravascular administration results

in a PCR positive signal in the liver. In other embodiments, the polynucleotide cassette is administered to an artery that supplies the oviduct or the liver. These methods of administration may also be combined with any methods for facilitating transfection, including without limitation, electroporation, gene guns, injection of
5 naked DNA, and use of dimethyl sulfoxide (DMSO).

The transposon-based vectors may be administered to the animal at any point during the lifetime of the animal, however, it is preferable that the vectors are administered prior to the animal reaching sexual maturity. The transposon-based vectors are preferably administered to a chicken oviduct between approximately 14
10 and 16 weeks of age and to a quail oviduct between approximately 5 and 10 weeks of age, more preferably 5 and 8 weeks of age, and most preferably between 5 and 6 weeks of age, when standard poultry rearing practices are used. The vectors may be administered at earlier ages when exogenous hormones are used to induce early sexual maturation in the bird. In some embodiments, the transposon-based vector is
15 administered to an animal's oviduct following an increase in proliferation of the oviduct epithelial cells and/or the tubular gland cells. Such an increase in proliferation normally follows an influx of reproductive hormones in the area of the oviduct. When the animal is an avian, the transposon-based vector is administered to the avian's oviduct following an increase in proliferation of the oviduct epithelial cells
20 and before the avian begins to produce egg white constituents.

The present invention also includes a method of intraembryonic administration of a transposon-based vector containing a polynucleotide cassette to an avian embryo comprising the following steps: 1) incubating an egg on its side at room temperature for two hours to allow the embryo contained therein to move to top dead center
25 (TDC); 2) drilling a hole through the shell without penetrating the underlying shell membrane; 3) injecting the embryo with the transposon-based vector in solution; 4) sealing the hole in the egg; and 5) placing the egg in an incubator for hatching. Administration of the transposon-based vector can occur anytime between immediately after egg lay (when the embryo is at Stage X) and hatching. Preferably,
30 the transposon-based vector is administered between 1 and 7 days after egg lay, more preferably between 1 and 2 days after egg lay. The transposon-based vectors may be introduced into the embryo in amounts ranging from about 5.0 µg to 10 pg, preferably 1.0 µg to 100 pg. Additionally, the transposon-based vector solution volume may be

between approximately 1 μ l to 75 μ l in quail and between approximately 1 μ l to 500 μ l in chicken.

The present invention also includes a method of intratesticular administration of a transposon-based vector containing a polynucleotide cassette including injecting
5 a bird with a composition comprising the transposon-based vector, an appropriate carrier and an appropriate transfection reagent. In one embodiment, the bird is injected before sexual maturity, preferably between approximately 4-14 weeks, more preferably between approximately 6-14 weeks and most preferably between 8-12 weeks old. In another embodiment, a mature bird is injected with a transposon-based
10 vector an appropriate carrier and an appropriate transfection reagent. The mature bird may be any type of bird, but in one example the mature bird is a quail.

A bird is preferably injected prior to the development of the blood-testis barrier, which thereby facilitates entry of the transposon-based vector into the seminiferous tubules and transfection of the spermatogonia or other germline cells.
15 At and between the ages of 4, 6, 8, 10, 12, and 14 weeks, it is believed that the testes of chickens are likely to be most receptive to transfection. In this age range, the blood/testis barrier has not yet formed, and there is a relatively high number of spermatogonia relative to the numbers of other cell types, e.g., spermatids, etc. See J. Kumaran et al., 1949. Poultry Sci., 29:511-520. See also E. Oakberg, 1956. Am. J. Anatomy, 99:507-515; and P. Kluin et al., 1984. Anat. Embryol., 169:73-78.
20

The transposon-based vectors may be introduced into a testis in an amount ranging from about 0.1 μ g to 10 μ g, preferably 1 μ g to 10 μ g, more preferably 3 μ g to 10 μ g. In a quail, about 5 μ g is a preferred amount. In a chicken, about 5 μ g to 10 μ g per testis is preferred. These amounts of vector DNA may be injected in one dose or
25 multiple doses and at one site or multiple sites in the testis. In a preferred embodiment, the vector DNA is administered at multiple sites in a single testis, both testes being injected in this manner. In one embodiment, injection is spread over three injection sites: one at each end of the testis, and one in the middle. Additionally, the transposon-based vector solution volume may be between approximately 1 μ l to
30 75 μ l in quail and between approximately 1 μ l to 500 μ l in chicken. In a preferred embodiment, the transposon-based vector solution volume may be between approximately 20 μ l to 60 μ l in quail and between approximately 50 μ l to 250 μ l in

chicken. Both the amount of vector DNA and the total volume injected into each testis may be determined based upon the age and size of the bird.

According to the present invention, the polynucleotide cassette is administered in conjunction with an acceptable carrier and/or transfection reagent. Acceptable carriers include, but are not limited to, water, saline, Hanks Balanced Salt Solution (HBSS), Tris-EDTA (TE) and lyotropic liquid crystals. Transfection reagents commonly known to one of ordinary skill in the art that may be employed include, but are not limited to, the following: cationic lipid transfection reagents, cationic lipid mixtures, polyamine reagents, liposomes and combinations thereof; SUPERFECT®, Cytofectene, BioPORTER®, GenePORTER®, NeuroPORTER®, and perfectin from Gene Therapy Systems; lipofectamine, cellfectin, DMRIE-C oligofectamine, and PLUS reagent from InVitrogen; Xtreme gene, fugene, DOSPER and DOTAP from Roche; Lipotaxi and Genejammer from Strategene; and Escort from SIGMA. In one embodiment, the transfection reagent is SUPERFECT®. The ratio of DNA to transfection reagent may vary based upon the method of administration. In one embodiment, a transposon-based vector containing a polynucleotide cassette is administered intratesticularly and the ratio of DNA to transfection reagent can be from 1:1.5 to 1:15, preferably 1:2 to 1:10, all expressed as wt/vol. Transfection may also be accomplished using other means known to one of ordinary skill in the art, including without limitation electroporation, gene guns, injection of naked DNA, and use of dimethyl sulfoxide (DMSO).

Depending upon the cell or tissue type targeted for transfection, the form of the transposon-based vector may be important. Plasmids harvested from bacteria are generally closed circular supercoiled molecules, and this is the preferred state of a vector for gene delivery because of the ease of preparation. In some instances, transposase expression and insertion may be more efficient in a relaxed, closed circular configuration or in a linear configuration. In still other instances, a purified transposase protein may be co-injected with a transposon-based vector containing the gene of interest for more immediate insertion. This could be accomplished by using a transfection reagent complexed with both the purified transposase protein and the transposon-based vector.

Testing for and Breeding Animals Carrying the Transgene

Following administration of a polynucleotide cassette to an animal, DNA is extracted from the animal to confirm integration of the genes of interest. Advantages provided by the present invention include the high rates of integration, or
5 incorporation, and transcription of the gene of interest when administered to a bird via an intraoviduct or intraovary route (including intraarterial administrations to arteries leading to the oviduct or ovary) and contained within a transposon-based vector.

Actual frequencies of integration can be estimated both by comparative strength of the PCR signal, and by histological evaluation of the tissues by
10 quantitative PCR. Another method for estimating the rate of transgene insertion is the so-called primed in situ hybridization technique (PRINS). This method determines not only which cells carry a transgene of interest, but also into which chromosome the gene has inserted, and even what portion of the chromosome. Briefly, labeled primers are annealed to chromosome spreads (affixed to glass slides) through one round of
15 PCR, and the slides are then developed through normal in situ hybridization procedures. This technique combines the best features of in situ PCR and fluorescence in situ hybridization (FISH) to provide distinct chromosome location and copy number of the gene in question. The 28s rRNA gene will be used as a positive control for spermatogonia to confirm that the technique is functioning properly.
20 Using different fluorescent labels for the transgene and the 28s gene causes cells containing a transgene to fluoresce with two different colored tags.

Breeding experiments may also be conducted to determine if germline transmission of the transgene has occurred. In a general bird breeding experiment performed according to the present invention, each male bird is exposed to 2-3
25 different adult female birds for 3-4 days each. This procedure is continued with different females for a total period of 6-12 weeks. Eggs are collected daily for up to 14 days after the last exposure to the transgenic male, and each egg is incubated in a standard incubator. The resulting embryos are examined for transgene presence at day 3 or 4 using PCR.

30 Any male producing a transgenic embryo is bred to additional females. Eggs from these females are incubated, hatched, and the chicks tested for the exogenous DNA. Any embryos that die are necropsied and examined directly for the transgene or protein encoded by the transgene, either by fluorescence or PCR. The offspring

that hatch and are found to be positive for the exogenous DNA are raised to maturity. These birds are bred to produce further generations of transgenic birds, to verify efficiency of the transgenic procedure and the stable incorporation of the transgene into the germ line. The resulting embryos are examined for transgene presence at day
5 3 or 4 using PCR.

It is to be understood that the above procedure can be modified to suit animals other than birds and that selective breeding techniques may be performed to amplify gene copy numbers and protein output.

Production of Desired Multimeric Proteins in Egg White

10 In one embodiment, a transposon-based vector containing a polynucleotide cassette of the present invention may be administered to a bird for production of desired proteins or peptides in the egg white. These transposon-based vectors preferably contain one or more of an ovalbumin promoter, an ovomucoid promoter, an ovalbumin signal sequence and an ovomucoid signal sequence. Oviduct-specific
15 ovalbumin promoters are described in B. O'Malley et al., 1987. EMBO J., vol. 6, pp. 2305-12; A. Qiu et al., 1994. Proc. Nat. Acad. Sci. (USA), vol. 91, pp. 4451-4455; D. Monroe et al., 2000. Biochim. Biophys. Acta, 1517 (1):27-32; H. Park et al., 2000. Biochem., 39:8537-8545; and T. Muramatsu et al., 1996. Poult. Avian Biol. Rev., 6:107-123.

20 Production of Desired Multimeric Proteins in Egg Yolk

The present invention is particularly advantageous for production of recombinant peptides and proteins of low solubility in the egg yolk. Such proteins include, but are not limited to, membrane-associated or membrane-bound proteins, lipophilic compounds; attachment factors, receptors, and components of second
25 messenger transduction machinery. Low solubility peptides and proteins are particularly challenging to produce using conventional recombinant protein production techniques (cell and tissue cultures) because they aggregate in water-based, hydrophilic environments. Such aggregation necessitates denaturation and re-folding of the recombinantly-produced proteins, which may deleteriously affect their
30 structure and function. Moreover, even highly soluble recombinant peptides and proteins may precipitate and require denaturation and renaturation when produced in sufficiently high amounts in recombinant protein production systems. The present

invention provides an advantageous resolution of the problem of protein and peptide solubility during production of large amounts of recombinant proteins.

In one embodiment of the present invention, deposition of a desired protein into the egg yolk is accomplished by attaching a sequence encoding a protein capable
5 of binding to the yolk vitellogenin receptor to a gene of interest that encodes a desired protein. This polynucleotide cassette can be used for the receptor-mediated uptake of the desired protein by the oocytes. In a preferred embodiment, the sequence ensuring the binding to the vitellogenin receptor is a targeting sequence of a vitellogenin protein. The invention encompasses various vitellogenin proteins and their targeting
10 sequences. In a preferred embodiment, a chicken vitellogenin protein targeting sequence is used, however, due to the high degree of conservation among vitellogenin protein sequences and known cross-species reactivity of vitellogenin targeting sequences with their egg-yolk receptors, other vitellogenin targeting sequences can be substituted. One example of a construct for use in the transposon-based vectors of the
15 present invention and for deposition of an insulin protein in an egg yolk is a transposon-based vector containing a vitellogenin promoter, a vitellogenin targeting sequence, a TAG sequence, a pro-insulin sequence and a synthetic polyA sequence. The present invention includes, but is not limited to, vitellogenin targeting sequences residing in the N-terminal domain of vitellogenin, particularly in lipovitellin I. In one
20 embodiment, the vitellogenin targeting sequence contains the polynucleotide sequence of SEQ ID NO:77.

In a preferred embodiment, the transposon-based vector contains a transposase gene operably-linked to a constitutive promoter and a gene of interest operably-linked to a liver-specific promoter and a vitellogenin targeting sequence.

25 Isolation and Purification of Desired Multimeric Proteins

For large-scale production of protein, an animal breeding stock that is homozygous for the transgene is preferred. Such homozygous individuals are obtained and identified through, for example, standard animal breeding procedures or PCR protocols.

30 Once expressed, peptides, polypeptides and proteins can be purified according to standard procedures known to one of ordinary skill in the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis, high performance liquid chromatography, immunoprecipitation and the like.

Substantially pure compositions of about 50 to 99% homogeneity are preferred, and 80 to 95% or greater homogeneity are most preferred for use as therapeutic agents.

In one embodiment of the present invention, the animal in which the desired protein is produced is an egg-laying animal. In a preferred embodiment of the present invention, the animal is an avian and a desired peptide, polypeptide or protein is
5 isolated from an egg white. Egg white containing the exogenous protein or peptide is separated from the yolk and other egg constituents on an industrial scale by any of a variety of methods known in the egg industry. See, e.g., W. Stadelman et al. (Eds.), Egg Science & Technology, Haworth Press, Binghamton, NY (1995). Isolation of the
10 exogenous peptide or protein from the other egg white constituents is accomplished by any of a number of polypeptide isolation and purification methods well known to one of ordinary skill in the art. These techniques include, for example, chromatographic methods such as gel permeation, ion exchange, affinity separation, metal chelation, HPLC, and the like, either alone or in combination. Another means
15 that may be used for isolation or purification, either in lieu of or in addition to chromatographic separation methods, includes electrophoresis. Successful isolation and purification is confirmed by standard analytic techniques, including HPLC, mass spectroscopy, and spectrophotometry. These separation methods are often facilitated if the first step in the separation is the removal of the endogenous ovalbumin fraction
20 of egg white, as doing so will reduce the total protein content to be further purified by about 50%.

To facilitate or enable purification of a desired protein or peptide, the polynucleotide cassettes may include one or more additional epitopes or domains. Such epitopes or domains include DNA sequences encoding enzymatic, chemical or
25 photolabile cleavage sites including, but not limited to, an enterokinase cleavage site; the glutathione binding domain from glutathione S-transferase; polylysine; hexahistidine or other cationic amino acids, and sites cleaved by cyanogen bromide, hydroxylamine, formic acid, and acetic acid; thioredoxin; hemagglutinin antigen; maltose binding protein; a fragment of gp41 from HIV; and other purification
30 epitopes or domains commonly known to one of skill in the art. Other proteolytic cleavage sites that may be included in the polynucleotide cassettes are cleavage sites recognized by exopeptidases such as carboxypeptidase A, carboxypeptidase B, aminopeptidase I, and dipeptidylaminopeptidase; endopeptidases such as trypsin, V8-

protease, enterokinase, factor Xa, collagenase, endoproteinase, subtilisin, and thrombin; and proteases such as Protease 3C IgA protease (Igase) Rhinovirus 3C(preScission)protease. Self-splicing cleavage sites such as inteins may also be included in the polynucleotide cassettes of the present invention.

5 In one representative embodiment, purification of desired proteins from egg white utilizes the antigenicity of the ovalbumin carrier protein and particular attributes of a TAG linker sequence that spans ovalbumin and the desired protein. The TAG sequence is particularly useful in this process because it contains 1) a highly antigenic epitope, a fragment of gp41 from HIV, allowing for stringent affinity purification,
10 and, 2) a recognition site for the protease enterokinase immediately juxtaposed to the desired protein. In a preferred embodiment, the TAG sequence comprises approximately 50 amino acids. A representative TAG sequence is provided below.

Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp
15 Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Thr Thr Cys Ile Leu Lys Gly Ser Cys
Gly Trp Ile Gly Leu Leu *Asp Asp Asp Asp Lys* (SEQ ID NO:90)

The underlined sequences were taken from the hairpin loop domain of HIV gp-41 (SEQ ID NO:87). Sequences in italics represent the cleavage site for enterokinase
20 (SEQ ID NO:89). The spacer sequence upstream of the loop domain was made from repeats of (Pro Ala Asp Asp Ala) (SEQ ID NO:85) to provide free rotation and promote surface availability of the hairpin loop from the ovalbumin carrier protein.

Isolation and purification of a desired protein is performed as follows:

1. Enrichment of the egg white protein fraction containing ovalbumin and the
25 transgenic ovalbumin-TAG-desired protein.
2. Size exclusion chromatography to isolate only those proteins within a narrow range of molecular weights (a further enrichment of step 1).
3. Ovalbumin affinity chromatography. Highly specific antibodies to ovalbumin will eliminate virtually all extraneous egg white proteins except ovalbumin
30 and the transgenic ovalbumin-TAG-desired protein.
4. gp41 affinity chromatography using anti-gp41 antibodies. Stringent application of this step will result in virtually pure transgenic ovalbumin-TAG-desired protein.

5. Cleavage of the transgene product can be accomplished in at least one of two ways:

- a. The transgenic ovalbumin-TAG-desired protein is left attached to the gp41 affinity resin (beads) from step 4 and the protease enterokinase is added. This liberates the transgene target protein from the gp41 affinity resin while the ovalbumin-TAG sequence is retained. Separation by centrifugation (in a batch process) or flow through (in a column purification), leaves the desired protein together with enterokinase in solution. Enterokinase is recovered and reused.
 - b. Alternatively, enterokinase is immobilized on resin (beads) by the addition of poly-lysine moieties to a non-catalytic area of the protease. The transgenic ovalbumin-TAG-desired protein eluted from the affinity column of step 4 is then applied to the protease resin. Protease action cleaves the ovalbumin-TAG sequence from the desired protein and leaves both entities in solution. The immobilized enterokinase resin is recharged and reused.
 - c. The choice of these alternatives is made depending upon the size and chemical composition of the transgene target protein.
6. A final separation of either of these two (5a or 5b) protein mixtures is made using size exclusion, or enterokinase affinity chromatography. This step allows for desalting, buffer exchange and/or polishing, as needed.

Cleavage of the transgene product (ovalbumin-TAG-desired protein) by enterokinase, then, results in two products: ovalbumin-TAG and the desired protein. More specific methods for isolation using the TAG label is provided in the Examples. Some desired proteins may require additions or modifications of the above-described approach as known to one of ordinary skill in the art. The method is scalable from the laboratory bench to pilot and production facility largely because the techniques applied are well documented in each of these settings.

It is believed that a typical chicken egg produced by a transgenic animal of the present invention will contain at least 0.001 mg, from about 0.001 to 1.0 mg, or from about 0.001 to 100.0 mg of exogenous protein, peptide or polypeptide, in addition to the normal constituents of egg white (or possibly replacing a small fraction of the latter).

One of skill in the art will recognize that after biological expression or purification, the desired proteins, fragments thereof and peptides may possess a conformation substantially different than the native conformations of the proteins, fragments thereof and peptides. In this case, it is often necessary to denature and
5 reduce protein and then to cause the protein to re-fold into the preferred conformation. Methods of reducing and denaturing proteins and inducing re-folding are well known to those of skill in the art.

Production of Multimeric Proteins in Milk

In addition to methods of producing eggs containing transgenic proteins or
10 peptides, the present invention encompasses methods for the production of milk containing transgenic proteins or peptides. These methods include the administration of a transposon-based vector described above to a mammal. In one embodiment, the transposon-based vector contains a transposase operably-linked to a constitutive promoter and a gene of interest operably-linked to mammary specific promoter.
15 Genes of interest can include, but are not limited to antiviral and antibacterial proteins and immunoglobulins.

The following examples will serve to further illustrate the present invention without, at the same time, however, constituting any limitation thereof. On the contrary, it is to be clearly understood that resort may be had to various embodiments,
20 modifications and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the invention.

EXAMPLE 1

25 *Preparation of Transposon-Based Vector pTnMod*

A vector was designed for inserting a desired coding sequence into the genome of eukaryotic cells, given below as SEQ ID NO:57. The vector of SEQ ID NO:57, termed pTnMod, was constructed and its sequence verified.

This vector employed a cytomegalovirus (CMV) promoter. A modified Kozak
30 sequence (ACCATG) (SEQ ID NO:5) was added to the promoter. The nucleotide in the wobble position in nucleotide triplet codons encoding the first 10 amino acids of transposase was changed to an adenine (A) or thymine (T), which did not alter the amino acid encoded by this codon. Two stop codons were added and a synthetic

polyA was used to provide a strong termination sequence. This vector uses a promoter designed to be active soon after entering the cell (without any induction) to increase the likelihood of stable integration. The additional stop codons and synthetic polyA insures proper termination without read through to potential genes downstream.

The first step in constructing this vector was to modify the transposase to have the desired changes. Modifications to the transposase were accomplished with the primers High Efficiency forward primer (Hef) Altered transposase (ATS)-Hef 5' ATCTCGAGACCATGTGTGAACTTGATATTTTACATGATTCTCTTTACC 3' (SEQ ID NO:91) and Altered transposase- High efficiency reverse primer (Her) 5' GATTGATCATTATCATAATTTCCCAAAGCGTAACC 3' (SEQ ID NO:92, a reverse complement primer). In the 5' forward primer ATS-Hef, the sequence CTCGAG (SEQ ID NO:93) is the recognition site for the restriction enzyme Xho I, which permits directional cloning of the amplified gene. The sequence ACCATG (SEQ ID NO:5) contains the Kozak sequence and start codon for the transposase and the underlined bases represent changes in the wobble position to an A or T of codons for the first 10 amino acids (without changing the amino acid coded by the codon). Primer ATS-Her (SEQ ID NO:92) contains an additional stop codon TAA in addition to native stop codon TGA and adds a Bcl I restriction site, TGATCA (SEQ ID NO:94), to allow directional cloning. These primers were used in a PCR reaction with pTnLac (p defines plasmid, tn defines transposon, and lac defines the beta fragment of the lactose gene, which contains a multiple cloning site) as the template for the transposase and a FailSafeTM PCR System (which includes enzyme, buffers, dNTP's, MgCl₂ and PCR Enhancer; Epicentre Technologies, Madison, WI). Amplified PCR product was electrophoresed on a 1% agarose gel, stained with ethidium bromide, and visualized on an ultraviolet transilluminator. A band corresponding to the expected size was excised from the gel and purified from the agarose using a Zymo Clean Gel Recovery Kit (Zymo Research, Orange, CA). Purified DNA was digested with restriction enzymes Xho I (5') and Bcl I (3') (New England Biolabs, Beverly, MA) according to the manufacturer's protocol. Digested DNA was purified from restriction enzymes using a Zymo DNA Clean and Concentrator kit (Zymo Research).

Plasmid gWhiz (Gene Therapy Systems, San Diego, CA) was digested with restriction enzymes Sal I and BamH I (New England Biolabs), which are compatible with Xho I and Bcl I, but destroy the restriction sites. Digested gWhiz was separated on an agarose gel, the desired band excised and purified as described above. Cutting the vector in this manner facilitated directional cloning of the modified transposase (mATS) between the CMV promoter and synthetic polyA.

To insert the mATS between the CMV promoter and synthetic polyA in gWhiz, a Stratagene T4 Ligase Kit (Stratagene, Inc. La Jolla, CA) was used and the ligation set up according to the manufacturer's protocol. Ligated product was transformed into *E. coli* Top10 competent cells (Invitrogen Life Technologies, Carlsbad, CA) using chemical transformation according to Invitrogen's protocol. Transformed bacteria were incubated in 1 ml of SOC (GIBCO BRL, CAT# 15544-042) medium for 1 hour at 37° C before being spread to LB (Luria-Bertani media (broth or agar)) plates supplemented with 100 µg/ml ampicillin (LB/amp plates). These plates were incubated overnight at 37° C and resulting colonies picked to LB/amp broth for overnight growth at 37° C. Plasmid DNA was isolated using a modified alkaline lysis protocol (Sambrook et al., 1989), electrophoresed on a 1% agarose gel, and visualized on a U.V. transilluminator after ethidium bromide staining. Colonies producing a plasmid of the expected size (approximately 6.4 kbp) were cultured in at least 250 ml of LB/amp broth and plasmid DNA harvested using a Qiagen Maxi-Prep Kit (column purification) according to the manufacturer's protocol (Qiagen, Inc., Chatsworth, CA). Column purified DNA was used as template for sequencing to verify the changes made in the transposase were the desired changes and no further changes or mutations occurred due to PCR amplification. For sequencing, Perkin-Elmer's Big Dye Sequencing Kit was used. All samples were sent to the Gene Probes and Expression Laboratory (LSU School of Veterinary Medicine) for sequencing on a Perkin-Elmer Model 377 Automated Sequencer.

Once a clone was identified that contained the desired mATS in the correct orientation, primers CMVf-NgoM IV (5' TTGCCGGCATCAGATTGGCTAT (SEQ ID NO:95); underlined bases denote NgoM IV recognition site) and Syn-polyA-BstE II (5' AGAGGTCACCGGGTCAATTCTTCAGCACCTGGTA (SEQ ID NO:96); underlined bases denote BstE II recognition site) were used to PCR amplify the entire CMV promoter, mATS, and synthetic polyA for cloning upstream of the transposon

in pTnLac. The PCR was conducted with FailSafe™ as described above, purified using the Zymo Clean and Concentrator kit, the ends digested with NgoM IV and BstE II (New England Biolabs), purified with the Zymo kit again and cloned upstream of the transposon in pTnLac as described below.

5 Plasmid pTnLac was digested with NgoM IV and BstE II to remove the ptac promoter and transposase and the fragments separated on an agarose gel. The band corresponding to the vector and transposon was excised, purified from the agarose, and dephosphorylated with calf intestinal alkaline phosphatase (New England Biolabs) to prevent self-annealing. The enzyme was removed from the vector using a
10 Zymo DNA Clean and Concentrator-5. The purified vector and CMVp/mATS/polyA were ligated together using a Stratagene T4 Ligase Kit and transformed into *E. coli* as described above.

Colonies resulting from this transformation were screened (mini-preps) as describe above and clones that were the correct size were verified by DNA sequence
15 analysis as described above. The vector was given the name pTnMod (SEQ ID NO:57) and includes the following components:

Base pairs 1-130 are a remainder of F1(-) on from pBluescriptII sk(-) (Stratagene), corresponding to base pairs 1-130 of pBluescriptII sk(-).

Base pairs 131 - 132 are a residue from ligation of restriction enzyme sites
20 used in constructing the vector.

Base pairs 133 -1777 are the CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems), corresponding to bp 229-1873 of pGWiz. The CMV promoter was modified by the addition of an ACC sequence upstream of ATG.

Base pairs 1778-1779 are a residue from ligation of restriction enzyme sites
25 used in constructing the vector.

Base pairs 1780 - 2987 are the coding sequence for the transposase, modified from Tn10 (GenBank accession J01829) by optimizing codons for stability of the transposase mRNA and for the expression of protein. More specifically, in each of the codons for the first ten amino acids of the transposase, G or C was changed to A or T
30 when such a substitution would not alter the amino acid that was encoded.

Base pairs 2988-2993 are two engineered stop codons.

Base pair 2994 is a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 2995 - 3410 are a synthetic polyA sequence taken from the pGWiz vector (Gene Therapy Systems), corresponding to bp 1922-2337 of 10 pGWiz.

Base pairs 3415 - 3718 are non-coding DNA that is residual from vector pNK2859.

5 Base pairs 3719 - 3761 are non-coding λ DNA that is residual from pNK2859.

Base pairs 3762 - 3831 are the 70 bp of the left insertion sequence recognized by the transposon Tn10.

Base pairs 3832-3837 are a residue from ligation of restriction enzyme sites used in constructing the vector.

10 Base pairs 3838 - 4527 are the multiple cloning site from pBluescriptII sk(20), corresponding to bp 924-235 of pBluescriptII sk(-). This multiple cloning site may be used to insert any coding sequence of interest into the vector.

Base pairs 4528-4532 are a residue from ligation of restriction enzyme sites used in constructing the vector.

15 Base pairs 4533 - 4602 are the 70 bp of the right insertion sequence recognized by the transposon Tn10.

Base pairs 4603 - 4644 are non-coding λ DNA that is residual from pNK2859.

Base pairs 4645 - 5488 are non-coding DNA that is residual from pNK2859.

Base pairs 5489 - 7689 are from the pBluescriptII sk(-) base vector -
20 (Stratagene, Inc.), corresponding to bp 761-2961 of pBluescriptII sk(-).

Completing pTnMod is a pBlueScript backbone that contains a colE I origin of replication and an antibiotic resistance marker (ampicillin).

It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s). Missing nucleotide sequences
25 in the above construct represent restriction site remnants.

All plasmid DNA was isolated by standard procedures. Briefly, *Escherichia coli* containing the plasmid was grown in 500 mL aliquots of LB broth (supplemented with an appropriate antibiotic) at 37°C overnight with shaking. Plasmid DNA was recovered from the bacteria using a Qiagen Maxi-Prep kit (Qiagen, Inc., Chatsworth,
30 CA) according to the manufacturer's protocol. Plasmid DNA was resuspended in 500 μ L of PCR-grade water and stored at -20°C until used.

EXAMPLE 2

Transposon-Based Vector pTnMCS

Another transposon-based vector was designed for inserting a desired coding sequence into the genome of eukaryotic cells. This vector was termed pTnMCS and its constituents are provided below. The sequence of the pTnMCS vector is provided in SEQ ID NO:56. The pTnMCS vector contains an avian optimized polyA sequence operably-linked to the transposase gene. The avian optimized polyA sequence contains approximately 75 nucleotides that precede the A nucleotide string.

- 10 Bp 1 – 130 Remainder of F1 (-) ori of pBluescriptII sk(-) (Stratagene) bp1-130
- Bp 133 – 1777 CMV promoter/enhancer taken from vector pGWIZ (Gene Therapy Systems) bp 229-1873
- Bp 1783 – 2991 Transposase, from Tn10 (GenBank accession #J01829) bp 108-1316
- Bp 2992 – 3344 Non coding DNA from vector pNK2859
- 15 Bp 3345 – 3387 Lambda DNA from pNK2859
- Bp 3388 – 3457 70 bp of IS10 left from Tn10
- Bp 3464 – 3670 Multiple cloning site from pBluescriptII sk(-), thru the XmaI site bp 924-718
- Bp 3671 - 3715 Multiple cloning site from pBluescriptII sk(-), from the XmaI site thru the XhoI site. These base pairs are usually lost when cloning into pTnMCS bp 717-673
- 20 Bp 3716 – 4153 Multiple cloning site from pBluescriptII sk(-), from the XhoI site bp 672-235
- Bp 4159 - 4228 70 bp of IS10 right from Tn10
- 25 Bp 4229 - 4270 Lambda DNA from pNK2859
- Bp 4271 – 5114 Non-coding DNA from pNK2859
- Bp 5115 - 7315 pBluescript sk (-) base vector (Stratagene, Inc.) bp 761-2961.

EXAMPLE 3

30 *Production of Antibody in Egg White*

A transposon-based vector containing a CMV promoter/cecropin prepro/antibody heavy chain/cecropin pro/Antibody light chain/conalbumin poly A (SEQ ID NO:97) was injected into the oviduct of quail and chickens. A total of 20 birds were injected (10 chickens and 10 quail) and eggs were harvested from the birds

once the eggs were laid. Partially purified egg white protein (EW) was then run on a gel under both reducing and non-reducing conditions. Figure 5 is a picture of the gel. Lanes 1 & 18: molecular weight markers, Lanes 2 and 3: EW #1, non-reduced, reduced, respectively; Lanes 4 and 5: EW #2, non-reduced, reduced, respectively, 5 Lanes 6 and 7: EW #3, non-reduced, reduced, respectively, Lanes 8 and 9: EW #4, non-reduced, reduced, respectively; Lanes 10 and 11: EW #5, non-reduced, reduced, respectively; Lanes 12 and 13: EW #6, non-reduced, reduced, respectively; Lanes 14 and 15: EW #7, non-reduced, reduced, respectively; and Lanes 16 and 17: EW #8 Control, non-reduced, reduced, respectively. Based upon the gel results, the 10 possibility that the egg white in the treated chicken and quail contains antibody produced by the above-mentioned transposon-based vector cannot be excluded.

EXAMPLE 4

Additional Transposon-Based Vectors for Administration to an Animal

The following example provides a description of various transposon-based 15 vectors of the present invention and several constructs for insertion into the transposon-based vectors of the present invention. These examples are not meant to be limiting in any way. The constructs for insertion into a transposon-based vector are provided in a cloning vector pTnMCS or pTnMod, both described above.

pTnMOD (CMV-prepro-HCPro-Lys-CPA) (SEQ ID NO:97)

- 20 Bp 1–4090 from vector pTnMod, bp 1 - 4090
 Bp 4096–5739 CMV promoter/enhancer taken from vector pGWIZ (Gene therapy systems), bp 230-1864
 Bp 5746-5916 Capsite/Prepro taken from GenBank accession # X07404, bp 563–733
 Bp 5923-7287 Heavy Chain gene construct taken from antibody RM2 provided by 25 Mark Glassy (Shantha West, Inc)
 Bp 7288-7302 Pro taken from GenBank accession # X07404, bp 719-733 (includes Lysine)
 Bp 7309–7953 Light Chain gene construct taken from antibody RM2 provided by Mark Glassy (Shantha West, Inc)
 30 Bp 7960–8372 Conalbumin polyA taken from GenBank accession # Y00407, bp 10651-11058
 Bp 8374–11973 from cloning vector pTnMod, bp 4091-7690

pTnMCS (CHOVep-prepro-HCPro-CPA) (SEQ ID NO:98)

- Bp 1–3715 from vector pTnMCS, bp 1-3715
- Bp 3721–4395 Chicken Ovalbumin enhancer taken from GenBank accession # S82527.1, bp 1–675
- Bp 4402–5738 Chicken Ovalbumin promoter taken from GenBank accession # J00899-M24999, bp 1-1336
- Bp 5745–5915 Capsite/Prepro taken from GenBank accession # X07404, bp 563–733
- Bp 5922–7286 Heavy Chain gene construct taken from antibody RM2 provided by Mark Glassy (Shantha West, Inc)
- Bp 7287–7298 Pro taken from GenBank accession # X07404, bp 719-730 (does not include Lysine)
- Bp 7305–7949 Light Chain gene construct taken from antibody RM2 provided by Mark Glassy (Shantha West, Inc)
- Bp 7956–8363 Conalbumin polyA taken from GenBank accession # Y00407, bp 10651-11058
- Bp 8365–11964 from cloning vector pTnMCS, bp 3716-7315

pTnMCS(CHOVep-prepro-HCPro-Lys-CPA) (SEQ ID NO:99)

- Bp 1 – 3715 from vector pTnMCS, bp 1-3715
- Bp 3721 – 4395 Chicken Ovalbumin enhancer taken from GenBank accession # S82527.1, bp 1–675
- Bp 4402 - 5738 Chicken Ovalbumin promoter taken from GenBank accession # J00899-M24999, bp 1-1336
- Bp 5745 – 5915 Capsite/Prepro taken from GenBank accession # X07404, bp 563–733
- Bp 5922 - 7286 Heavy Chain gene construct taken from antibody RM2 provided by Mark Glassy (Shantha West, Inc)
- Bp 7287 - 7301 Pro taken from GenBank accession # X07404, bp 719-733 (includes Lysine)
- Bp 7308 – 7952 Light Chain gene construct taken from antibody RM2 provided by Mark Glassy (Shantha West, Inc)
- Bp 7959 – 8366 Conalbumin polyA taken from GenBank accession # Y00407, bp 10651-11058

Bp 8368 – 11967 from cloning vector pTnMCS, bp 3716-7315

pTnMCS (CMV-prepro-HCPro-CPA) (SEQ ID NO:100)

Bp 1 – 3715 from vector pTnMCS, bp 1-3715

- 5 Bp 3721 – 5364 CMV promoter/enhancer taken from vector pGWIZ (Gene therapy systems), bp 230-1864

Bp 5371-5541 Capsite/Prepro taken from GenBank accession # X07404, bp 563–733

Bp 5548 - 6912 Heavy Chain gene construct taken from antibody RM2 provided by Mark Glassy (Shantha West, Inc)

- 10 Bp 6913 - 6924 Pro taken from GenBank accession # X07404, bp 719-730 (does not Lysine)

Bp 6931 – 7575 Light Chain gene construct taken from antibody RM2 provided by Mark Glassy (Shantha West, Inc)

Bp 7582 – 7989 Conalbumin polyA taken from GenBank accession # Y00407, bp

- 15 10651-11058

Bp 7991 – 11590 from cloning vector pTnMCS, bp 3716-7315

pTnMCS (CMV-prepro-HCPro-Lys-CPA) (SEQ ID NO:101)

Bp 1 – 3715 from vector pTnMCS, bp 1-3715

- 20 Bp 3721 – 5364 CMV promoter/enhancer taken from vector pGWIZ (Gene therapy systems), bp 230-1864

Bp 5371-5541 Capsite/Prepro taken from GenBank accession # X07404, bp 563–733

Bp 5548 - 6912 Heavy Chain gene construct taken from antibody RM2 provided by Mark Glassy (Shantha West, Inc)

- 25 Bp 6913 - 6927 Pro taken from GenBank accession # X07404, bp 719-733 (includes Lysine)

Bp 6934 – 7578 Light Chain gene construct taken from antibody RM2 provided by Mark Glassy (Shantha West, Inc)

Bp 7585 – 7992 Conalbumin polyA taken from GenBank accession # Y00407, bp

- 30 10651-11058

Bp 7994 – 11593 from cloning vector pTnMCS, bp 3716-7315

pTnMod (CHOvep-prepro-HCPro-CPA) (SEQ ID NO:102)

- Bp 1–4090 from vector pTnMod, bp 1-4090
- Bp 4096–4770 Chicken Ovalbumin enhancer taken from GenBank accession # S82527.1, bp 1–675
- 5 Bp 4777-6113 Chicken Ovalbumin promoter taken from GenBank accession # J00899-M24999, bp 1-1336
- Bp 6120-6290 Capsite/Prepro taken from GenBank accession # X07404, bp 563–733
- Bp 6297-7661 Heavy Chain gene construct taken from antibody RM2 provided by Mark Glassy (Shantha West, Inc)
- 10 Bp 7662-7673 Pro taken from GenBank accession # X07404, bp 719-730 (does not include Lysine)
- Bp 7680–8324 Light Chain gene construct taken from antibody RM2 provided by Mark Glassy (Shantha West, Inc)
- Bp 8331–8738 Conalbumin polyA taken from GenBank accession # Y00407, bp
- 15 10651-11058
- Bp 8740–12339 from cloning vector pTnMod, bp 3716-7315

pTnMod (CHOvep-prepro-HCPro-LYS-CPA) (SEQ ID NO:103)

- Bp 1–4090 from vector pTnMod, bp 1-4090
- 20 Bp 4096–4770 Chicken Ovalbumin enhancer taken from GenBank accession # S82527.1, bp 1–675
- Bp 4777-6113 Chicken Ovalbumin promoter taken from GenBank accession # J00899-M24999, bp 1-1336
- Bp 6120-6290 Capsite/Prepro taken from GenBank accession # X07404, bp 563–733
- 25 Bp 6297-7661 Heavy Chain gene construct taken from antibody RM2 provided by Mark Glassy (Shantha West, Inc)
- Bp 7662-7676 Pro taken from GenBank accession # X07404, bp 719-733 (includes Lysine)
- Bp 7683–8327 Light Chain gene construct taken from antibody RM2 provided by
- 30 Mark Glassy (Shantha West, Inc)
- Bp 8334–8741 Conalbumin polyA taken from GenBank accession # Y00407, bp 10651-11058
- Bp 8743–12342 from cloning vector pTnMod, bp 3716-7315

pTnMod (CMV-prepro-HCPro-CPA) (SEQ ID NO:104)

- Bp 1–4090 from vector pTnMod, bp 1–4090
- Bp 4096–5739 CMV promoter/enhancer taken from vector pGWIZ (Gene therapy
5 systems), bp 230–1864
- Bp 5746–5916 Capsite/Prepro taken from GenBank accession # X07404, bp 563–733
- Bp 5923–7287 Heavy Chain gene construct taken from antibody RM2 provided by
Mark Glassy (Shantha West, Inc)
- Bp 7288–7299 Pro taken from GenBank accession # X07404, bp 719–730 (does not
10 include Lysine)
- Bp 7306–7950 Light Chain gene construct taken from antibody RM2 provided by
Mark Glassy (Shantha West, Inc)
- Bp 7557–7969 Conalbumin polyA taken from GenBank accession # Y00407, bp
10651–11058
- 15 Bp 7971–11970 from cloning vector pTnMod, bp 3716–7315

All patents, publications and abstracts cited above are incorporated herein by
reference in their entirety. It should be understood that the foregoing relates only to
preferred embodiments of the present invention and that numerous modifications or
20 alterations may be made therein without departing from the spirit and the scope of the
present invention as defined in the following claims.

CLAIMS

We claim:

1. An isolated polynucleotide comprising two or more genes of interest and two or more pro nucleotide sequences, wherein each gene of interest is operably-linked to a pro nucleotide sequence and each of the two or more genes of interest may be the same or different.
2. The polynucleotide of claim 1, wherein a most 5' pro nucleotide sequence of the two or more pro nucleotide sequences is a part of a prepro nucleotide sequence.
3. The polynucleotide of claim 1, wherein two genes of interest and two pro nucleotide sequences are arranged in the following order: a prepro nucleotide sequence, a first gene of interest, a pro nucleotide sequence, and a second gene of interest.
4. The polynucleotide of claim 3, wherein the prepro nucleotide sequence is a cecropin prepro nucleotide sequence and the pro nucleotide sequence is a cecropin pro sequence.
5. The polynucleotide of claim 3, wherein the prepro nucleotide sequence comprises a sequence shown in SEQ ID NO:3 or SEQ ID NO:4 and the pro nucleotide sequence comprises a sequence shown in SEQ ID NO:1 or SEQ ID NO:2.
6. The polynucleotide of claim 1, wherein a first gene of interest encodes for an antibody heavy chain and a second gene of interest encodes for an antibody light chain.
7. A method of producing a multimeric protein in an individual comprising administering to the individual a polynucleotide comprising two or more genes of interest, wherein each gene of interest encodes a part of the multimeric protein, each gene of interest is operably-linked to a pro nucleotide sequence, and each of the two or more genes of interest may be the same or different.
8. The method of claim 7, wherein the multimeric protein is an associated multimeric protein.

9. The method of claim 7, wherein the multimeric protein is a multivalent multimeric protein.
- 5 10. The method of claim 7, wherein a most 5' pro nucleotide sequence of the two or more pro sequences is a part of a prepro nucleotide sequence.
- 10 11. The method of claim 7, wherein the polynucleotide comprises two genes of interest and two pro nucleotide sequences arranged in the following order: a prepro nucleotide sequence, a first gene of interest, a pro nucleotide sequence, and a second gene of interest.
- 15 12. The method of claim 7, wherein a first gene of interest encodes for an antibody heavy chain and a second gene of interest encodes for an antibody light chain.
- 20 13. A method of producing a protein in an individual comprising administering to the individual a polynucleotide comprising a cecropin prepro nucleotide sequence operably-linked to one or more genes of interest, each gene of interest encoding the multimeric protein.
- 25 14. The method of claim 13, wherein a first gene of interest is an antibody heavy chain and a second gene of interest is an antibody light chain.
- 30 15. The method of claim 13, wherein the protein is a multimeric protein and the cecropin prepro nucleotide sequence is operably-linked to two or more genes of interest, wherein each gene of interest encodes a part of the multimeric protein.
- 35 16. The method of claim 15, wherein the multimeric protein is an associated multimeric protein.
17. The method of claim 15, wherein the multimeric protein is a multivalent multimeric protein.
18. A method of producing a multimeric protein in an individual comprising administering to the individual a polynucleotide comprising two or more genes of interest, wherein each gene of interest encodes a part of the

multimeric protein and wherein each gene of interest is operably linked to a gene encoding for a cleavage site.

5 19. The method of claim 18, wherein a transposon-based vector comprises the polynucleotide and further comprises a transposase gene operably linked to a first promoter and wherein;

a) the first promoter comprises a modified Kozak sequence comprising ACCATG;

10 b) the two or more genes of interest are each operably-linked to one or more additional promoters; and,

c) the two or more genes of interest and their operably-linked promoters are flanked by transposase insertion sequences recognized by a transposase encoded by the transposase gene.

15 20. The method of claim 18, wherein a transposon-based vector comprises the polynucleotide and further comprises a transposase gene operably linked to a first promoter and an avian optimized polyA sequence, and wherein;

a) the two or more genes of interest are each operably-linked to one or more additional promoters; and,

20 b) the two or more genes of interest and their operably-linked promoters are flanked by transposase insertion sequences recognized by a transposase encoded by the transposase gene.

25 21. The method of claim 18, wherein the multimeric protein is an associated multimeric protein.

22. The method of claim 18, wherein the multimeric protein is a multivalent multimeric protein.

30 23. The method of claim 18, wherein the polynucleotide further comprises a cleavage site.

24. An animal comprising the isolated polynucleotide of claim 1.

35 25. The animal of claim 24, wherein the animal is a bird.

26. An egg produced by the animal of claim 25.

27. The egg of claim 26, wherein the egg comprises a multimeric protein encoded by the isolated polynucleotide.
28. The animal of claim 24, wherein the animal is a mammal.
29. Milk produced by the mammal of claim 28.
30. The milk of claim 29, wherein the milk comprises a multimeric protein encoded by the isolated polynucleotide.
31. A method of producing a multimeric protein comprising:
- a) administering to an egg-laying animal a composition comprising the polynucleotide of claim 1 in an acceptable carrier; and,
 - b) permitting the one or more genes of interest to be expressed into the multimeric protein.
32. The method of claim 31, further comprising
- a) collecting an egg from the egg-laying animal;
 - b) harvesting egg white comprising the multimeric protein; and,
 - c) purifying the multimeric protein.
33. The method of claim 31, wherein the egg-laying animal is a bird.
34. A method of producing a multimeric protein comprising:
- a) administering to an intramammary duct system of a mammal a composition comprising the polynucleotide of claim 1 in an acceptable carrier, and,
 - b) permitting the one or more genes of interest to be expressed into the multimeric protein.
35. The method of claim 34, further comprising
- a) collecting milk from the mammal, wherein the milk comprises the multimeric protein;
 - b) purifying the multimeric protein.
36. The polynucleotide of any of the preceding claims, wherein the prepro nucleotide sequence comprises a sequence shown in SEQ ID NO:3 or SEQ ID NO:4.

37. The polynucleotide of any of the preceding claims, wherein the two or more pro nucleotide sequences each comprise a sequence shown in SEQ ID NO:1 or SEQ ID NO:2.

5

38. The polynucleotide of any of the preceding claims, wherein the prepro nucleotide sequence is a cecropin prepro nucleotide sequence.

10

39. The polynucleotide of any of the preceding claims, wherein the pro nucleotide sequence is a cecropin pro nucleotide sequence.

15

FIGURE 1

Prom	prepro	Gene of Interest	pro	Gene of interest	polyA
------	--------	------------------	-----	------------------	-------

FIGURE 2

IS	Oval Prom	prepro	Heavy chain	pro	Light chain	polyA	IS
----	-----------	--------	-------------	-----	-------------	-------	----

FIGURE 3


Prom	Cecropin prepro	Gene of Interest	CS	Gene of Interest	polyA
------	-----------------	------------------	----	------------------	-------

FIGURE 4

IS	Prom	SS	Gene of Interest	CS	Gene of Interest	polyA	IS
----	------	----	------------------	----	------------------	-------	----

5/5

FIGURE 5



Appendix A

- 5 SEQ ID NO:1 (cecropin pro)
GCG CCA GAG CCG AAA
- SEQ ID NO:2 (cecropin pro extended)
GCG CCA GAG CCG AAA TGG AAA GTC TTC AAG
- 10 SEQ ID NO:3 (cecropin prepro)
AAT TTC TCA AGG ATA TTT TTC TTC GTG TTC GCT TTG GTT CTG GCT TTG TCA
ACA GTT TCG GCT GCG CCA GAG CCG AAA
- 15 SEQ ID NO:4 (cecropin prepro extended)
AAT TTC TCA AGG ATA TTT TTC TTC GTG TTC GCT TTG GTT CTG GCT TTG TCA
ACA GTT TCG GCT GCG CCA GAG CCG AAA TGG AAA GTC TTC AAG
- 20 SEQ ID NO:5 (modified Kozak sequence)
ACCATG
- SEQ ID NO:6
atg ctg ggc atc tgg acc ctc cta cct ctg gtt ctt acg tct gtt gct aga
25 tta
- SEQ ID NO:7
atg att cct gcc aga ttt gcc ggg gtg ctg ctt gct ctg gcc ctc att ttg
cca ggg acc ctt tgt
- 30 SEQ ID NO:8
atgg gcagagcaat ggtggccagg ctggggctgg ggctgctgct gctggcactg
ctcctacca cgcagattta ttcc
- 35 SEQ ID NO:9
atgaatctat cgaacatttc tgccgtaaaa gtattaacac tgggtggttag cgtgcccac gct
- SEQ ID NO:10
- 40 atgaccatcc ttttccttac tatggttacc tcatacttca gttgcatgaa agctgccccg
atgaaagaag ctagtgttaag aggacatggc agcttggctt acccaggtct tcggaccacac
gggactcttg aaagcctaac tgggccaat gctggttcaa gaggactgac atcactggcg
gacacttttg aacacgtgat agaggagctt ctatagtaag atcaggacat ccagcccagt
gaggaaaaca aggatgcgga cttgtacaca tcccgagtca tgetgagcag tcaagtgcct
45 ttggaacccc cactgctctt tctgctcgag gagtacaaaa actacctgga tgetgcaaac
atgtccatga ggtccggcg tcactctgac
- SEQ ID NO:11
cgtctttttc tcttatcttt tctcgttttc gctcttttct cgtcggcgat tgetttctcc
50 gacgacgac cgttgatccg acaagttgta tcgggaaacg atgacaacca tatgttaaac
gccgagcatc acttttcaact tttt
- SEQ ID NO:12
55 atg tccatcttgt tttatgtgat atttcttgca tatcttcgtg gcattcagtc aactaatatg
gatcaaagga gtttgccaga agattcaatg aattctctca ttattaaact cattcgggca
gacatcttga aaaacaagct ttctaagcag gtgatggatg tcaaggaaaa ctatcaaac
atagtgcaga aagtagagga ccaccaggag atggatggag atgaaaatgt gaaatcagac
ttcagccag ttatttcaat ggatacagac ctctaaggc agcagagacg ctacaactct
tc tctaagtga caacacacca ctggaaccac caccactgta cctcacagag
tg gaagttcagt ggtattaaac agaacctctc gaaggaaaag gt

- SEQ ID NO:13
 5 atggtgcatc tgactcctga ggagaagtct gccgttactg ccctgtgggg caaggtgaac
 gtggatgaag ttggtggtga ggccctgggc aggtctctgg tggcttacct ttggaccag
 aggttctttg agtcctttgg gatctgtcc actcctgatg ctgttatggg caaccctaag
 gtgaaggctc atggcaagaa agtgctcggg gcctttagtg atggcctggc tcacctggac
 aacctcaagg gcacctttgc cacactgagt gagctgcact gtgacaaget gcacgtggat
 cctgagaact tcaggctcct gggcaacgtg ctggtctgtg tgctggccca tcactttggc
 aaagaattca cccaccagt gcaggctgcc tatcagaaag tggtagctgg tgtggctaata
 10 gccctggccc acaagtatca ctaagctgcg tttcttgcgt tccaatttct attaaaggtt
 cctttgttcc ctaagtcaa ctactaaact ggggatatt atgaagggcc ttgagcatct
 ggattctgcc taataaaaaa catttatttt cattgc
- 15 SEQ ID NO:14
 gcatggggac ggcgttctc cagcgcgggg gctgctttct cctgtgcctt tcgctgctgc
 tcctgggctg ctgggcggag ctgggcagcggg
- 20 SEQ ID NO:15
 cgaaacgatt caaaacctct ttactgccgt tatttgcgtg atttttattg ctgttttatt
 tggttctggc aggac
- 25 SEQ ID NO:16
 ggagtctggg ggaggcttag tgcagcctgg agagtccctg aaactctcct gtgaatccaa
 tgaatacga tcccttccc atgacatgtc ttgggtccgc aagactccgg agaagaggct
 ggagttgggc gcagccatta atagtatgg tggtagcacc tactatccag acaccatgga
 gagacgattc atcatctcca gagacaatac caagaagacc ctgtacctgc aaatgagcag
 tctgaggtct gagcacacag ccttgtatta ctgtgcaaga cacacgatga gcaaaagtta
 30 ctgtgagctc aaactaaac ctctgcaga gcatccagga ccagcagggg gcgcggagag
 acacagagtt gtgaaat
- 35 SEQ ID NO:17
 acatccattc ttctgtgagt ttactcga gagcagcgtg tcaactgcga caagccagcc
 agctcaccat ggctggacct cccagggtac cagacctctg ggaactggcc ctgagcctca
 cttcacggac acaggctgcc cgccaaagtg ggtctcagag caacagtgtg tgcatgtctc
 gtcacatctt cctcttgctt tgcatgactg actacacca agaagtgtgc cctggggagg
 aaagcatatt tggcaaccag atcataataa aatcagaaat gcagcaaac tttaaaatat
 40 ccagacttgg
- SEQ ID NO:18
 tggagcaag agggagtatg ctaacttcat g
- 45 SEQ ID NO:19
 atcaattaca agaggg
- 50 SEQ ID NO:20
 atgaagttmg catactccct cttgcttcca ttggcaggag tcagtgtctc agtkatcaat
 tacaagaga
- SEQ ID NO:21
 aattcttaat taattattgt ggtgtcacia taacttttc
- 55 SEQ ID NO:22
 cccccggat ccatggcgc taaattcgtc gtggttctgg ccgcttgcgt cgccctgagc
 cactcggcta tggtagcgcg caagaagaac ggctac
- 60 SEQ ID NO:23
 cccccggat ccatgaaact cctggtcgtg ttgccatgt gctgcccgc tgccagcgt

SEQ ID NO:24

cagtgtacgg cggctcgagg cagaagtcgg gacgcata

5

SEQ ID NO:25

gaattcatta tcagcacgga ccagatttct ggatcaggat agaagtctga cgtttacggg
 ttctgaagca cagaacgcat tcgttagcgt aagtgtcacc gtcggtacgg caaacggagc
 ggtattccag agtgcaaccg ttcagttcgt tgtagcattt agcttcacga ccagagagt
 10 ccatggatcc cccctccgct gtcttctcag ttccaagcat tgcgattttg ttaagcaacg
 cactctcgat tcgtagagcc tcgttcggtt tgtttgacg aaccatattg

SEQ ID NO:26

ttcacaggca gggtttttgta gagaggggca tgtcatagtc ctcaactgtgg
 15

SEQ ID NO:27

aagcttctcg tgaaaaccaa cccaattagt tagtattgca ttctgtgtac tatagtttgg
 aatattaaaa atattttaaa atacctccat tttgcttacc ctttttagtga agatgatacc
 tgcaaaagac atggctaaag ttatgattgt catgttgga atttggtttc ttacaaaatc
 20 ggatgggaaa tctgttaagt aagtactgtt ttgccttggg attggatttt taatgttgac
 tttatcattt cgaagtgggg agctaattggg aagtggccct ctctgtttct cttcttccca
 ggaagagat

SEQ ID NO:28

atgggtacag gctcccgga cgtccctgctc ctggcttttg gctgtctctg cctgcccagg
 25 cttcaagagg gcagtgcc

SEQ ID NO:29

atgaggtct ttgctaattct tgggtgctttg
 30 cttcctgccc ctggctgctc tgggg

SEQ ID NO:30

atgc acctgagaat ccacgcgaga cggaaacctc ctgcgcggcc ggcctggagc
 35 cttgggatct ggccctttt ctggggatgt atcgtcagct ct

SEQ ID NO:31

atg gccattagt gagtccctgt gctaggattt ttcacatag ctgtgctgat gagcgctcag
 gaatcatggg ctatcaaaga agaacatgtg atcatccagg ccgagttcta tctgaatcct
 40 gaccaatcag gcgagtttat gtttgac

SEQ ID NO:32

agggggggatc cccggagacc ttcgggtagc aactgtcacc ttgatgctgg cgatcctgag
 ctctcactg gctgagggc

45 SEQ ID NO:33

atg gtgtgtctga ggctccctgg aggtcctgc atggcagttc tgacagtgc
 actgatggg ctgagctccc cactggcttt ggct

50 SEQ ID NO:34

1 gaacgattta aggagcgaat actactggta aactaatgga agaaatctgc tgcaccactg
 61 gatattggga gtgtgtggca tgcaccccca tcatcaggaa actctaaaaa agaaccgagt
 121 ggtgctagcc aaacagctgt tgttgagcga attgttagaa catcttcttg agaaggacat
 181 catcaccttg gaaatgaggg agtcatcca ggccaaagtg ggcagtttca gccagaatgt
 241 ggaactcctc aacttgctgc ctaagagggg tccccaagct tttgatgctc tctgtgaagc
 301 actgagggag accaagcaag gccacctgga ggatattgtg ctccaccacc tttctgggct
 361 tcagcatgta ctcccacgt tgagctgtga ctacgacttg agtctccctt ttccgggtgtg
 421 tgagtcctgt cccctttaca agaagctccg cctgtcgaca gatactgtgg aacactccct
 481 agacaataaa gatggctctg tctgccttca ggtgaagcct tgcactcctg aattttatca

541 aacacacttc cagctggcat ataggttgca gtctcggcct cgtggcctag cactgggtgtt
 601 gagcaatgtg cacttcactg gagagaaaga actggaattt cgctctggag gggatgtgga
 661 ccacagtact ctagtacccc tcttcaagct tttgggctat gacgtccatg ttctatgtga
 721 ccagactgca caggaaatgc aagagaaact gcagaatttt gcacagttac ctgcacaccg
 5 781 agtcacggac tcttgcacgt tggcactcct ctcgcatggg gtggaggggc ccatctatgg
 841 tgtggatggg aaactgctcc agctccaaga ggtttttcag ctctttgaca acgccaactg
 901 cccaagccta cagaacaaac caaaaatggt ctcatccag gctgcccgtg gaggtgctat
 961 tggatccctt gggcacctcc ttctgttcac tgcgccacc gctctcttg ctctatgaga
 1021 ctgacgtggg ggttgacca caagatggaa agaaccacgc aggatccctt
 10 ggtgcgagg
 1081 agagtgatgc cggtaaagaa aagttgccga agatgagact gcccacgcgc
 tcagacatga
 1141 tatcgcgcta tgcctgcctc aaagggaactg ccgccatgag gaacacccaa
 cgaggttcct
 15 1201 ggtacatcga ggctcttgtt caagtgtttt ctgagcgggc ttgtgatatg
 cacgtggccg
 1261 acatgctggt taagtgaaac gcacttatca aggatcggga aggttatgct
 cctggcacag
 1321 aattccaccg gtgcaaggag atgtctgaat actgcagcac tctgtgccgc
 20 cactctacc
 1381 tgttcccagg acaccctccc acatgatgtc acctcccat catccacgcc
 aagtgggaagc
 1441 cactggacca caggaggtgt gatagagcct ttgatcttca ggatgcacgg
 tttctgttct
 25 1501 gccccctcag ggatgtggga atctcccaga ctgttttctt gtgcccatca
 tctctgcctt
 1561 tgagtgtggg actccaggcc agctcctttt ctgtgaagcc ctttgctgt
 agagccagcc
 1621 ttggttggaac ctattgccag gaatgtttca gctgcagttg aagagcctga
 30 caagtgaagt
 1681 tgtaaacaca gtgtggttat ggggagaggg catataaatt ccccatattt
 gtgttcagtt
 1741 ccagcttttg tagatggcac tttagtgtt gcttttatta cattagttaa
 gatgtctgag
 35 1801 agaccatctc ctatctttta tttcatctat atcctccgcc ctttttgtcc
 tagagtgaga
 1861 gtttggaagg tgtccaaatt taatgtagac attatctttt ggctctgaag
 aagcaaacat
 1921 gactagagac gcaccttgct gcagtgtcca gaagcggcct gtgcgttccc
 40 ttcagtactg
 1981 cagcgccacc cagtgggaagg acactcttgg ctcggttggg ctcaaggcac
 cgcagcctgt
 2041 cagccaacat tgccttgcat ttgtacotta ttgatctttg cccatggaag
 tctcaaagat
 45 2101 ctttcgttgg ttgtttctct gagctttgtt actgaaatga gcctcgtggg
 gagcatcaga
 2161 gaaggccagg aagaatggtg tgtttcccta gactctgtaa ccacctctct
 gtctttttcc
 2221 ttcttgagaa acgtccatct ctctccotta ctattccac ttctattcaa
 50 tcaacctgca
 2281 cttcatatct agatttctag aaaagcttcc tagcttatct cctgcttca
 tatctctccc
 2341 ttctttacct tcatttcac ctgttggtg ctgccacca atctgtctag
 aatcctgctt
 55 2401 tacaggatca tgtaaatgct caaagatgta atgtagttct ttgttctgc
 tttctcttcc
 2461 agtattaaac tctccttga tattatgtgg cttttatttc agtgccatac
 atgttattgt
 2521 tttcaaccta gaaaccttta tccctgotta tctgaaactt cccaacttcc
 60 ctgttcttta

2581 agactttttt tttttttttt tttttttttg agacagagtc tcgctctgtc
 gcccaggctg
 2641 gagggcagtg gcacgatctc agctcactgc aagctccaac tcccgggttc
 acgccattct
 5 2701 cctgcctcag ccttccaagt agctgggact acaggtgccc gccaccgtgc
 ccggctaatt
 2761 tttttgtatt tttagtagag acagggtttc accatgttag ccgggatggc
 cttgatctcc
 10 2821 tgacctcatg atccaccac ctcagcctcc caaagtgttg ggattacagg
 cgtgagccac
 2881 tgcgcccggg caagacctt ttttaaaaaa aaaaaaaaaa aaacttccat
 tctttcttcc
 2941 tccagtctgt tctcacataa cagagtagtt ttggttttta attttttttg
 gttgtttgct
 15 3001 gttttttgtt ttttaagggtg agttctcact atgtttctca gactggctctc
 gaactcctgg
 3061 cctcaagcca tcttcccgc ctcagcctctc aaatagctgg gcttacaggc
 atgagccacc
 3121 acacctgggc aggatttggg tgtttaataa taaatctgat cccccctg
 20 cttagaaccc
 3181 ttctgctttc tattaccctt catttaaaat gtaaactctt caccttgggt
 tatgagaact
 3241 ggttcttgcc ttccccttga acctcattaa atggtgattt cttgctaagc
 tccagccga
 25 3301 gtggtctcct ctcagcttct aattttgtgc tctttctgc ccttttctg
 ggcttctca
 3361 gctctccacc cccaccctc ttgactcagg tgggtgcctt ctctctcaag
 tcttgacaat
 3421 tcccggggccc ttcagtcctt gagcagtcta cttctgtgtc tgtcaccaca
 30 tcttgtcttt
 3481 tcccctcatt gcatttattg cagtttatat atatgctact tttacttgtt
 catttctgtc
 3541 tcccctacca ggctgtaaat gagggcagaa accttgtttg ttttattcac
 catcatgtac
 35 3601 caagtgcctg gcacatagtg ggccttcatt aaatgtttgt tgaataaaag
 agggaagaag
 3661 gcaagccaac cttagctaca atcctacctt ttgataaaat gttccttttg
 acaatataca
 3721 cggattatta tttgtacttt gtttttccat gtgttttgct tttatccact
 40 ggcattttta
 3781 gctccttgaa gacatatcat gtgtgagata acttccttca catctcccat
 ggtccctagc
 3841 aaaatgctag gcctgtagta gtcaagggtgc tcaataaata tttgtttggg
 tggtttgta
 45 3901 gccttgctgc caagtctgc ctttgggtcg acatagtatg gaagtatttg
 agagagagaa
 3961 cctttccact cccactgcc ggattttgta ttgccatcgg gtgccaata
 aatgctcata
 4021 tttattaaaa aaaaaaaaaa aaaaa

50

SEQ ID NO:35

1 tccagatcat ctgtcctcac caccaaggcc atggtgtctt cagcgactat ctgcagtttg
 61 ctactcctca gcattgctctg gatggacatg gccatggcag gttccagctt cttgagccca
 55 121 gagcaccaga aagcccagca gagaaggaa tccaagaagc caccagctaa actgcagcca
 181 cgagctctgg aaggctggct ccaccagag gacagaggac aagcagaaga ggcagaggag
 241 gagctggaaa tcagggtcaa tgctcccttc gatgttggca tcaagctgtc aggagctcag
 301 taccagcagc atggccgggc cttgggaaag tttcttcagg atatcctctg ggaagaggctc
 361 aaagaggcgc cagctaaca gtaaccactg acaggactgg tccctgtact ttctcctaa
 60 421 gcaagaactc acatccagct tctgctcct ctgcaactcc cagcactctc ctgctgactt
 481 acaataaat gttcaagctg t

SEQ ID NO:36
 5 atgaagctgc ttgcaatggt tgcactgctg gtcaccatct gtagcctaga aggagctttg
 gttcggagac

SEQ ID NO:37
 10 atgaagctgc ttgcaatggt tgcactgctg gtcaccatct gtagcctaga aggagctttg
 gttcggagac

SEQ ID NO:38
 15 atggcctt gccaacggct cgaccctgt tggggctctg tgggacccc gccctcggca
 gcctcctgtt cctgctcttc agcctcggat gggcgcagcc c

SEQ ID NO:39
 20 atgccgcgcc tgttctccta cctcctaggt gtctggctgc tcctgagcca acttcccaga
 gaaatcccag gc

SEQ ID NO:40
 atgacagc atcaactgtc gttttaccat cgctttggtt aatattaatt atttttactg
 caccctatac tcaactgt

SEQ ID NO:41
 25 atgaaagtc ctgctttgtg acctgctgct gctcagtctc ttctccagtg tgttcagcag
 ttgtcagagg gactgtctca catgccagga gaagctccac ccagccctgg acagcttcga
 cctggagggtg tgcactcctc agtgcgaaaga gaaggctctc cccagccccc tctggactcc
 atgcaccaag gtcattggcca ggagctcttg gcagctcagc cctgccgccc cagagcatgt
 30 ggccggctgct ctctaccagc cgagagcttc ggagatgcag catctgcggc gaatgccccg
 agtccggagc ttgttccagg agcaggaaga gcccgagcct ggcatggagg aggctgggtga
 gatggagcag aagcagctgc agaagagat

SEQ ID NO:42
 35 aattcatgaa gtgggttact ttcactctct tgttgttctt gttctcttct gcttactcta
 gaggtgtttt cagacg

SEQ ID NO:43
 40 atgaagtggg ttactttcat ctctttgttg ttcttgttct cttctgctta ctctagagg
 gttttcagac gc

SEQ ID NO:44
 1 gaattctcaa tggcaaaagg aagtgtacat tataaatagc aaaacagctg gcttggacca
 61 tgttgccggc cagtcaccca gttgagggat ttgaatgaca tcataaccct caagagggtta
 45 121 ttgctagcca gctggtgtta ttagaatac acaaaaatca gagaaagaaa acacactctg
 181 gcacacagac tccctctgtc atacacacac acacacacac acacacacac acacacacac
 241 agagggttga gttatatgga aaattcaaac aacaggaaaa ttgtttgccc ccaggttacc
 301 cttctcccag agtgggtggg tggggagggg acagtgcag gcagcctagt agaagaataa
 361 agaaaaatgt tctatttcag ttgggtttta cagctcggca tagtctttgc ctcatcgag
 50 421 gagaaaaagt atgagacagt gccctaaagg gaccaatcca atgctgcttg cccctccata
 481 cgttctagga aatgagatca caccctcac ttggcaactg ggacaagggg tcaccagagt
 541 gctgtcttcc aatctacttt accccagtc cttcagggtt aaaattgtag agtttgctgg
 601 agagggtctt atcgtccttt ctttcttttt ttgtttttaa taatgcattt gctctagaat
 661 ctaaaattgc tctcccatcc cccatattcc ttttaatact gtaagggtga ttagcagacg
 55 721 tttgtgtctt catgcccagc agaaagttaa tcagaaaaa gatccttatt ttctatggca
 781 gcataagtat tttaatgtct gcgaacctg tcagtaacac acattctttt aagggaaaaa
 841 aatgcttctg tgctctagtt ttaaaatgca aaggatgat gttatttctg accatgcccc
 901 aaaaagtcct tactcaataa ctttgccaga agaggagag agagagaagg caaatgttcc
 961 ccagctgtt tctgtctac agtgtctgtg tttttagat aaatgtgagg attttgtga

- 1021 aatccctctt ctgtttgcta aatctcactg tcaactgctaa attcagagca
gatagagcct
1081 ggcgaatgga ataaagtctt caaaattgaa atgtgacatt gctctcaaca
tctcccatct
- 5 1141 ctctggattt ctttttgctt cattattcct gctaaccaat tcattttcag
actttgtact
1201 tcagaagcaa tgggaaaaat cagcagtctt ccaacccaat tattttaagt
ctgcttttgt
1261 gatttcttga aggtaaatat ttcttactct ttgaagtcac tggggaattc
10 ggatccact
1321 gtaataatag catctttcat ttccgtagta aacgtttcta gatattttgt
ctcaattcat
1381 tgaaatagga acccataaag aaaggggttc agggaggact cctccaaaga
tccacagtag
- 15 1441 ccaggggaat aaacacaggt tgttgatgc cgagacacgc tccatccaca
actccctgct
1501 gggttctcat gtactctatt ggcttctgtg ctgggtagtc ctgattaatg
acagtcgtgg
1561 aatcgtggga gtcaatgcac ttctgtccca cccactccc cttgcaagga
20 tcaaggagga
1621 aacctgaacc tccctctgtt tcttgggcag gtgaagatgc acaccatgct
ctcctcgcat
1681 ctcttctacc tggcgtgtg cctgctcacc ttcaccagct ctgccacgc t
- 25
- SEQ ID NO:45
- 30 atgaag ccaattcaaa aactcctagc tggccttatt ctactgactt cgtgcgtgga
aggctgctcc agccagcact ggctctatgg actgcgcctt ggaggaaaga gagatgccga
aaattt
- SEQ ID NO:46
- 35 atgagatt tcttcaatt tttactgcag ttttattcgc agcatcctcc gcattagctg
ctccagtcaa cactacaaca gaagatgaaa cggcacaat tccggctgaa gctgtcatcg
gttacttaga tttagaaggg gatttcgatg ttgctgtttt gccattttcc aacagcacia
ataacgggtt attgtttata aatactacta ttgccagcat tgctgctaaa gaagaagggg
tatctttgga taaaagagag gctgaagctt
- 40
- SEQ ID NO:47
- atgaa gtgggtaacc tttatttccc ttctttttct cttagctcg gcttattcca
ggggtgtgtt tcgtcgaga
- 45
- SEQ ID NO:48
- 1 atgaagatgg tctctcctc ggcctccgc tgctcctcg tgcctctgct gtccctgacc
61 gcctccatca gctgctcctt cgcgggacag agagactcca aactcgcct gctgctgac
121 cggtaaccgc tgcagggtc caaacaggac atgactcgtc cgccttggc cgagctgctc
181 ctgtcggacc tctgcaggg ggagaacgag gctctggagg aggagaactt cctctggcc
50 241 gaaggaggac ccgaggacgc ccacgccgac ctgagcggg ccgccagcgg ggggcctctg
301 ctgcctccc gggagagaaa ggccggctgc aagaacttct tctggaaaac ctccacctcc
361 tgctga
- SEQ ID NO:49
- 55 atggccgggc gagggggcag cgcgtgctg gctctgtgcg gggcactggc tgctgcggg
tggtcctgg gcgccgaagc ccaggagccc ggggcgccc cggcgggcat gaggcggcgc
cggcggtgct agcaagagga cggcatctcc ttcgagtacc accgctaccc cgagctgcgc
gaggcgtcgt gtccgtgtg gctgcagtgc accgccatca gcaggattta cacggtgggg
cgcagcttgc agggccggga gctcctggtc atcgagctgt ccgacaaccc tggcgtccat
60 gagcctggg agcctgaatt taaatacatt ggaatatgc atgggaatga ggctgttga

- 5 cgagaactgc tcatttttctt ggcccagtag ctatgcaacg aataccagaa ggggaacgag
 acaattgtca acctgatcca cagtaccgcg attcacatca tgccctccct gaaccagat
 ggctttgaga aggcagcgtc tcagcctggg gaactcaagg actggtttgt gggcgaagc
 aatgccagg gaatagatct gaaccggaac ttccagacc tggataggat agtgtagctg
 aatgagaaag aaggtgggtcc aaataatcat ctggtgaaaa atatgaagaa aattgtggat
 caaaacacaa agcttgcctc tgagaccaag gctgtcattc attggattat ggatattcct
 tttgtgcttt ctgccaatct ccatggagga gaccttggg ccaattatcc atatgatgag
 acgcggagtg gtagtgctca cgaatacagc tccctcccag atgacgccat ttccaaaagc
 ttggccccgg catactcttc tttcaaccgg gccatgtctg accccaatcg gccaccatgt
 10 cgcaagaatg atgatgacag cagctttgta gatggaacca ccaacgggtg tgcttggtac
 agcgtacctg gagggatgca agacttcaat taccttagca gcaactgttt tgagatcacc
 gtggagctta gctgtgagaa gttcccacct gaagagactc tgaagacctc ctgggaggat
 aacaaaaact cctcattag ctaccttgag cagatacacc gaggagttaa aggatttgc
 cgagaccttc aaggtaaacc aattgcgaat gccaccatct ccgtggaagg aatagaccac
 15 gatgttaccat ccgcaaagga tgggtgattac tggagattgc ttataacctg aaactataaa
 cttacagcct cagctccagg ctatctggca ataacaaaga aagtggcagt tccctacagc
 cctgctgctg ggggtgattt tgaactggag tcattttctg aaaggaaaga agaggagaag
 gaagaattga tggatgggtg gaaaatgatg tcagaaaactt taaatttt
- 20 SEQ ID NO:50
 atggctctct cactcttcac tgttggacaa ttaattttct tattttggac actcagaatc
 actgaagcc
- 25 SEQ ID NO:51
 atgaacaaa ctagcaattc tcgctatcat cgtatggta cttttcagcg caaacgcctt
 cagactccaa agcagattga gatcaaatat ggaagcttct gccagag
- 30 SEQ ID NO:52
 a tggtcagtgt gtgcaggtc ttgctgggtg ctgccttgcg gctgtgtttg caagcacagc
 tgtctttctc tcagcactgg tctcatggct ggtaccctgg aggaaagaga gaaatcgact
 cctacagctc accagagata tctggggaga ttaaactgtg tgaagcggga gaatgcagct
 atctcaggcc actgaggacc aacatcctaa agagcatcct gattgacacc cttgcaagga
 aattccaaaa gaggaatga.
- 35 SEQ ID NO:53
 1 tgtgttttgt agataaatgt gaggattttc tctaaatccc tcttctgctt gctaaatctc
 61 actgtcgtg ctaaattcag agcagataga gcctgcgcaa tcgaaataaa gtctcaaaa
 121 ttgaaatgtg actttgctct aacatctccc atctctctgg atttcttttt gctcattat
 181 tctgcccac caattcattt ccagactttg tacttcagaa gcgatgggga aaatcagcag
 40 241 tcttccaact caattattta agatctgcct ctgtgacttc ttgaagataa agatacacat
 301 catg
- 45 SEQ ID NO:54
 atgtc aggcggagg acgtgcttct gtctaccgtc ggtctttgta ctagtactgc
 tgagtctcag cacttcggca ctaggg
- 50 SEQ ID NO:55
 mspaaqlaka aarstcmtrl psgirvatap snshfaavgv yvdagpiyet sidrgvshfv
 sslafksthg atesqvlktm aglgnlfcct atresilyqg svlhhdprl vqlladttlr
 50 palteeeiae rratiafeae dlhrpdafi gemmhavafg grglgnsifc epqrarnmts
 dtireyfaty lhpsrmvavg tgvahaelvd lvskafvpss trapssvths dietayvgs
 hqlvipkppp thpnyeqtlh hvqvaftpvp fthpdmfpvs tlqvlmgggg afsagggpgk
 mysrlytnvl nryrwmesca afqhayssts lfgisascvp sfnpnlcnvl agefvhmarn
 lsdeevarak nqlkssllmn lesqvited igrqvlagnq rleplelvnn isavtrddlv
 55 rvaalvakp ptmvavgedl tkldiketl aafnasgeal qpvsagsfg rvtm
- 60 SEQ ID NO:56 (pTnMCS)
 1 ctgacgcgcc ctgtagcgcc gcattaagcg cggcgggtgt ggtgggttac cgcagcgtga
 61 ccgtacact tgccagcgcc ctacgcgcc atcctttgcg tttcttccct tctttctcg

121 ccacgttcgc cggcatcaga ttggctattg gccattgcat acgttgatc catatcataa
 181 tatgtacatt tatattggct catgtccaac attaccgcca tgttgacatt gattattgac
 241 tagttattaa tagtaataa ttacgggggc attagttcat agcccatata tggagttccg
 301 cgttacataa cttacggtaa atggcccgcc ttggtgaccg cccaacgacc cccgcccatt
 361 gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca
 421 atgggtggag tatttacggt aaactgcccc cttggcagta catcaagtgt atcatatgcc
 481 aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta
 541 catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac
 601 catggtgatg cgtttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg
 661 atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg
 721 ggactttcca aaatgtcgta acaactccgc ccatttgacg caaatgggag gtaggcgtgt
 781 acggtgggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg cctggagacg
 841 ccatccacgc tgttttgacc tccatagaag acaccgggac cgatccagcc tccgcgccg
 901 ggaacggtgc attggaacgc ggaattcccc tgccaagagt gacgtaagta cccgctatag
 961 actctatagg cacacccctt tggctcttat gcatgtata ctgttttttg cttggggcct
 1021 atacaccccc gcttccttat gctatagggt atggtatagc ttagcctata ggtgtgggtt
 1081 attgaccatt attgaccact cccctatttg tgacgatact ttcattact aatccataac
 1141 atggctcttt gccacaacta tctctatttg ctatatgcca atactctgtc cttcagagac
 1201 tgacacggac tctgtatttt tacaggatgg ggtcccattt attatttaca aattcacata
 1261 tacaacaacg cgtcccccgc tgcccgcagt ttttattaaa catagcgtgg gatctccacg
 1321 cgaatctcgg gtacgtgttc cggacatggg ctcttctcgc gtacggcgcc agcttccaca
 1381 tccgagccct ggtcccatgc ctccagcggc tcatggtcgc tggcagctc cttgctcta
 1441 acagtggagg ccagacttag gcacagcaca atgcccacca ccaccagtgt gccgcacaag
 1501 gccgtggcgg tagggatagt gtctgaaaat gagcgtggag attgggctcg caccgctgac
 1561 gcagatggaa gacttaaggc agcggcagaa gaagatgcag gcagctgagt tgtgttatc
 1621 tcgaagaagt cagaggtaac tccggttgcc gtgctgttaa cgggtggaggc cagtgtatgc
 1681 tgacgagtac tctgtgtcgc cgcgcgcgcc accagacata atagctgaca gactaacaga
 1741 ctgttccctt ccatgggtct tttctgcagt caccgtcgga ccatgtgcga actcgatatt
 1801 ttacacgact ctctttacca attctgcccc gaattacact taaaacgact caacagctta
 1861 acgttggtct gccacgcatt acttgactgt aaaaactctca ctcttaccga acttggccgt
 1921 aacctgccaa ccaaagcgag acaaaaacat aacatcaaac gaatcgaccg attggttagt
 1981 aatcgtcacc tccacaaaga gcgactcgct gtataccggt ggcatgctag ctttatctgt
 2041 tccggcaata cgtatgccc tgtacttgtt gactggctct atattcgtga gcaaaaacga
 2101 ctatggttat tgcgagcttc agtcgcacta cagcgtcgtt ctgttactct cttgtgaaa
 2161 cgttcccgcc tttcagagca atgttcaaag aaagctcatg accaatttct agccgacctt
 2221 gcgagcatte taccagataa caccacaccg ctcatgtgca gtgatgctgg ctttaaagtg
 2281 ccatgggtata aatccgttga gaagctgggt tggtagctgt taagtgcagt aagaggaaaa
 2341 gtacaatatg cagacctaag agcggaaaaac tggaaacctc tcagcaactt acatgatatg
 2401 tcatctagtc actcaaaagc tttagggtat aagaggctga ctaaaaagca tccaatctca
 2461 tgcacaaattc tattgtataa atctcgtctt aaaggccgaa aaaatcagcg ctgcacacgg
 2521 actcattgtc accaccgcgc acctaaaatc tactcagcgt cggcaaaagg gccatgggtt
 2581 gtacgaacta acttacctgt tgaatttcga acaccacaaac aacttgtaa tatctattcg
 2641 aagcgaatgc agattgaaga aaccttccga gacttgaaaa gtctgccta cggactaggc
 2701 ctacgccata gccgaacgag cagctcagag cgttttgata tcatgctgct aatcgccctg
 2761 atgcttcaac taacatgttg gcttgccggc gttcatgtct agaaaacagg ttgggacaag
 2821 cacttccagg ctaacacagt cagaaatcga aacgtactct caacagttcg cttaggcatt
 2881 gaagtttttg ggcattcttg ctacacaata acaagggaag acttactcgt ggttgcaacc
 2941 ctactagctc aaaatttatt cacacatggt tacgcttttg ggaaattatg aggggatcgc
 3001 tctagagcga tccgggatct cgggaaaaagc gttggtgacc aaaggtgcct tttatcatca
 3061 ctttaaaaaa aaaaaacaat tactcagtcg ctgttataag cagcaattaa ttagtatga
 3121 tgcctacatc acaacaaaaa ctgatttaac aaatggttgg tctgccttag aaagtatat
 3181 tgaacattat cttgattata ttattgataa taataaaaaa cttatcccta tccaagaagt
 3241 gatgcctatc attggttggg atgaacttga aaaaaattag ccttgaatac attactggta
 3301 aggtaaacgc cattgtcagc aaattgatcc aagagaacca acttaagct ttcctgacgg
 3361 aatgttaatt ctgcttgacc ctgagcactg atgaatcccc taatgatttt ggtaaaaatc
 3421 attaaagtaa ggtggatata catcttgtca tatgatccc gtaatgtgag ttagctcact
 3481 cattaggcac cccaggcttt acactttatg cttccggctc gtatgttgtg tggaaattgt
 3541 agcggataac aatttcacac aggaacacgc tatgaccatg attacgcaa gcgcgcaatt
 3601 aacctcact aaagggaaca aaagctggag ctccaccgag gtggcgccg ccttagaact
 3661 agtggatccc cggggctgca ggaattcgat atcaagctta tcgataccgc tgacctcgag
 3721 ggggggcccgt gtacccaatt cgcctatag tgagtctgat tacgcgcgt cactggccgt
 3781 cgttttataa cgtcgtgact gggaaaaccc tggcgttacc caacttaatc gccttgacg
 3841 acatccccct ttcgccagct ggcgttaatg cgaagaggcc cgcaccgatc gcccttcca
 3901 acagtgtcgc agcctgaatg gcgaatggaa attgtaagcg ttaatatatt gttaaaaatc
 3961 gcgttaaat tttgttaaat cagctcattt ttaaccaat aggcggaat cgcgaaaatc
 4021 ccttataaat caaaagaata gaccgagata ggggttgagt ttgttccagt ttggaacaag
 4081 agtccactat taaagaacgt ggaactcaac gtcaaaaggc gaaaaacgt cctcagggc
 4141 gatggccac tactccggga tcatatgaca agatgtgtat ccaccttaac ttaatgattt

4201 ttacccaaat cattagggga ttcacagtg ctcagggtca acgagaatta acattccgtc
 4261 aggaagcgtt atgatgatga tgtgcttaaa aacttactca atggctgggt atgcatatcg
 4321 caatacatgc gaaaaaccta aaagagcttg ccgataaaaa aggccaatat attgctatatt
 5 4381 acccgcggtt ttatttgagc ttgaaagata aataaaatag ataggtttta ttgaaagcta
 4441 aatcttcttt atcgtaaaaa atgcccctctt ggggttatcaa gagggtcatt atatttcgag
 4501 gaataacatc atttgggtgac gaaataacta agcacttgct tcctgtttac tcccttgagc
 4561 ttgaggggtt aacatgaagg tcatcgatag caggataata atacagtaaa acgctaaacc
 4621 aataatccaa atccagccat cccaaattgg tagtgaatga ttataaataa cagcaaacag
 4681 taatgggcca ataacaccgg ttgcattgggt aagggtcacc aataatccct gtaaagcacc
 10 4741 ttgctgatga ctctttgttt ggatagacat cactccctgt aatgcaggta aagcgatccc
 4801 accaccagcc aataaaatta aaacaggga aactaaccaa ccttcagata taacgctaa
 4861 aaaggcaaat gcactactat ctgcaataaa tccgagcagt actgccgttt ttccgccat
 4921 ttatgtggcta tcttctctgc cacaaggct tggaatactg agtgtaaaag accaagacc
 4981 gtaatgaaaa gccaacatc atgctattca tcatcacgat ttctgtaata gcaccacacc
 15 5041 gtgctggatt ggctatcaat gcgctgaaat aataatcaac aatggcctc gttaaataag
 5101 tgatgtatac cgatcagctt ttgttccctt tagtgaagggt taattgcgag cttggcgtaa
 5161 tcatgggtcat agctgtttcc tgtgtgaaat tgttatccgc tcacaattcc acacaacata
 5221 cgagccggaa gcataaagt taaagcctgg ggtgcctaata gagtgaagta actcacatta
 5281 attcggttgc gctcactgcc cgctttccag tcgggaaacc tgcgtgcca gctgcattaa
 20 5341 tgaatggcc aacgcggcgg gagaggcgggt ttgctattg ggcgctcttc cgcttccctg
 5401 ctactgact cgctgcgctc ggtcggtcgg ctgcggcgag cggatcagc tcaactcaag
 5461 gcgtaatac ggttatccac agaatacagg gataacgcag gaaagaacat gtgagcaaaa
 5521 ggccagcaaa aggccaggaa ccgtaaaaag gccgcgttgc tggcggtttt ccataggctc
 5581 gcggcccttg acgagcatca caaaaatcga cgctcaagtc agagggtggcg aaaccgcaga
 25 5641 ggctataaaa gataccaggc gtttccctcc ggaagctccc tcgtgcgctc tctgttccg
 5701 accctgccgc ttaccggata cctgtccgcc tttctccctt cgggaagcgt ggcgctttct
 5761 catagctcac gctgtagcta tctcagttcg gtgtaggtcg ttcgctccaa gctgggctgt
 5821 gtgcacgaac ccccggttca gcccgaccgc tgcgccttat ccggtacta tcgcttgag
 5881 tccaaccgg taagacacga cttatcgcca ctggcagcag ccactggtaa caggattagc
 30 5941 agagcgaggt atgtaggcgg tgctacagag ttcttgaagt ggtggccta ctacggctac
 6001 actagaagga cagtatttgg tatctgcgct ctgctgaagc cagttacctt cggaaaaaga
 6061 gttggtagct cttgatccgg caaacaacc accgctggta gcggtggtt tttgtttgc
 6121 agcagcaga ttacgcgag aaaaaaagg tctcaagaag atcctttgat ctttctacg
 6181 gggctgacg ctacgtggaa cgaaaactca cgttaaggga ttttggcat gagattatca
 35 6241 aaaaggatct tcacttagat ccttttaaat taaaaatgaa gttttaaat aatctaaagt
 6301 atatatgagt aaacttggtc tgacagttac caatgcttaa tcagtgaagg acctatctca
 6361 gcgatctgtc tatttoggtt atccatagtt gcctgactcc ccgtcgtgta gataactacg
 6421 atacgggagg gcttaccatc tggccccagt gctgcaatga taccgcgaga cccacgctca
 6481 ccggctccag atttatcagc aataaaccag ccagccggaa gggccgagcg cagaagtggg
 40 6541 cctgcaactt tatccgctc catccagctt attaatgtt gccgggaagc tagagtaagt
 6601 agttcgccag ttaattagtt gcgcaacggt gttgccattg ctacaggcat cgtggtgtca
 6661 cgctcgtcgt ttggtatggc ttcatcagc tccggttccc aacgatcaag gcgagttaca
 6721 tgatcccca tgggtgcaaa aaaagcgggt agctccttcg gtccctcgat cgttgcaga
 6781 agtaagttgg ccgcagtggt atcactcatg gttatggcag cactgcataa ttctcttact
 45 6841 gtcattgccat ccgtaagatg cttttctgtg actgggtgag actcaaccaa gtcattctga
 6901 gaatagtgta tgcggcgacc gagggtgctt tgcggcggt caatacggga taataccgag
 6961 ccacatagca gaactttaaa agtgcctcat attggaaaac gttcttcggg gcgaaaactc
 7021 tcaaggatct taccgctggt gagatccagt tcgatgtaac ccactcgtgc acccaactga
 7081 tcttcagcat cttttacttt caccagcgtt tctgggtgag caaaaacagg aaggcaaat
 50 7141 gccgcaaaaa aggggaataag ggcgacacgg aatggtgaa tactcatact cttctttttt
 7201 caatattatt gaagcattta tcagggttat tgtctcatga gcggatacat atttgaatgt
 7261 atttagaaaa ataaacaaat aggggttccg cgcacatttc cccgaaaagt gccac

55 SEQ ID NO:57 (pTnMod)

CTGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG 50
 CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTTCG 100
 TTTCTTCCCT TCCTTTCTCG CCACGTTTCG CGGCATCAGA TTGGCTATTG 150
 60 GCTTTCAT ACCTTGTATC CATATCATAA TATGTACATT TATATTGGCT 200
 CATGTCCAAC ATTACGCCA TGTTGACATT GATTATTGAC TAGTTATTAA 250
 TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA TGGAGTTCCG 300
 CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 350
 CCCGCCCAT GACGTCATA ATGACGTATG TTCCCATAGT AACGCCAATA 400
 65 GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT AACTGCCCA 450
 CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCC CCTATTGACG 500

	TCAATGACGG	TAAATGGCCC	GCCTGGCATT	ATGCCAGTA	CATGACCTTA	550
	TGGGACTTTC	CTACTTGGCA	GTACATCTAC	GTATTAGTCA	TCGTATTAC	600
	CATGGTGATG	CGGTTTTGGC	AGTACATCAA	TGGGCGTGGA	TAGCGGTTTG	650
	ACTCACGGGG	ATTTCCAAGT	CTCCACCCCA	TTGACGTCAA	TGGGAGTTTG	700
5	TTTGGGCACC	AAAATCAACG	GGACTTTCCA	AAATGTGTA	ACAACTCCGC	750
	CCCATTGACG	CAAATGGGCG	GTAGGCGTGT	ACGGTGGGAG	GTCTATATA	800
	GCAGAGCTCG	TTTAGTGAAC	CGTCAGATCG	CCTGGAGACG	CCATCCACGC	850
	TGTTTTGACC	TCCATAGAAG	ACACCGGGAC	CGATCCAGCC	TCCGCGGCCG	900
	GGAACGGTGC	ATTGGAACGC	GGATTCCCCG	TGCCAAGAGT	GACGTAAGTA	950
10	CCGCTATAG	ACTCTATAGG	CACACCCCTT	TGGCTCTTAT	GCATGCTATA	1000
	CTGTTTTTGG	CTTGGGGCCT	ATACACCCCT	GCTTCCTTAT	GCTATAGGTG	1050
	ATGGTATAGC	TTAGCCTATA	GGTGTGGGTT	ATTGACCATT	ATTGACCACT	1100
	CCCCTATTGG	TGACGATACT	TTCCATTACT	AATCCATAAC	ATGGCTCTTT	1150
	GCCACAACCTA	TCTCTATTGG	CTATATGCCA	ATACTCTGTC	CTTCAGAGAC	1200
15	TGACACGGAC	TCTGTATTTT	TACAGGATGG	GGTCCCATT	ATTATTTACA	1250
	AATTCACATA	TACAACAACG	CCGTCCCCCG	TGCCCGCAGT	TTTTATTAAA	1300
	CATAGCGTGG	GATCTCCACG	CGAATCTCCG	GTACGTGTTC	CGGACATGGG	1350
	CTCTTCTCCG	GTAGCGGCGG	AGCTTCCACA	TCCGAGCCCT	GGTCCCATGC	1400
	CTCCAGCGGC	TCATGGTCGC	TCGGCAGCTC	CTTGCTCCTA	ACAGTGGAGG	1450
20	CCAGACTTAG	GCACAGCACA	ATGCCCCACCA	CCACCAGTGT	GCCGCACAAG	1500
	GCCGTGGCGG	TAGGGTATGT	GTCTGAAAAT	GAGCGTGGAG	ATTGGGCTCG	1550
	CACGGCTGAC	GCAGATGGAA	GACTTAAGGC	AGCGGCAGAA	GAAGATGCAG	1600
	GCAGCTGAGT	TGTTGTATTC	TGATAAGAGT	CAGAGGTAAC	TCCCGTTGCG	1650
	GTGCTGTTAA	CGGTGGAGGG	CAGTGTAGTC	TGAGCAGTAC	TCGTTGCTGC	1700
25	CGCGCGCGCC	ACCAGACATA	ATAGCTGACA	GAATAACAGA	CTGTTCCCTT	1750
	CCATGGGTCT	TTCTGTCAGT	CACCGTCGGA	CCATGTGTGA	ACTTGATATT	1800
	TTACATGATT	CTCTTTACCA	ATTCTGCCCC	GAATTACACT	TAAAACGACT	1850
	CAACAGCTTA	ACGTTGGCTT	GCCACGCATT	ACTTGACTGT	AAAACCTCTCA	1900
	CTCTTACCGA	ACTTGGCCGT	AACCTGCCAA	CCAAAGCGAG	AACAAAACAT	1950
30	AACATCAAAC	GAATCGACCG	ATTGTTAGGT	AATCGTCACC	TCCACAAAAG	2000
	GCGACTCGCT	GTATACCGTT	GGCATGCTAG	CTTTATCTGT	TCGGGAATAC	2050
	GATGCCCCATT	GTACTTGTTG	ACTGGTCTGA	TATTCTGTAG	CAAAAACGAC	2100
	TTATGGTATT	GCGAGCTTCA	GTCGCACTAC	ACGGTCGTTT	TGTTACTCTT	2150
	TATGAGAAAG	CGTTCCCGCT	TTCAGAGCAA	TGTTCAAAGA	AAGCTCATGA	2200
35	CCAATTTCTA	GCCGACCTTG	CGAGCATTCT	ACCGAGTAAC	ACCACACCGC	2250
	TCATTGTGTC	TGATGCTGGC	TTTAAAGTGC	CATGGTATAA	ATCCGTTGAG	2300
	AAGCTGGGTT	GGTACTGGTT	AAGTCGAGTA	AGAGGAAAAG	TACAATATGC	2350
	AGACCTAGGA	GCGGAAAAC	GGAACCTAT	CAGCAACTTA	CATGATATGT	2400
	TACGCCATAG	CTCAAAGACT	TTAGGCTATA	AGAGGCTGAC	TAAAAGCAAT	2450
40	CCAATCTCAT	GCCAAATTCT	ATTGTATAAA	TCTCGCTCTA	AAGGCCGAAA	2500
	AAATCAGCGC	TCGACACGGA	CTCATTGTCA	CCACCCGTCA	CCTAAAATCT	2550
	ACTCAGCGTC	GGCAAAGGAG	CCATGGGTTT	TAGCAACTAA	CTTACCTGTT	2600
	GAAATTCGAA	CACCCAAACA	ACTTGTTAAT	ATCTATTCTGA	AGCGAATGCA	2650
	GATTGAAGAA	ACCTTCCGAG	ACTTGAAAAG	TCCTGCCTAC	GGACTAGGCC	2700
45	TACGCCATAG	CCGAACGAGC	AGCTCAGAGC	GTTTTGATAT	CATGCTGCTA	2750
	ATCGCCCTGA	TGCTTCAACT	AACATGTTGG	CTTGCGGGCG	TTTATGCTCA	2800
	GAAACAAGGT	TGGGACAAGC	ACTTCCAGGC	TAACACAGTC	AGAAATCGAA	2850
	ACGTACTCTC	AACAGTTCGC	TTAGGCATGG	AAGTTTTGCG	GCATTCTGGC	2900
	TACACAATAA	CAAGGGAAGA	CTTACTCGTG	GCTGCAACCC	TACTAGCTCA	2950
50	AAATTTATTC	ACACATGGTT	ACGCTTTGGG	GAAATTATGA	TAATGATCCA	3000
	GATCACTTCT	GGCTAATAAA	AGATCAGAGC	TCTAGAGATC	TGTGTGTTGG	3050
	TTTTTTGTGG	ATCTGCTGTG	CCTTCTAGTT	GCCAGCCATC	TGTTGTTTGC	3100
	CCCTCCCCCG	TGCCTTCCTT	GACCCGGA	GGTGCCACTC	CCACTGTCCT	3150
	TTCTTAATAA	AATGAGGAAA	TTCATCGCA	TTGTCTGAGT	AGGTGTCATT	3200
55	CTATTCTGGG	GGGTGGGGTG	GGGCAGCACA	GCAAGGGGGA	GGATTGGGAA	3250
	GACAAATAGCA	GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	GTACCTCTCT	3300
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCGGTAC	CTCTCTCTCT	3350
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCAGG	TGCTGAAGAA	3400
	TTGACCCGGT	GACCAAAGGT	GCCTTTTATC	ATCACTTTAA	AAATAAAAAA	3450
60	CAATTACTCA	GTGCCGTGTA	TAAGCAGCAA	TTAATTATGA	TTGATGCCCTA	3500
	CATCACAACA	AAAACGATT	TAACAAATGG	TTGGTCTGCC	TTAGAAAGTA	3550

TATTTGAACA TTATCTTGAT TATATTATTG ATAATAATAA AAACCTTATC 3600
 CCTATCCAAG AAGTGATGCC TATCATTGGT TGAATGAAC TTGAAAAAAA 3650
 TTAGCCTTGA ATACATTACT GGTAAGGTAA ACGCCATTGT CAGCAAATTG 3700
 ATCCAAGAGA ACCAACTTAA AGCTTTCCTG ACGGAATGTT AATTCTCGTT 3750
 5 GACCCTGAGC ACTGATGAAT CCCCTAATGA TTTTGGTAAA AATCATTAAAG 3800
 TTAAGGTGGA TACACATCTT GTCATATGAT CCCGGTAATG TGAGTTAGCT 3850
 CACTCATTAG GCACCCAGG CTTTACACTT TATGCTTCCG GCTCGTATGT 3900
 TGTGTGGAAT TGTGAGCGGA TAACAATTTT ACACAGGAAA CAGCTATGAC 3950
 CATGATTACG CCAAGCGCGC AATTAACCCT CACTAAAGGG AACAAAAGCT 4000
 10 GGAGCTCCAC CGCGGTGGCG GCCGCTCTAG AACTAGTGGA TCCCCGGGGC 4050
 TGCAGGAATT CGATATCAAG CTTATCGATA CCGCTGACCT CGAGGGGGGG 4100
 CCCGGTACCC AATTCGCCCT ATAGTGAGTC GTATTACGCG CGCTCACTGG 4150
 CCGTCGTTTT ACAACGTCGT GACTGGGAAA ACCCTGGCGT TACCCAACTT 4200
 AATCGCCTTG CAGCACATCC CCCTTTCGCC AGCTGGCGTA ATAGCGAAGA 4250
 15 GGCCCGCACC GATCGCCCTT CCCAACAGTT GCGCAGCCTG AATGGCGAAT 4300
 GGAAATTGTA AGCGTTAATA TTTTGTAAA ATTGCGGTTA AATTTTTGTT 4350
 AAATCAGCTC ATTTTTTAAC CAATAGGCCG AAATCGGCAA AATCCCTTAT 4400
 AAATCAAAAG AATAGACCGA GATAGGGTTG AGTGTGTGTC CAGTTTGGAA 4450
 CAAGAGTCCA CTATTAAAGA ACGTGGACTC CAACGTCAA GGCAGAAAAA 4500
 20 CCGTCTATCA GGGCGATGCG CCACTACTCC GGGATCATAT GACAAAGATGT 4550
 GTATCCACCT TAACTTAATG ATTTTACCA AAATCATTAG GGGATTATC 4600
 AGTGCTCAGG GTCAACGAGA ATTAACATTC CGTCAGGAAA GCTTATGATG 4650
 ATGATGTGCT TAAAACTTA CTCAATGGCT GGTTATGCAT ATCGCAATAC 4700
 ATGCGAAAAA CCTAAAAGAG CTTGCCGATA AAAAAGGCCA ATTTATTGCT 4750
 25 ATTTACCGCG GCTTTTTATT GAGCTTGAAG GATAAATAA ATAGATAGGT 4800
 TTTATTTGAA GCTAAATCTT CTTTATCGTA AAAAAAGCCC TCTTGGGTTA 4850
 TCAAGAGGGT CATTATATTT CGCGGAATAA CATCATTTGG TGACGAAATA 4900
 ACTAAGCACT TGTCTCCTGT TTAATCCCCT GAGCTTGAGG GGTTAACATG 4950
 AAGGTCATCG ATAGCAGGAT AATAATACAG TAAAACGCTA AACCATAAAT 5000
 30 CCAAAATCCAG CCATCCCAAA TTGGTAGTGA ATGATTATAA ATAACAGCAA 5050
 ACAGTAATGG GCCAATAACA CCGGTTGCAT TGGTAAGGCT CACCAATAAT 5100
 CCCTGTAAAG CACCTTGCTG ATGACTCTTT GTTTGGATAG ACATCACTCC 5150
 CTGTAATGCA GGTAAAGCGA TCCCACCACC AGCCAATAAA ATTAAGACAG 5200
 GGAAAACTAA CCAACCTTCA GATATAAAGC CTAAAAAGGC AAATGCACTA 5250
 35 CTATCTGCAA TAAATCCGAG CAGTACTGCC GTTTTTTCGC CCATTTAGTG 5300
 GCTATTCTTC CTGCCACAAA GGCTTGGAAT ACTGAGTGTA AAAGACCAAG 5350
 ACCCGTAATG AAAAGCCAAC CATCATGCTA TTCATCATCA CGATTCTGT 5400
 AATAGCACCA CACCGTGCTG GATTGGCTAT CAATGCGCTG AAATAATAAT 5450
 CAACAAAAGG CATCGTTAAA TAAGTGATGT ATACCGATCA GCTTTTGTTC 5500
 40 CCTTTAGTGA GGGTTAATFG CGCGCTTGGC GTAATCATGG TCATAGCTGT 5550
 TTCCTGTGTG AAATTGTTAT CCGCTCACAA TTCCACACAA CATACGAGCC 5600
 GGAAGCATAA AGTGTAAGC CTGGGGTGCC TAATGAGTGA GCTAATCTAC 5650
 ATTAATTGCG TTGCGCTCAC TGCCCGCTTT CCAGTCGGGA AACCTGTCGT 5700
 GCCAGCTGCA TTAATGAATC GGCCAACGCG CGGGGAGAGG CGGTTTGCCT 5750
 45 ATTGGGCGCT CTTCGCTTC CTCGCTCACT GACTCGCTGC GCTCGGTCGT 5800
 TCGGCTGCGG CGAGCGGTAT CAGCTCACTC AAAGGCGGTA ATACGGTTAT 5850
 CCACAGAATC AGGGGATAAC GCAGGAAAGA ACATGTGAGC AAAAGGCCAG 5900
 CAAAAGGCCA GGAACCGTAA AAAGGCCGCG TTGCTGGCGT TTTTCCATAG 5950
 GC'TCCGCCCC CCTGACGAGC ATCACAATAA TCGACGCTCA AGTCAGAGGT 6000
 50 GGCGAAAACC GACAGGACTA TAAAGATACC AGGCGTTTCC CCCTGGAAGC 6050
 TCCCTCGTGC GCTCTCCTGT TCCGACCTG CCGCTTACCG GATACCTGTC 6100
 CGCCTTTCTC CTTTCGGGAA GCGTGGCGCT TTCTCATAGC TCACGCTGTA 6150
 GGTATCTCAG TTCGGTGTAG GTCGTTGCT CCAAGCTGGG CTGTGTGCAC 6200
 GAACCCCCCG TTCAGCCCGA CCGCTGCGCC TTATCCGGTA ACTATCGTCT 6250
 55 TGAGTCCAAC CCGTAAGAC ACGACTTATC GCCACTGGCA GCAGCCACTG 6300
 GTAACAGGAT TAGCAGAGCG AGGTATGTAG GCGGTGCTAC AGAGTTCTTG 6350
 AAGTGGTGGC CTAACCTACG CTACACTAGA AGGACAGTAT TTGGTATCTG 6400
 CGCTCTGCTG AAGCCAGTTA CCTTCGGAAA AAGAGTTGGT AGCTCTTGAT 6450
 CCGGCAACA AACCACCGCT GGTAGCGGTG GTTTTTTTGT TTGCAAGCAG 6500
 60 CAGATTACGC GCAGAAAAAA AGGATCTCAA GAAGATCCTT TGATCTTTTC 6550
 TACGGGGTCT GACGCTCAGT GGAACGAAAA CTCACGTTAA GGGATTTTGG 6600

5 TCATGAGATT ATCAAAAAGG ATCTTCACCT AGATCCTTTT AAATTAAAAA 6650
 TGAAGTTTTA AATCAATCTA AAGTATATAT GAGTAAACTT GGTCTGACAG 6700
 TTACCAATGC TTAATCAGTG AGGCACCTAT CTCAGCGATC TGTCTATTTT 6750
 GTTCATCCAT AGTTGCCTGA CTCCCCGTCG TGTAGATAAC TACGATACGG 6800
 5 GAGGGCTTAC CATCTGGCCC CAGTGCTGCA ATGATACCGC GAGACCCACG 6850
 CTCACCGGCT CCAGATTTAT CAGCAATAAA CCAGCCAGCC GGAAGGGCCG 6900
 AGCGCAGAAG TGGTCCTGCA ACTTTATCCG CCTCCATCCA GTCTATTAAT 6950
 TGTTCGCCGG AAGCTAGAGT AAGTAGTTCG CCAGTTAATA GTTTGCGCAA 7000
 CGTTGTTGCC ATTGCTACAG GCATCGTGGT GTCACGCTCG TCGTTTGGTA 7050
 10 TGGCTTCATT CAGCTCCGGT TCCCAACGAT CAAGGCGAGT TACATGATCC 7100
 CCCATGTTGT GCAAAAAAGC GGTTAGCTCC TTCGGTCCTC CGATCGTTGT 7150
 CAGAAGTAAG TTGCCCGCAG TGTTATCACT CATGGTTATG GCAGCACTGC 7200
 ATAATTCTCT TACTGTCATG CCATCCGTAA GATGCTTTTC TGTGACTGGT 7250
 GAGTACTCAA CCAAGTCATT CTGAGAATAG TGTATGCGGC GACCGAGTTG 7300
 15 CTCTTGCCCG GCGTCAATAC GGGATAATAC CGCGCCACAT AGCAGAACTT 7350
 TAAAAGTGCT CATCATGGA AAACGTTCTT CGGGGCGAAA ACTCTCAAGG 7400
 ATCTTACCGC TGTGAGATC CAGTTCGATG TAACCCACTC GTGCACCCAA 7450
 CTGATCTTCA GCATCTTTTA CTTTCACCAG CGTTTCTGGG TGAGCAAAAA 7500
 CAGGAAGGCA AAATGCCGCA AAAAAGGGAA TAAGGGCGAC ACGGAAATGT 7550
 20 TGAATACTCA TACTCTTCCT TTTTCAATAT TATTGAAGCA TTTATCAGGG 7600
 TTATTGTCTC ATGAGCGGAT ACATATTTGA ATGTATTTAG AAAAATAAAC 7650
 AAATAGGGGT TCCGCGCACA TTTCCCCGAA AAGTGCCAC 7689

25 SEQ ID NO:58 (a Kozak sequence)
 ACCATGG

SEQ ID NO:59 (a Kozak sequence)
 ACCATGT

30 SEQ ID NO:60 (a Kozak sequence)
 AAGATGT

SEQ ID NO:61 (a Kozak sequence)
 ACGATGA

35 SEQ ID NO:62 (a Kozak sequence)
 AAGATGG

SEQ ID NO:63 (a Kozak sequence)
 40 GACATGA

SEQ ID NO:64 (a Kozak sequence)
 ACCATGA

45 SEQ ID NO:65 (a Kozak sequence)
 ACCATGT

SEQ ID NO:66 (conalbumin polyA)
 50 tctgccattg ctgttctc tgcccttccct cgtcactctg aatgtggctt cttcgctact
 gccacagcaa gaaataaaat ctcaacatct aaatggggtt cctgaggttt ttcaagagtc
 gttaagcaca ttcttcccc agcaccctt gctgcaggcc agtgccaggc accaacttgg
 ctactgctgc ccatgagaga aatccagttc aatattttcc aaagcaaaat ggattacata
 tggccttagat cctgattaac aggcgtttgt attatctagt gctttcgctt caccagatt
 atcccatgtc ctccc

55 SEQ ID NO:67 (synthetic polyA)
 GGCGCTGGATCCAGATCACTTCTGGCTAATAAAAGATCAGAGCTCTAGAGATCTGTGTGTTGGTTTTT
 TGTGGATCTGCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCCTCCCCGTGCCCTTCCTTGACC

5

10

15

20

35

40

55

60

14

atgaaaaggc aatttccaca ctccacaatat gcaacaaaga caaacagaga acaattaatg
 tgctccttcc taatgtcaaa attgtagtgg caaagaggag aacaaaatct caagttctga
 gtaggtttta gtgattggat aagaggcttt gacctgtgag ctccacctgga cttcatatcc
 ttttggataa aaagtgtctt tataactttc aggtctccga gtctttattc atgagactgt
 5 tggtttaggg acagaccac aatgaaatgc ctggcatagg aaagggcagc agagccttag
 ctgacctttt cttgggacaa gcattgtcaa acaatgtgtg acaaaactat ttgtactgct
 ttgcacagct gtgctgggca gggcaatcca ttgccaccta tcccaggtaa cttccaact
 gcaagaagat tgttgcttac tctctctaga

10

SEQ ID NO:72 (5' untranslated region)
 GTGGATCAACATACAGCTAGAAAGCTGTATTGCCTTTAGCACTCAAGCTCAAAAGACAACCTCAGAGTTC
 ACC

15

SEQ ID NO:73 (putative cap site)
 ACATACAGCTAG AAAGCTGTAT TGCCTTTAGC ACTCAAGCTC AAAAGACAAC TCAGAGTTCA

20

SEQ ID NO:74 (Chicken Ovalbumin Signal Sequence)
 ATG GGCTCCATCG GCGCAGCAAG CATGGAATTT TGTTTTGATG TATTCAAGGA GCTCAAAGTC
 CACCATGCCA ATGAGAACAT CTTCTACTGC CCCATTGCCA TCATGTCAGC TCTAGCCATG
 GTATACCTGG GTGCAAAAGA CAGCACCAGG ACACAGATAA ATAAGGTTGT TCGCTTTGAT
 AAACCTCCAG GATTTCGGAGA CAGTATTGAA GCTCAGTGTG GCACATCTGT AACGTTTAC
 25 TCTTCACTTA GAGACATCCT CAACCAATC ACCAAACCAA ATGATGTTTA TTCGTTGAGC
 CTTGCCAGTA GACTTTATGC TGAAGAGAGA TACCCAATCC TGCCAGAATA CTTGCAGTGT
 GTGAAGGAAC TGTATAGAGG AGGCTTGGA CCTATCAACT TTCAAACAGC TGCAGATCAA
 GCCAGAGAGC TCATCAATTC CTGGGTAGAA AGTCAGACAA ATGGAATTAT CAGAAATGTC
 CTTTCAGCCAA GCTCCGTGGA TTCTCAAACT GCAATGGTTC TGGTTAATGC CATTGTCCTC
 30 AAAGGACTGT GGGAGAAAAC ATTTAAGGAT GAAGACACAC AAGCAATGCC TTTCAGAGTG
 ACTGAGCAAG AAAGCAAACC TGTGCAGATG ATGTACCAGA TTGTTTATTT TAGAGTGGCA
 TCAATGGCTT CTGAGAAAAT GAAGATCCTG GAGCTTCCAT TTGCCAGTGG GACAATGAGC
 ATGTTGGTGC TGTGCTCTGA TGAAGTCTCA GGCCTTGAGC AGCTTGAGAG TATAATCAAC
 TTTGAAAAAC TGACTGAATG GACCAGTTCT AATGTTATGG AAGAGAGGAA GATCAAAGTG
 35 TACTTACCTC GCATGAAGAT GGAGGAAAAA TACAACCTCA CATCTGTCTT AATGGCTATG
 GGCATTACTG ACGTGTCTTCT CTCTTCAGCC AATCTGTCTG GCATCTCCTC AGCAGAGAGC
 CTGAAGATAT CTCAAGCTGT CCATGCAGCA CATGCAGAAA TCAATGAAGC AGGCAGAGAG
 GTGGTAGGGT CAGCAGAGGC TGGAGTGGAT GCTGCAAGCG TCTCTGAAGA ATTTAGGGCT
 GACCATCCAT TCCTCTTCTG TATCAAGCAC ATCGCAACCA ACGCCGTTCT CTTCTTTGGC
 40 AGATGTGTTT CCCCT

SEQ ID NO:75 (Chicken Ovalbumin Signal Sequence-shortened approx.
 50bp)

45 ATG GGCTCCATCG GCGCAGCAAG CATGGAATTT TGTTTTGATG TATTCAAG

SEQ ID NO:76 (Chicken Ovalbumin Signal Sequence-shortened approx.
 100bp)

50 ATG GGCTCCATCG GCGCAGCAAG CATGGAATTT TGTTTTGATG TATTCAAGGA GCTCAAAGTC
 CACCATGCCA ATGAGAACAT CTTCTACTGC CCCATTGCCA TC

SEQ ID NO:77 (vitellogenin targeting sequence)
 55 ATGAGGGGGATCATACTGGCATTAGTGCTCACCTTGTAGGCAGCCAGAAGTTTGACATTGGT

SEQ ID NO:78 (p146 protein)
 KYKKALKKLAKLL

60

SEQ ID NO:79 (p146 coding sequence)

AAATACAAAAAGCACTGAAAAAACTGGCAAACTGCTG

- 5 SEQ ID NO:80 (pro-insulin sequence)
 TTGTGAACCAACACCTGTGCGGCTCACACCTGGTGGAGCTCTCTACCTAGTGTGCGGGAACGAGGC
 TTCTTCTACACACCCAAGACCCGCGGGAGGCAGAGGACCTGCAGGTGGGGCAGGTGGAGCTGGGCGGG
 GGCCCTGGTGCAGGCAGCCTGCAGCCCTTGGCCCTGGAGGGGTCCCTGCAGAAGCGTGGCATTGTGGAA
 CAATGCTGTACCAGCATCTGCTCCCTCTACCAGCTGGAGAACTCTGCAACTAG
- 10 SEQ ID NO:81 (spacer)
 (GPGG)_x
- 15 SEQ ID NO:82 (spacer)
 GPGGGPGGPGG
- 20 SEQ ID NO:83 (spacer)
 GGGSGGGSGGGGS
- 25 SEQ ID NO:84 (spacer)
 GGGSGGGSGGGSGGGGS
- 30 SEQ ID NO:85 (repeat domain in TAG spacer sequence)
 Pro Ala Asp Asp Ala
- 35 SEQ ID NO:86 (TAG spacer sequence)
 Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp
 Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp
- 40 SEQ ID NO:87 (gp41 epitope)
 Ala Thr Thr Cys Ile Leu Lys Gly Ser Cys Gly Trp Ile Gly Leu Leu
- 45 SEQ ID NO:88 (polynucleotide sequence encoding gp41 epitope)
 Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Thr Thr Cys Ile Leu Lys Gly
 Ser Cys Gly Trp Ile Gly Leu Leu Asp Asp Asp Asp Lys
- 50 SEQ ID NO:89 (enterokinase cleavage site)
 DDDDK
- 55 SEQ ID NO:90 (TAG sequence)
 Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp
 Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Thr Thr Cys Ile Leu Lys Gly Ser Cys
 Gly Trp Ile Gly Leu Leu Asp Asp Asp Asp Lys
- SEQ ID NO:91 (altered transposase Hef forward primer)
 ATCTCGAGACCATGTGTGAACTTGATATTTTACATGATTCTCTTACC

SEQ ID NO:92 (altered transposase Her reverse primer)
GATTGATCATTATCATAATTTCCCAAGCGTAACC

5 SEQ ID NO:93 (Xho I restriction site)
CTCGAG

10 SEQ ID NO:94 (Bcl I restriction site)
TGATCA

15 SEQ ID NO:95 (CMVf-NgoM IV primer)
TTGCCGGCATCAGATTGGCTAT

SEQ ID NO:96 (Syn-polyAr-BstE II primer)
AGAGGTCACCGGTCAATTCTTCAGCACCTGGTA

20 SEQ ID NO:97 (pTnMOD (CMV-prepro-HCPro-Lys-CPA)

1 ctgacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga
61 ccgctacact tggcagcgcc ctgacgcccc ctcccttcgc tttcttccct tcctttctcg
121 ccacgttcgc cggcatcaga ttggtatttg gccattgcat acgttgatc catatcataa
181 tatgtacatt tatattggct catgtccaac attaccgcca tgttgacatt gattattgac
241 tagttattaa tagtaataa ttacggggtc attagtccat agcccatata tggagttccg
301 cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt
361 gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca
421 atgggtggag tatttacggg aaactgccca cttggcagta catcaagtgt atcatatgcc
481 aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta
541 catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac
601 catggtgatg cgggttttggc agtacatcaa tgggcgttga tagcgtttg actcacgggg
661 atttccaagt ctccaccoca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg
721 ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggag gtaggcgtgt
781 acggtgggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg cctggagacg
841 ccatccacgc tgttttgacc tccatagaag acacggggac cgtaccagcc tccgcccgcg
901 ggaacggtgc attggaacgc ggattccccg tgccaagagt gacgtaagta ccgctatag
961 actctatagg cacaccctt tggctcttat gcatgctata ctgtttttgg cttggggcct
1021 atacaccccc gcttccttat gctatagggt atggtatagc ttacgctata ggtgtgggtt
1081 attgaccatt attgaccact cccctatttg tgacgatact ttccattact aatccataac
1141 atggctcttt gccacaacta tctctatttg ctatatgcc aatctctgtc cttcagagac
1201 tgacacggac tctgtatttt tacaggatgg ggtcccattt attatttaca aattcacata
1261 tacaacaacg ccgtcccccg tgcccgcagt ttttattaaa catagcgtgg gatctccaag
1321 cgaatctcgg gtacgtgttc cggacatggg ctcttctccg gtacggcgcg agcttccaca
1381 tccgagccct ggtcccatgc ctccagcgcc tcatggtcgc tccgcagctc cttgtccta
1441 acagtgagg ccagacttag gcacagcaca atgcccacca ccaccagtgt gccgcacaag
1501 gccgtggcgg tagggtatgt gtctgaaaat gagcgtggag attgggctcg cacggctgac
1561 gcagatggaa gacttaaggc agcggcagaa gaagatgcag gcagctgagt tgttgtattc
1621 tgataagagt cagaggtaac tcccgttgcg gtgctgttaa cgggtggagg cagtgtagtc
1681 tgagcagtag tcgttgctgc ccgcgcgcgc accagacata atagctgaca gactaacaga
1741 ctgttccttt ccatgggtct tttctgcagt caccgtcgga ccatgtgtga acttgatatt
1801 ttacatgatt ctctttacca attctgcccc gaattacact taaaacgact caacagctta
1861 acgttggtt gccacgcatt acttgactgt aaaactctca ctcttaccga acttggccgt
1921 aacctgccaa ccaaaagcag aacaaaacat aacatcaaac gaatcgaccg attgttaggt
1981 aatcgtcacc tccacaaga ggcactcgct gtataccgtt ggcattgtag ctttatctgt
2041 tccggcaata cgatgcccct tgtacttggt gactgggtct atattcgtga gcaaaaaaga
2101 cttatggtat tgcgagcttc agtcgcacta caccgttcgt ctgttactct ttatgagaaa
2161 cgttcccgcc tttcagagca atgttcaaaag aaagctcatg accaatttct agccgacctt
2221 gcgagcattc taccagagtaa caccacaccg ctcatgtgca gtgatgctgg ctttaaagtg
2281 ccatggtata aatccgttga gaagctgggt tggtagctgt taagtgcagt aagaggaaaa
2341 gtacaatatg cagacctagg agcggaaaac tggaaacctc tcagcaactt acatgatag
2401 tcatctagtc actcaaagac tttaggctat aagaggctga ctaaaagcaa tccaatctca
2461 tgccaaatcc tattgtataa atctcgctct aaaggccgaa aaaatcagcg ctcgacacgg
2521 actcattgtc accaccgctc acctaaaatc tactcagcgt cggcaaggga gccatgggtt
2581 ctagcaacta acttacctgt tgaaattcga acacccaaac aacttggttaa tatctattcg

5

10

15

20

25

30

35

40

45

50

55

60

65

2641 aagcgaatgc agattgaaga aaccttccga gacttgaaaa gtccctgccta cggactagggc
 2701 ctacgccata gccgaacgag cagctcagag cgttttgata tcatgctgct aatcgccctg
 2761 atgcttcaac taacatgttg gcttgccggc gttcatgctc agaacaagg ttgggacaag
 2821 cacttccagg ctaacacagt cagaatcga aacgtactct caacagttcg cttaggcatg
 2881 gaagttttgc ggcattcttg ctacacaata acaagggaag acttactcgt ggctgcaacc
 2941 ctactagctc aaaatttatt cacacatggg tacgctttgg ggaattatg ataatgatcc
 3001 agatcacttc tggctaataa aagatcagag ctctagagat ctgtgtgttg gttttttgtg
 3061 gatctgctgt gccttctagt tggcagccat ctgttgtttg cccctccccc gtgccttccct
 3121 tgaccctgga aggtgccact cccactgtcc tttcctaata aaatgaggaa attgcatcgc
 3181 attgtctgag taggtgtcat tctattctgg ggggtggggg ggggcagcac agcaaggggg
 3241 aggattggga agacaatagc aggcattgctg gggatgcggg gggctctatg ggtacctctc
 3301 tctctctctc tctctctctc tctctctctc tctctcggtc cctctctctc tctctctctc
 3361 tctctctctc tctctctctc tccgtaccag gtgctgaaga attgaccggg tgaccaagg
 3421 tgccttttat catcacttta acaataaaaa acaattactc agtgccctgtt ataagcagca
 3481 attaatattg attgatgcct acatcacaaac aaaaactgat ttaacaaatg gttggctcgc
 3541 cttagaaagt atatttgaac attatcttga ttatattatt gataataata aaaaccttat
 3601 ccctatccaa gaagtgtatg ctatcattgg ttggaatgaa ctgaaaaaaa attagccctg
 3661 aatacattac tggtaaggta aacgccattg tcagcaaat gatccaagag aaccaactta
 3721 aagctttcct gacggaatgt taattctcgt tgacctgag cactgtgaa tcccctatg
 3781 attttggtta aatcattaa gtttaagggtg atacacatct tgtcatatga tcccggtaat
 3841 gtgagttagc tcaactcatta ggcaccccg gctttacact ttatgcttcc ggctcgtatg
 3901 ttgtgtggaa ttgtgagcgg ataacaattt cacacaggaa acagctatga ccatgattac
 3961 gccaaagcgg caattaaacc tccataaagg gaacaaaagc tggagctcca ccgcgggtgg
 4021 ggccgctcta gaactagtgg atcccccggt ctgcaggaa tccgatataa gcttatcgat
 4081 accgctgacc tcgagcatca gattggctat tggccattgc atacgttga tccatcatat
 4141 aatatgtaca tttatattgg ctcatgtcca acattacgcg catgttgaca ttgattattg
 4201 actagtattt aatagtaatc aattacgggg tcattagttc atagcccca tatggagttc
 4261 cgcgttacat aactacggg aaatggcccg cctggctgac cgcaccaaga ccccccacca
 4321 ttgacgtcaa taatgacgta tgttcccata gtaacgccaa tagggacttt ccatgacgt
 4381 caatgggtgg agtatttacg gtaaaactgcc cacttggcag tacatcaagt gtatcatatg
 4441 tcaagtacgc cccctattga cgtcaatgac ggtaaaatgg ccgcctggca ttatgccag
 4501 tacatgaact tatgggactt tccacttgg cagtacatct acgtattagt catcgctatt
 4561 accatgggtg tgcggttttg gcagtacatc aatgggcgtg gatagcgggt tgactcacgg
 4621 ggatttccaa gtcttcaccc cattgacgtc aatgggagtt tgttttgga ccaaaatcaa
 4681 cgggactttc caaaatgtcg taacaaactcc gccccattga cgcaaaatgg cgttagcgct
 4741 gtacgggtgg aggtctatat aagcagagct cgtttagtga accgtcagat cgcctggaga
 4801 cgccatccac gctgttttga cctccataga agacacgggg accgatccag cctcccgggc
 4861 cgggaacggg gcattggaac ggcgattccc cgtgccaaaga gtgacgtaag taccgctat
 4921 agactctata ggcacacccc ttgggtcctt atgcatgcta tactgttttt ggcttggggc
 4981 ctatacacc cgccttcctt atgctatagg tgatgggtata gcttagccta taggtgtggg
 5041 ttattgacca ttattgacca ctccctattt ggtgacgata ctttccatta ctaatccata
 5101 acatggctct ttgcccacac tatctctatt ggtatatgc caatactctg tccctcagag
 5161 actgacacgg actctgtatt ttacaggat ggggtcccat ttattattta caaattcaca
 5221 tatacaacaa cgccttcccc cgtgcccgca gtttttatta aacatagcgt gggatctcca
 5281 cgcgaatctc gggtagctgt tccggacatg ggtctctctc cggtagcggc ggagcttcca
 5341 catccgagcc ctgggtcccat gccctccagcg gctcatggtc gctcggcagc tccctgtctc
 5401 taacagtgga ggcacagca aggcacagca caatgccac caccacagc gtcgcgaca
 5461 aggcgtggc ggtaggggat gtgtctgaaa atgagcgtgg agattgggct cgcacggctg
 5521 acgcagatgg aagacttaag gcagcggcag aagaagatgc aggcagctga gttgtgtgat
 5581 tctgataaga gtcagaggta actcccggtg cgtgtgctgt aacgggtggg ggcagtgtag
 5641 tctgagcagt actcgttgct gccgcgcgcg ccaccagaca taatagctga cagactaaca
 5701 gactgttctt ttccatgggt cttttctgca gtcaccgtcg gatcaatcat tcatctctg
 5761 acttcttctg gtgtgggtgt tacctatata tctaaattta atatttctgt tattaaaatt
 5821 taatatattt cgacgatgaa tttctcaagg atattttct tctgttctgc tttgttctg
 5881 gctttgtcaa cagtttcggc tgcgcagag ccgaaaggta ccaggtgca gctgcaggag
 5941 tcggggggag gcttggtaaa gccggggggg tcccttagag tctcctgtgc agctctgga
 6001 ttcactttca gaaacgcctg gatgagctgg gtcgccagg ctcaggga ggggctggag
 6061 tgggtcggcc gtattaaaag caaaattgat ggtgggacaa cagactatgc tgcaccctg
 6121 aaaggcagat tcaccatctc aagagatgat tcaaaaaaca cgttatatct gcaaatgaat
 6181 agcctgaaag ccgaggtatat tactgtacca cgggggttat gtaaacattt
 6241 gggggagtta tccctcccc gaattggggc cagggaaacc tggtcaccgt ctctcagcc
 6301 tccaccaagg gcccatcggt ctccccctg gcaccctct ccaagagcac ctctggggg
 6361 acagcggccc tgggctgcct ggtcaaggac tacttccccg aaccgggtgac ggtgtcgtgg
 6421 aactcaggcg cctgaccag cgcgtgcac acctttccgg ctgtctaca gtcctcagga
 6481 ctctacttcc ttagcaacgt ggtgaccgtg cctccagca gcttgggac ccagacctac
 6541 atctgcaacg tgaatcacia gccagcaac accaaggtgg acaagaaagt tgagcccaaa
 6601 tcttgtgaca aaactcacac atgcccacgg tgcacagcac ctgaactcct ggggggacgg
 6661 tcagtcttcc tcttcccccc aaaaaccagg gacacccca tgatctcccg gaaccttagg

	6721	gtcacatgcy	tgggtggtgga	cgtgagccac	gaagaccctg	agggtcaagtt	caactgggtac
	6781	gtggacggcg	tggagggtgca	taatgccaag	acaaagccgc	gggaggagca	gtacaacagc
	6841	acgtaccgtg	tggtcagcgt	cctcaccgtc	ctgcaccagg	actgggtgaa	tggcaaggag
5	6901	tacaagtgc	agggtctcaa	caaagccctc	ccagccccc	tcgagaaaac	catctccaaa
	6961	gccaaaggcg	agccccgaga	accacaggtg	tacacccctg	ccccatcccg	ggatgagctg
	7021	accaagaacc	agggtcagcct	gacctgcctg	gtcaaaggct	tctatcccg	cgacatcgcc
	7081	gtggagtggg	agagcaatgg	gcagccggag	aacaactaca	agaccacgcc	tcccgtgctg
	7141	gactccgacg	gctccttctt	cctctacagc	aagctcaccg	tggacaagag	cagggtggcag
10	7201	cagggggaacg	tcttctcatg	ctcgtgatg	catgaggctc	tgcacaacca	ctacacgcag
	7261	aagagcctct	cctgtctctc	gggtaaagcg	ccagagccga	aaaagcttcc	ctatgagctg
	7321	accacgccac	cctcgggtgc	agtgtcccca	ggacaaacgg	ccaggatcac	ctgctctgga
	7381	gatgcattgc	cagaaaaata	tgtttattgg	taccagcaga	agtcaggcca	ggccccgtg
	7441	gtggtcatct	atgaggacag	caaacgaccc	tccgggatcc	ctgagagatt	ctctggctcc
15	7501	agctcaggga	caatggccac	cttgactatc	agtggggccc	agggtggaaga	tgaagggtgac
	7561	tactactgtt	actcaactga	cacagctggg	tatcataggg	agggtgttcc	cggaggagacc
	7621	aagctgaccg	tcttaggtca	gccccaggtc	gccccctcgg	tactctgtgt	cccacccctc
	7681	tctgaggagc	tccaagccaa	caaggccaca	ctgggtgtgtc	tataaagtga	ctcctaccgg
	7741	ggagccgtga	cagtggtcgt	gaaggcagat	agcagccccc	tcaaggccgg	agtgagagacc
20	7801	accacaccct	ccaaacaaag	caacaacaag	tacgcggcca	gcagctacct	gagcctgacg
	7861	cttgagcagt	ggaagtccca	caaaagctac	agctgccagg	tcacgcctga	agggagcacc
	7921	gtggagaaga	cagtggtccc	tgagaatgt	tcaccgcgga	gggagggaag	ggcccccttt
	7981	gaagggggag	gaaactctgc	gccatgactc	ctctcgtgcc	ccccgcacgg	aacactgatg
25	8041	tgagagggcg	ccctgccttc	tgtgtcttcc	ctgtcccttc	ctcgtcactc	gtgattgtgg
	8101	ttctttgcta	ctgccacagc	aagaaataaa	atctcaacat	ctaaatgggt	ttcctgagat
	8161	ttttcaagag	togttaagca	catctcctcc	ccagcaccoc	ttgctgcagg	ccagtgccag
	8221	gcaccaactt	ggctactgct	gccccatgag	gaaatccagt	tcaatatttt	ccaaagcaaa
	8281	atggattaca	tatgccttag	atctcgatta	acaggtgttt	tgtattatct	gtgcttctgc
	8341	ttcaccacac	ttatcccat	gcctccctc	gactcgaggg	ggggcccggt	acccaattcg
30	8401	ccctatagtg	agtcgtatta	cgccggtcca	ctggccgtcg	ttttacaacg	tcgtgactgg
	8461	gaaaaccctg	gcgtttacca	acttaatcgc	cttgacgac	atcccccttt	cgccagctgg
	8521	cgtaaatagc	aagaggcccg	accgatcgc	ccttcccaac	agttgcgcat	cctgaatggc
	8581	gaatggaaat	tgtaaagcgt	aatattttgt	taaaattcgc	gttaaatatt	tgttaaatca
	8641	gctcattttt	taaccaatag	gcccgaatcg	gcaaaatccc	ttataaatca	aaagaataga
35	8701	ccgagatagg	ggttagtggt	gttccagttt	ggaacaagag	tccactatta	aagaacgtgg
	8761	actccaacgt	caaaggcgct	aaaaccgtct	atcagggcga	tggcccaacta	tggccggatc
	8821	atatgacaag	atgtgtatcc	acccttaact	aatgattttt	acccaaatca	ttaggggatt
	8881	catcagtgct	caggggtcaac	gagaattaac	attccgtcag	gaaagcttat	gatgatgatg
	8941	tgtctaaaaa	cttactcaat	gggtgggtat	gcataatcga	atacatcgca	aaaacctaaa
40	9001	agagcttgcc	gataaaaaag	gccaaattat	tgctattttac	cgccggtttt	tattgagctt
	9061	gaaagataaa	taaaatagat	agggtttatt	tgaagctaaa	tcttctttat	cgttaaaat
	9121	gccctcttgg	gttatcaaga	gggtcattat	atttcgcgga	ataacatcat	ttggtgacga
	9181	aataactaag	cacttgtctc	ctgtttactc	ccctgagctt	gaggggttaa	catgaaggct
	9241	atcgatagca	ggataataat	acagtaaaac	gctaaccaca	taatccaat	ccagccatcc
45	9301	caaattggta	gtgaatgatt	ataaataaca	gcaaacagta	atggggccaat	aacaccgggt
	9361	gcattggtaa	ggctcaccac	taatccctgt	aaagcacctt	gctgatgact	ctttgtttgg
	9421	atagacatca	ctccctgtaa	tgcaggtaaa	gcgatccac	caccagccaa	taaaattaaa
	9481	acagggaaaa	ctaaccaacc	ttcagatata	aacgctaaaa	aggcaaatgc	actactatct
	9541	gcaataaatc	cgagcagtac	tgcggttttt	tcgcccattt	agtggtctat	cttctcgcca
50	9601	caaaggcttg	gaatactgag	tgtaaaagac	caagaccctg	aatgaaaagc	caaccatcat
	9661	gctattcatc	atcacgattt	ctgtaatagc	accacaccgt	gctggattgg	ctatcaatgc
	9721	gctgaaataa	taatcaacaa	atggcatcgt	taaataagtg	atgtataccg	atcagctttt
	9781	gttcccttta	gtgagggtta	attcgcgctc	tggcgttaac	atgggtcatag	ctgtttcctg
	9841	tgtgaaattg	ttatccgctc	acaattccac	acaacatacg	agccgggaagc	ataaagtgtg
55	9901	aagcctgggg	tgcctaatag	gtgagctaac	tcacattaat	tgcgttgccg	tcaactgccc
	9961	ctttccagtc	gggaaacctg	tcgtgcccag	tgcattaatg	aatcgggcca	cgcgcgggga
	10021	gagggcggtt	gcgtattggg	cgtcttcccg	cttccctcgt	cactgactcg	ctgcgctcgg
	10081	tcgttcggct	gcggcgagcg	gtatcagctc	actcaaaggc	ggtaataacg	ttatccacag
	10141	aatcagggga	taacgcagga	agaacatgt	gagcaaaagg	ccagcaaaag	gccagggaac
60	10201	gtaaaaaggc	cgcgttgctg	gcgtttttcc	ataggctccg	cccccttgac	gagcatcaca
	10261	aaaatcgacg	ctaaagtcag	aggttcgcaa	accgcagagg	actataaaga	taccaggcgt
	10321	ttccccctgg	aagctccctc	gtgcgctctc	ctgttccgac	cctgcgcttt	accggatacc
	10381	tgtccgcctt	tctcccttcg	ggaagcgtgg	cgctttctca	tagctcacgc	tgtagggtatc
	10441	tcagttcggg	gtagggtcgt	cgtcccaagc	tgggctgtgt	gcacgaaccc	cccgttcagc
65	10501	ccgaccgctg	cgccttatcc	ggtaactatc	gtcttgagtc	caaccgggta	agacacgact
	10561	tatcgccact	ggcagcagcc	actggttaaca	ggattagcag	agcgagggtat	gtaggcggtg
	10621	ctacagagtt	cttgaagtgg	tggcctaact	acggctacac	tagaaggaca	gtatttggtg
	10681	tctgcgctct	gctgaagcca	gttacccttc	gaaaaagagt	tggtagctct	tgtatccggca
	10741	aacaaaccac	cgttggttagc	ggtggttttt	ttgtttgcaa	gcagcagatt	acgcgcagaa

10801 aaaaggatc tcaagaagat cctttgatct tttctacggg gtctgacgct cagtggaaacg
 10861 aaaactcacg ttaagggatt ttgggtcatga gattatcaaa aaggatcttc acctagatcc
 10921 ttttaaatga ttaaatgaagt ttttaaatcaa tctaaagtat atatgagtaa acttgggtctg
 10981 acagttacca atgcttaate agtgaggcac ctatctcagc gatctgtcta tttcgttcat
 5 11041 ccatagttgc ctgactcccc gtctgttaga taactacgat acgggagggc ttaccatctg
 11101 gccccagtgc tgcaatgata ccgcgagacc cagctcacc ggctccagat ttatcagcaa
 11161 taaaccagcc agccggaagg gccgagcgca gaagtgggtcc tgcaacttta ccgcctcca
 11221 tccagtctat taattgttgc cgggaagcta gagtaagtag ttcgccagtt aatagtttgc
 11281 gcaacgttgc tgccattgct acaggcatcg ttggtgcacg ctgctggttt ggtagggctt
 10 11341 cattcagctc cggttcccaa cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa
 11401 aagcgggttag ctctctcggc cctccgatcg ttgtcagaag taagtgggccc gcagtgttat
 11461 cactcatggt tatggcagca ctgcataatt ctcttactgt catgccatcc gtaagatgct
 11521 tttctgtgac ttggtgagtag tcaaccaagt cattctgaga atagtgtatg cggcgaccga
 11581 gttgctcttg ccggcgctca ataccgggata ataccggccc acatagcaga actttaaagg
 15 11641 tgctcatcat tggaaaacgt tcttcggggc gaaaactctc aaggatctta ccgctgttga
 11701 gatccagttc gatgtaaccc actcgtgcac ccaactgac ttcagcatct tttactttca
 11761 ccagcgtttc ttgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggg
 11821 cgacacggaa atgttgaata ctcatctct tcttttttca atattattga agcatttatc
 11881 agggttattg tctcatgagc ggatacatat ttgaatgtat ttagaaaaat aaacaaatag
 20 11941 ggggtccgag cacatttccc cgaaaagtgc cac

SEQ ID NO: 98 (pTnMCS (CHOVep-prepro-HCPro-CPA))

1 ctgacgcgcc ctgtagcgcc gcattaaagg cggcggggtgt ggtggttacg cgcagcgtga
 61 ccgctacact tgccagcgcc cttagcgccc ctcccttcgc tttcttccct tctttctcgc
 25 121 ccagcttcgc cggcatcaga ttggctattg gccattgcat acgttgtatc catatcataa
 181 tatgtacatt tatattggct catgtccaac attacgcgca tggtagactt gattattgac
 241 tagttattaa tagtaataca ttacgggggtc attagtctat agcccatata tggagttccg
 301 cgttacataa cttacggtaa atggcccgcc ttggtgacgg cccaacgacc ccgcccatt
 361 gacgtcaata atgacgtatg ttcccatagt aacgcgaata gggactttcc attgacgtca
 421 atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt atcatatgcc
 481 aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgccagta
 541 catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tgcctattac
 601 catgggtgatg cggttttggc agtacatcaa tgggcgtgga tagcgggtttg actcaacggg
 661 atttccaaat ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg
 35 721 ggactttcca aaatgtcgtg acaactccgc cccattgacg caaatgggccc gtaggcgtgt
 781 acgggtggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg cctggagacg
 841 ccattccacgc tgttttgacc tccatagaag acaccgggac cgatccagcc tccgcgcccg
 901 ggaacggtgc attggaacgc ggattccccg tgccaagagt gacgtaagta ccgctatag
 961 actctatagg cacacccttt tggctcttat gcattgctata ctgttttttg cttggggcct
 40 1021 atacaccccc gcttctctat gctatagggt atgggtatagc ttagcctata ggtgtgggtt
 1081 attgaccatt attgaccact cccctattgg tgacgatact tccattactt aatccataac
 1141 atgggtcttt gccacaacta tctctattgg ctatatgcca atactctgtc cttcagagac
 1201 tgacacggac tctgtatttt tacaggatgg ggtccatttt attatttaca aattccata
 45 1261 tacaacaacg ccgtccccgc tgcccgcagt ttttattaaa catagcgttg gatctccacg
 1321 cgaatctcgc gtacgtgttc cggacatggg ctcttctccg gtacggcgcc agcttccaca
 1381 tccgagccct gggtccatgc ctccagcgcc tcatggtcgc tcggcagctc cttgctccta
 1441 acagtggagg ccagacttag gcacagcaca atgccacca ccaccagtg gcccacaaag
 1501 gccgtggcgg taggggtatg gtctgaaaat gagcgtggag attgggctcg cagggtgac
 50 1561 gcagatggaa gacttaaggc agcggcagaa gaagatgcag gcagctgagt tgtgtattc
 1621 tgataagagt cagaggtaac tcccggttgc gtgctgttaa cgggtggagg cagtgtagt
 1681 tgagcagtag tgggtgtgct cgcgcgcgcc accagacata atagctgaca gactaacaga
 1741 ctgttccctt ccatgggtct tttctgcagt caccgtcgga ccatgtcgca actcgatatt
 1801 ttacacgact ctctttacca attctgcccc gaattacact taaaacgact caacagctta
 55 1861 acgttggctt gccacgcatt acttgactgt aaaactctca ctcttacga acttggccgt
 1921 aacctgcaa ccaaagcgag aacaaaacat aacatcaaac gaatcgaccg attgttaggt
 1981 aatcgtcacc tccacaaaga gcgactcget gtataccggt ggcatgctag ctttatctgt
 2041 tcgggcaata cgtatgccat tgtacttgtt gactggctctg atattcgtga gcaaaaacga
 2101 cttatggtat tgcgagcttc agtcgcacta caccgtcgtt ctgttactct ttatgagaaa
 60 2161 gcgttcccgcc tttcagagca atgttcaaag aaagctcatg accaatttct agocgacctt
 2221 gcgagcattc taccagtaga caccacacgc ctcatgtgca gtgagtctcg ctttaaagt
 2281 ccatggtata aatccgttga gaagctgggt ttggtactgt taagtcagat aagaggaaaa
 2341 gtacaatatg cagacctagg agcggaaaac tggaaaccta tcagcaactt acatgatatg
 2401 tcatctagtc actcaaaagc ttttagctat aagaggctga ctaaaagcaa tccaatctca
 2461 tgccaaattc tattgtataa atctcgetct aaaggccgaa aaaatcagc cctgacacgg
 65 2521 actcattgtc accaccgcgc acctaaaatc tactcagcgt cggcaaaagg gccatgggtt
 2581 ctacgaacta acttacctgt tgaaattcga acaccaaaac aacttggtta tatctattcg
 2641 aagcgaatgc agattgaaga aaccttccga gacttgaaaa gtctgtccta cggactaggc
 2701 ctacgcacata gccgaacgag cagctcagag cgttttgata tcatgctgct aatcgccctg

2761 atgcttcaac taacatgttg gcttgcgggc gttcatgctc agaaacaagg ttgggacaag
 2821 cacttccagg ctaacacagt cagaatcga aacgtactct caacagttcg cttaggcatg
 2881 gaagttttgc ggcattcttg ctacacaata acaagggaag acttactcgt ggctgcaacc
 2941 ctactagctc aaaattttatt cacacatggg tacgcttttg ggaattatg aggggactgc
 5 3001 tctagagcga tccgggatct cgggaaaagc gttggtgacc aaagggtgct tttatcatca
 3061 ctttaaaaat aaaaaacaat tactcagtcg ctgttataag cagcaattaa ttatgattga
 3121 tgcctacatc acaacaaaaa ctgatttaac aaatgggttg tctgccttag aaagtatatt
 3181 tgaacattat cttgattata ttattgataa taataaaaaa cttatcccta tccaagaagt
 10 3241 gatgcctatc attggttgga atgaacttga aaaaaattag cttgaatac attactggta
 3301 aggtaaacgc cattgtcagc aaatttgatcc aagagaacca acttaaagct ttctgacgg
 3361 aatgttaatt ctggttgacc ctgagcactg atgaatcccc taatgatttt ggtaaaaaatc
 3421 tgaacattat cttgattata ttattgataa taataaaaaa cttatcccta tccaagaagt
 3481 cattaggcac cccaggcttt acactttatg cttccggctc gtatgttggt tggaaattgtg
 15 3541 agcggataac aatttcacac aggaacacgc tatgaccatg attacgcca ggcgcgaatt
 3601 aacctcact aaagggaaca aaagctggag ctccaccgag gtggcggcgg ctctagaact
 3661 agtggatccc cgggctgaca ggaattcgat atcaagctta tcgataccgc tgacctcgag
 3721 ctgcagaaaa atgcccagggt gactatgaac tcacatccaa aggagcttga cctgatacct
 3781 gatatttcttc aaacagggga aacaacacaa tcccacaaaa cagctcagag agaaaccatc
 3841 actgatggct acagcaccac ggtatgcaat ggcaatccat tcgacattca tctgtgacct
 20 3901 gagcaaatg atttctctct ccatgaatgg ttgcttcttt cctcatgaa aaggcaattt
 3961 ccacactcac aatatgcgac aaagacaaa agagaacaat taatgtgctc ctctactatg
 4021 tcaaaattgt agtggcaaa aggagaacaa aatctcaagt tctgagttag ttttagtgat
 4081 tggataagag gctttgacct gtgagctcac ctggacttca tatccttttg gataaaaagt
 25 4141 gcttttataa ctttcaggct tccagctctt tattcatgag actgttggtt tagggacaga
 4201 cccacaatga aatgcctggc ataggaagg gcagcagagc cttagctgac ctttcttggt
 4261 gacaagcatt gtcaacaat gtgtgacaaa actatttgta ctgctttgca cagctgtgct
 4321 gggcaggggc atccattgac accatccca ggtaacctc caactgcaag aagattgttg
 4381 ctactctct ctagaagct tctgcagact gacatgcatt tcataggtag agataacatt
 30 4441 tactgggaag cacatctatc atcacaaaa gcaggcaaga ttttcagact tcttagtggt
 4501 ctgaaataga agcaaaagac gtaattaaaa acaaaatgaa acaaaaaaaa tcagttgata
 4561 cctgtggtgt agacatccag caaaaaata ttatttgacac taccatcttg tcttaagtcc
 4621 tcagacttag caaggagaat gtatgtttcc acagtatata tgttttcaca aaaggaagga
 4681 gagaaacaaa agaaaatggc actgactaaa cttcagctag tggataggaa aagtaattct
 35 4741 gcttaacaga gattgcagtg atctctatgt atgtcctgaa gaattatggt gtactttttt
 4801 cccccatttt taaatcaaac agtgccttac agaggtcaga atgggtttct tactgtttgt
 4861 caattctatt atttcaatac agaacaatag cttctataac tgaatatat ttgtatttgt
 4921 taattatgat tgtccctcga accatgaaca ctctccagc tgaattcac aattctctg
 4981 tcatctgcca ggccattaag ttattcatgg aagatctttg aggaacactg caagttcata
 5041 tcataaacac atttgaaatt gagtattggt ttgcatgtga tggagctatg ttttgctgta
 40 5101 tcctcagaaa aaaagtttgt tataaagcat tcacacccat aaaaagatag atttaaatat
 5161 tccagctata ggaaagaaag tgcgtctgct cttcactcta gtctcagtg gctcctcac
 5221 atgcattgct ctttattttc cctattttgt caagaaaata ataggtcacg tcttgttctc
 5281 acttatgtcc tgcctagcat ggctcagatg caggttgtag atacaagaag gatcaaatga
 45 5341 aacagacttc tggctgtgta cctacaacca tagtaataag cacactaact aataatttgt
 5401 aattatgttt tccatctcta aggttcccat atttttctgt tttttaaag atccatttat
 5461 ctggttgtaa ctgaagctca atggaacatg agcaatattt cccagctctc tctcccatcc
 5521 aacagtcctg atggattagc agaacaggca gaaaacacat tgttaccagc aattaaaaac
 5581 taatatttgc tctccattca atccaaaatg gacctattga aactaaaaatc taacccaatc
 50 5641 ccattaaatg atttctatgg tgtcaagggt caaacttctg aagggaacct gtgggtgggt
 5701 cacaattcag gctatatatt cccagggtg cagccagtgg atcaatcatt catctcgtga
 5761 cttcttcgtg tgtggtgttt acctatatat ctaaatttaa tatttcgttt attaaaattt
 5821 aatataattc gacgatgaat ttctcaagga tatttttctt cgtgttcgtg ttggttctggt
 5881 ctttgtcaac agtttcggct cgcgcagagc cgaagggtac ccagggtcag ctcctcgtg
 55 5941 cggggggagg cttggttaaag cggggggggt cccttagagt ctctgtgca gctcctggat
 6001 tcactttcag aaacgcctgg atgagctggg tccgcccaggc tccagggaag gggctggagt
 6061 gggctcgccg tattaanaagc aaaattgatg gtgggacaa agactatgct gcaccctga
 6121 aaggcagatt caccatctca agagatgatt caaaaaaac gttatatctg caaatgaata
 6181 gcctgaaagc cgaggacaca gccgtatat attgtaccac ggggattatg ataactttg
 60 6241 ggggagttat cctcccccag aattggggcc agggaaacct ggtcaccgtc tctcagcct
 6301 ccaccaaggg cccatcggtc ttccccctgg caccctctc caagagcacc tctgggggca
 6361 cagcggccct gggctgcctg gtcaggact acttcccoga accgggtgag gtgtcgtgga
 6421 actcaggcgc cctgaccagc gcgtgacaca ctttccgggc tgtcctcag tctcaggac
 6481 tctacttctc tagcaacgtg gtgaccgtgc cctccagcag cttgggcacc cagacctaca
 6541 tctgcaacgt gaatcacaag ccagcaaca ccaagggtgga caagaaagt gagcccaaat
 65 6601 cttgtgacaa aactcacaca tgcccaccgt gccagcacc tgaactcctg gggggaccgt
 6661 cagtcttctc cttccccca aaaccccaag acacctcat gatctccgg accctgagg
 6721 tcacatgcgt ggtggtggac gtgagccacg aagacctga ggtcaagtt aactggtacg
 6781 tggacggcgt ggaggtgcat aatgccaaga caaagccgag ggaggagcag tacaacagca

	5841	cgtaccgtgt	ggtcagcgctc	ctcaccgtcc	tgcaccagga	ctggctgaat	ggcaaggagt
	5901	acaagtgcga	gggtctccaac	aaagccctcc	cagcccccat	cgagaaaacc	atctccaaag
	5961	ccaaaggcca	gccccgagaa	ccacagggtg	acaccctgcc	cccatcccg	gatgagctga
5	7021	ccaagaacca	ggtcagcgctg	acctgcctgg	tcaaaggctt	ctatcccagc	gacatcgccg
	7081	tggagtgagg	gagcaatggg	cagccggaga	acaactacaa	gaccacgcct	cccggtgctg
	7141	actccgacgg	ctccttcttc	ctctacagca	agctcaccgt	ggacaagagc	aggtggcagc
	7201	aggggaacgt	cttctcatgc	tccgtgatgc	atgaggctct	gcacaaccac	tacacgcaga
	7261	agagcctctc	cctgtctccg	ggtaaagcgc	cagagccgaa	gctttcctat	gagctgacac
10	7321	agccaccctc	gggtgtcagt	tccccaggac	aaacggccag	gatcacctgc	tctggagatg
	7381	cattgcccaga	aaaatatgtt	tattggtacc	agcagaagtc	aggccaggcc	cctgtggtgg
	7441	tcatctatga	ggacagcaaa	cgaccctccg	ggatccctga	gagattctct	ggctccagct
	7501	cagggacaat	ggccaccttg	actatcagtg	gggcccagg	ggaagatgaa	ggtgactact
	7561	actgttactc	aactgacagc	agtgttatc	atagggaggt	gttcagccga	gggaccaagc
15	7621	tgaccgtcct	aggtcagccc	aagggtgccc	cctcggtcac	tctgttccca	ccctcctctg
	7681	aggagcttca	agccaacatg	gcacactgg	tggtgtctcat	aagtgcctcc	taccgggag
	7741	ccgtgacagt	ggcctggaag	gcagatagca	gccccgtcaa	ggcgggagtg	gagaccacca
	7801	caccctccaa	acaaagcaac	aaacaagtac	cggccagcag	ctacctgagc	ctgacgcttg
	7861	agcagtgga	gtcccacaaa	agctacagct	gccagggtcac	gcatgaagg	agcaccgtgg
20	7921	agaagacagt	ggccctctga	gaatgttcac	cgcggaggga	gggaagggcc	cttttgaag
	7981	ggggaggaaa	cttcgcgcga	tgactcctct	cgtgcccccc	gcacgggaaca	ctgatgtgca
	8041	gagggccctc	tgccattgct	gcttctctct	cccttccctg	tactctgaa	tgtggcttct
	8101	ttgctactgc	cacagcaaga	aataaaatct	caacatctaa	atgggttctc	tgagatthtt
	8161	caagagtcgt	taagcacatt	ccttcccag	caacccttgc	tgcaggccag	tgccaggcac
25	8221	caacttggct	actgtgcccc	atgagagaaa	tccagttcaa	tattttccaa	agcaaaatgg
	8281	attacatag	ccctagatcc	tgattaacag	gtgttttgta	ttatctgtgc	tttcgcttca
	8341	cccacattat	cccattgcct	cccctcgagg	ggggggcccg	tacccaattc	gccttatagt
	8401	gagtcgtatt	acgcgcgctc	actggccgtc	gttttacaac	gtcgtgactg	ggaaaacctc
	8461	ggcgttacc	aaacttaatc	ccttgcagca	catccccctt	tgcggagctg	gcgtaatagc
30	8521	gaagaggccc	gcaccgatcg	cccttcccaa	cagttgcgca	gcctgaatgg	cgaatggaaa
	8581	ttgtaagcgt	taatatthttg	ttaaaattcg	cgttaaaatt	ttgttaaatc	agctcatttt
	8641	ttaaccaata	ggccgaatcc	ggcaaaatcc	cttataaatc	aaaagaatag	accgagatag
	8701	ggttgagtgt	tgttccagtt	tggaacaaga	gtccactatt	aaagaacgtg	gactccaaag
	8761	tcaaaggggc	aaaaaccgtc	tatcagggcg	atggcccaat	actccgggat	catatgacaa
35	8821	gatgtgtatc	caccttaact	taatgatttt	taccaaaatc	attaggggat	tcatcagtcg
	8881	tcaggggtcaa	cgagaattaa	cattccgtca	ggaaagctta	tgatgatgat	gtgcttaaaa
	8941	acttactcaa	tggtctggta	tgcatatcgc	aatacatcgc	aaaaaacctaa	aaagagcttgc
	9001	cgataaaaaa	ggccaattta	ttgctattta	ccgcggcttt	ttattgagct	tgaagataaa
	9061	ataaaaataga	taggtttttat	ttgaagctaa	atcttcttta	tgcgtaaaaa	tgccctcttg
40	9121	ggttatcaag	agggtcatta	tatttcgcgg	aataacatca	tttggtgacg	aaataactaa
	9181	gcactttgtc	cctgtttact	cccttgagct	tgagggtgta	acatgaatg	catcgatagc
	9241	aggataataa	tacagtaaaa	cgctaaccac	ataatccaaa	tccagccatc	ccaaattggt
	9301	agtgaatgat	tataaataac	agcaaacagt	aatgggccc	taacaccggt	tgcatgtgta
	9361	aggtcacca	ataatccctt	taaagcacct	tgctgatgac	tctttgtttg	gatagacatc
45	9421	actccctgta	atgcaggtaa	agcgatccca	ccaccagcca	ataaaattaa	aacaggga
	9481	actaaccaac	cttcagatat	aaacgctaaa	aaggcaaatg	cactactatc	tgcaataaat
	9541	ccgagcagta	ctgcctgttt	ttcgccatt	tagtggtgat	tcttccctgc	acaaaggctt
	9601	ggaatactga	gtgtaaaaga	ccaagaccgc	taatgaaaag	ccaaccatca	tgctattcat
	9661	catcacgatt	tctgtaaatg	caccacacgc	tgctggattg	gctatcaatg	cgctgaaata
50	9721	ataatcaaca	aatggcatcg	ttaaataagt	gatgtatacc	gatcagcttt	tgctcccttt
	9781	agtgagggtt	aattgcgcgc	ttggcgtaat	catggtcata	gctgtttcct	gtgtgaaatt
	9841	gttatccgct	cacaattcca	cacaacatac	gagccggaag	cataaagtgt	aaagcctggg
	9901	gtgcctaag	agtgcagctaa	ctcacattaa	ttgcgttgcg	ctcactgccc	gctttccagt
	9961	cgggaaacct	gtcgtgocag	ctgcattaat	gaatcgccca	acgcgggggg	agaggcggtt
55	10021	tgcggtattg	gcgctcttcc	gcttccctgc	tcactgactc	gctgcgctcg	gtcgttcggc
	10081	tgccggcgagc	ggtatcagct	cactcaaagg	cggtaaatag	ggtatccaca	gaatcagggg
	10141	ataacgcagg	aaagaacatg	tgagcaaaa	gccagcaaaa	ggccaggga	cgtaaaaagg
	10201	ccgcgttgct	ggcgtttttc	cataggctcc	gccccctga	cgagcatcac	aaaaatcgac
	10261	gctcaagtca	gaggtggcga	aaccgcagac	gactataaag	ataccaggcg	tttccccctg
60	10321	gaagctccct	cgtgcgctct	cctgttccga	ccctgccgct	taccggatac	ctgtccgctc
	10381	ttctcccttc	gggaagcggtg	gcgctttctc	atagctcacg	ctgtaggatc	ctcgttcggg
	10441	tgtaggctct	tcgctccaag	ctgggctgtg	tgacgaacc	cccggttcag	cccgacccgt
	10501	gcgcctttatc	cggtaactat	cgtcttgagt	ccaacccggt	aagacacgac	ttatcgccac
	10561	tgccagcagc	cactggtaac	aggatttagca	gagcgaggta	tgtagggcgt	gctacagagt
65	10621	tcttgaagtgc	gtggccctaac	tacggctaca	ctagaaggac	agtatttggg	atctgcgctc
	10681	tgctgaagcc	agttaccttc	ggaaaaagag	ttggtagctc	ttgatccggc	aaacaacca
	10741	ccgctggtag	cgggtggttt	tttgtttgca	agcagcagat	tacgcgcaga	aaaaaaggat
	10801	ctcaagaaga	tcctttgatc	ttttctacgg	ggctgacgc	tcagtggaa	gaaaactcac
	10861	gttaagggat	tttggctatg	agattatcaa	aaaggatctt	cacctagatc	cttttaaat

10921 aaaaatgaag ttttaaatca atctaagta tatatgagta aacttgggtct gacagttacc
 10981 aatgcttaat cagtgaaggca cctatctcag cgtatgtctt atttgcgttca tccatagttg
 11041 cctgactccc cgtcgtgttag ataactacga tacgggagggt cttaccatct ggccccagtg
 11101 ctgcaatgat accgcgagac ccacgctcac cggctccaga tttatcagca ataaaccagc
 11161 cagccggaag ggccgagcgc agaagtgggc ctgcaacttt atccgcctcc atccagctca
 11221 ttaattgttg ccgggaagct agagtaagta gttcgcagc taatagtttg cgcacagttg
 11281 ttgccattgc tacaggcacc gtgggtgtcac gctcgtcgtt tggtagggct tcattcagct
 11341 ccggttccca acgatcaagg cgagttacat gatcccccatt gttgtgcaaa aaagcggtta
 11401 gctccttcgg tctcctcgatc gttgtcagaa gtaagttggc cgcagtggtta tccatcatgg
 11461 ttatggcagc actgcataat tctcttactg tcatgccatc cgtatagatgc ttttctgtga
 11521 ctgggtgagta ctcaaccaag tcattctgag aatagtgatg gcggcgaccg agttgctctt
 11581 gcccgccgctc aatacgggat aataccgccc caccatagcag aactttaaaa gtgctcatca
 11641 ttggaaaacg ttcttcgggg cgaaaactct caaggatctt accgctggtg agatccagtt
 11701 cgatgtaacc cactcgtgca cccaactgat cttcagcacc ttttactttc accagcgttt
 11761 ctgggtgagc aaaaacagga cgcgaaaaatg cgcgaaaaaa ggggaataag gcgacacgga
 11821 aatgttgatc actcactacc ttcttttttc aatattattg aagcatttat cagggttatt
 11881 gtctcatgag cggatcacata tttgaatgta tttagaaaaa taaacaaata ggggttccgc
 11941 gcacatttcc ccgaaaagtg ccac
 20
 SEQ ID NO:99 (pTnMCS(CHOVep-prepro-HCPro-Lys-CPA))
 1 ctgacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga
 61 ccgctacact tgcagcgccc ctacgcggcg ctcttctcgc tttcttccct tcttctctcg
 121 ccacgttcgc cggcatcaga ttggctattg gccattgcat acgttgatc catatcataa
 181 tatgtacatt tatattggct catgtccaac attaccgcca tgttgacatt gattattgac
 241 tagttattaa tagtaataca ttacgggggc attagttcat agcccatata tggagttccg
 301 cgttacataa cttacggtta atggcccgcc tggctgaccg cccaacgacc cccgcccatt
 361 gacgtcaata atgacgtatg ttcccatagt aacgcgaata gggactttcc attgacgtca
 421 atgggtggag tatttacggt aaactgccc cttggcagta catcaagtgt atcatatgcc
 481 aagtacgcc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta
 541 catgacctta tgggacttct ctacttggca gtacatctac gtattagta tgcgtattac
 601 catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg
 661 atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg
 721 ggactttcca aaatgtcgta acaactccgc cccattgacg caaatggggc gtaggcgtg
 781 acggtgggag gcttatataa gcatagctcg tttagtgaac cgtcagatcg cctggagagc
 841 ccatccacgc tgttttgacc tccatagaag acaccgggac cgtacagacc tccgcggccg
 901 ggaacgggtg attggaacgc ggattccccg tgccaagagt gacgtaagta ccgcctatag
 961 actctatagg cacacccttt tggctcttat gcattgtata ctgttttttg cttggggcct
 1021 atacaccccc gcttcttat gctatagtg atggtatagc ttacgtataa ggtgtgggtg
 1081 attgaccatt attgaccact cccctatttg tgacgatact ttccattact aatccataac
 1141 atggctcttt gccacaacta tctctatttg ctatatgcca atactctgct cttcagagac
 1201 tgacacggac tctgtatttt tacaggatgg ggtcccatct attatttaca aattcacata
 1261 tacaacaacg ccgtcccccgt ttttattaaa catagcgttg gatctccacg
 1321 cgaatctcgg gtacgtgttc cggacatggg ctcttctccg gtacggcggg agcttccaca
 1381 tccgagccct ggtcccatgc ctccagcggc tcatggtcgc tggcgagctc cttgctccta
 1441 acagtggagg ccagacttag gcacagcaca atgcccacca ccaccagtgt gccgcacaag
 1501 gccgtggcgg tagggatagt gtctgaaat gagcgtggag attgggctcg caccgctgac
 1561 gcagatggaa gacttaaggc agcggcagaa gaagatgcag gcagctgagt tgtgttatc
 1621 tgataagagt cagaggtaac tcccggttcg gtgctgttaa cgggtggagg cagtgtagtc
 1681 tgagcagtac tctgtgtgct cgcgcgcgcc accagacata atagctgaca gactaacaga
 1741 ctgttccctt ccatgggtct tttctgcagt caccgtcgga ccatgtgcga actcgatatt
 1801 ttacacgact ctctttacca attctgccc gaattacact taaaacgact caacagctta
 1861 acgttggctt gccacgcatt acttgactgt aaaactctca ctcttaccga acttggccgt
 1921 aacgtgccaa ccaagcggag acaaaaacat aacatcaaac gaatcgaccg attgttaggt
 1981 aatcgtcacc tccacaaaga gcgactcgt gtataccgtt ggcatgctag ctttatctgt
 2041 tccggcaata cgtatgccc tgtacttgtt gactgtctgt atattcgtga gcaaaaacga
 2101 cttatgggtat tgcgagcttc agtcgacta caccgtcgtt ctgttactct ttatgagaaa
 2161 gcgttccgcg tttcagagca atgttcaaag aaagctcatg accaatttct agccgacctt
 2221 cgcagcattc taccaggtaa caccacacgc ctcatgttca gtgatgctgg ctttaagtg
 2281 ccatggtata aatccgttga gaagctgggt tggtagtggg taagtccagt aagaggaaaa
 2341 gtacaatatg cagacctagg agcggaaaaa tggaaacctc tcagcaactt acatgatatg
 2401 tcatctagtc actcaaagac tttaggctat aagaggctga ctaaaagcaa tccaatctca
 2461 tgccaaattc tattgtataa atctcgtctt aaagggcgaa aaaatcagcg ctgcacacgg
 2521 actcattgtc accaccgct accbaaate tactcagcgt cggcaaggg ccatgggtt
 2581 ctagcaacta acttacctgt tgaatttcca acacccaaac aactgttaa tatctattcg
 2641 aagcgaatgc agattgaaga aaccttccga gacttgaaaa gtctgccta cggactaggc
 2701 ctacgccata gccgaacgag cagctcagag cgttttgata tcatgtgtct aatcgccctg
 2761 atgcttcaac taacatgttg gcttgcgggc gttcatgctc agaaaacaaag ttgggacaaag

	2821	cacttccagg	ctaacacagt	cagaaatcga	aacgtactct	caacagttcg	cttaggcattg
	2881	gaagttttgc	ggcatttctg	ctacacaata	acaagggaag	acttactcgt	ggctgcaacc
	2941	ctactagctc	aaaatttatt	caacacatgg	tacgctttgg	ggaaattatg	aggggatcgc
5	3001	tctagagcga	tccgggatct	cgggaaaagc	gttgggtgac	aaagggtgct	tttatcatca
	3061	ctttaaaaat	aaaaaacaat	tactcagtgc	ctgttataag	cagcaattaa	ttatgattga
	3121	tgccacatc	acaacaaaa	ctgatttaac	aaatggttgg	tctgccttag	aaagtattat
	3181	tgaacattat	cttgattata	ttattgataa	taataaaaac	cttatcccta	tccaagaagt
	3241	gatgcctatc	attggttgga	atgaacttga	aaaaaattag	ccttgaatac	attactggta
10	3301	aggtaaacgc	cattgtcagc	aaattgatcc	aagagaacca	acttaagctt	ttcctgacgg
	3361	aatgttaatt	ctcgttgacc	ctgagcactg	atgaatcccc	taatgatttt	ggtaaaaaatc
	3421	attaagttaa	gggtgataca	catcttgtea	tatgatcccg	gtaatgtgag	ttagctcact
	3481	cattaggcac	cccaggcttt	acactttatg	cttccggctc	gtatgttggt	tggaattgtg
	3541	agcggataac	aatttcacac	aggaaacagc	tatgaccatg	attacgcca	gcgcgcaatt
15	3601	aaccctcact	aaagggaaca	aaagctggag	ctccaccgcg	gtggcgcccg	ctctagaact
	3661	agtggatccc	ccgggctgca	ggaattcgat	atcaagctta	tcgatacccg	tgacctcgag
	3721	ctgcagaaaa	atgccagggtg	gactatgaac	tcacatccaa	aggagcttga	cctgatccct
	3781	gattttcttc	aaacagggga	aacaacacaa	tcacacaaa	cagctcagag	agaaaccatc
	3841	actgatggct	acagcaccaa	ggtagcaat	ggcaatccat	tcgacattca	tctgtgacct
20	3901	gagcaaaatg	atttctctct	ccatgaatgg	ttgcttcttt	cctcatgaa	aaggcaattt
	3961	ccacactcac	aatatgcgac	aaagacaaa	agagaacaa	taattgtgct	cttccatagt
	4021	tcaaaattgt	agtggcaaa	aggagaacaa	aatctcaagt	tctgagttag	ttttagtgat
	4081	tggaataag	gctttgacct	gtgagctcac	ctggacttca	tatccttttg	gataaaaagt
25	4141	gcttttataa	ctttcaggct	tccgagctct	tattcatgag	actgttggtt	tagggacaga
	4201	cccacaatga	aatgcctggc	ataggaaaag	gcagcagagc	cttagctgac	ctttcttttg
	4261	gacaagcatt	gtcaaacaa	gtgtgacaaa	actatttgta	ctgctttgca	cagctgtgct
	4321	gggcaggcgc	atccattgcc	acctatccca	ggtaaccttc	caactgcaag	aagattgttg
	4381	cttactctct	ctagaaagct	tctgcagact	gacatgcatt	tcataggtag	agataacatt
	4441	tactgggaag	cacatctatc	atcacaaaa	gcaggcaaga	ttttcagact	ttcttagttg
30	4501	ctgaaataga	agcaaaagac	gtaattaaaa	acaaaatgaa	acaaaaaaa	tcagttgata
	4561	cctgtgggtg	agacatccag	caaaaaaata	ttatttgca	taccatcttg	tcttaagtcc
	4621	tcagacttag	caaggagaat	gtagatttcc	acagtatata	tgttttcaca	aaaggaagga
	4681	gagaacacaa	agaaaatggc	actgactaaa	cttcagctag	tggtatagga	aagtaattct
	4741	gcttaacaga	gattgcagtg	atctctatgt	atgtcctgaa	gaattatgtt	gtactttttt
35	4801	ccccattttt	taaatcaaac	agtgttttac	agaggtcaga	atggtttctt	tactgtttgt
	4861	caattctatt	atttcaatc	agaacaatag	cttctataac	tgaatatat	ttgtctattg
	4921	atattatgat	tgtccctcga	accatgaaca	ctcctccagc	tgaatttcc	aatctctctg
	4981	tcacttgcca	ggccattaag	ttattcatgg	aagatctttg	aggaacactg	caagttcata
	5041	tcataaacac	atttgaaatt	gagtattggt	ttgcatgtga	tggagctatg	ttttgctgta
40	5101	tcctcagaaa	aaaagtgtgt	tataaagcat	tcacacccat	aaaaagatag	atttaaatat
	5161	tccagctata	ggaaagaaag	tgctgtctgt	cttcactota	gtctcagttg	gtcctctcac
	5221	atgcatgctt	ctttatttct	cctattttgt	caagaaaaata	atagggtcacg	tctgttcttc
	5281	acttatgtcc	tgcttagcat	ggctcagatg	caggtgttag	atcacagaag	gatcaaatga
	5341	aacagacttc	tggtctgtta	cctacaacca	tagtaataag	cacactaact	aataatttgc
45	5401	aattatgttt	tcactctcta	aggttcccat	atttttctgt	tttcttaag	atcccttat
	5461	ctggttgtaa	ctgaagctca	atggaacatg	agcaatat	cccagttctc	tctcccatcc
	5521	aacagtcctg	atggattagc	agaacaggca	gaaaacacat	tggtaccagg	aattaaaaac
	5581	taatatattg	tctccattca	atccaaaatg	gacctattga	aactaaaatc	taaccaaatc
	5641	ccattaaaatg	atttctatgg	gtcaaaaggt	caaaactctg	aagggaacct	gtgggtgggt
50	5701	cacaattcag	gctatatatt	ccccaggcct	cagccagtgg	atcaatcatt	catctcgtga
	5761	cttctctcgtg	tgtgggtgtt	acctatata	ctaaaatttaa	tatttcgttt	attaaaattt
	5821	aatatatttc	gaogatgaat	ttctcaagga	tatttttctt	cgtgttcgct	ttggttcttg
	5881	ctttgtcaac	agtttcggct	gcgccagagc	cgaaaggtag	ccaggtgcag	ctgcaggagt
	5941	cggggggagg	cttggttaa	ccgggggggt	cccttagagt	ctcctgtgca	gcctctggat
55	6001	tcactttcag	aaacgcctgg	atgagctggg	tcggccaggc	tcagggaag	gggctggagt
	6061	gggtcggcgc	tattaaaagc	aaaattgatg	gtgggacaac	agactatgct	gcaccctgta
	6121	aaggcagatt	caccatctca	agagatgatt	caaaaaacac	gttatatctg	caaatgaata
	6181	gcctgaaagc	cgaggacaca	gccttatatt	actgtaccac	ggggattatg	ataacatttg
	6241	ggggagttat	ccctccccgc	aattggggcc	agggaacctc	gggtcacgct	tctcagcct
60	6301	ccaccaaggg	cccatcggtc	ttccccctgg	cacctcctc	caagagcacc	tctgggggca
	6361	cagcggccct	gggctgcctg	gtcaaggact	acttccccga	accggtgacg	gtgtcgtgga
	6421	actcaggcgc	cctgaccagc	ggcgtgcaca	cctttccggc	tgctctacag	ctcctaggac
	6481	tctacttctc	tagcaacgtg	gtgaccgtgc	cctccagcag	cttgggcacc	cagacctaca
	6541	tctgcaacgt	gaatcacaa	ccagcaaca	ccaaggtgga	caagaaggtt	gagcccaaat
65	6601	cttgtgacaa	aactcacaca	tgcccaccgt	gcccagcacc	tgaactcctg	gggggaccgt
	6661	cagtcttctc	cttcccccca	aaacccaagg	acacctcat	gatctcccg	accctgagg
	6721	tcacatgcgt	gggtggtggac	gtgagccacg	aagacctga	gggtcaagttc	aactgggtacg
	6781	tggacggcgt	ggaggtgcat	aatgccaaga	caaagccgcg	ggaggagcag	tacaacagca
	6841	cgtaccgtgt	ggctcagctc	ctcaccgtcc	tgcaccagga	ctggctgaat	ggcaaggagt

5 6901 acaagtgcac ggtctccaac aaagccctcc cagcccccac cgagaaaacc atctccaaag
 6961 ccaaagggca gcccgcagaa ccacaggtgt acaccctgcc cccatcccgg gatgagctga
 7021 ccaagaacca ggtcagcctg acctgcctgg tcaaaaggctt ctatcccagg gacatcgccg
 7081 tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct cccgtgctgg
 7141 actccgacgg ctctctcttc ctctacagca agctcaccgt ggacaagagc aggtggcagc
 7201 aggggaacgt cttctcatgc tccgtgatgc atgaggtctt gcacaaccac tacacgcaga
 7261 agagcctctc cctgtctccg ggtaaacgcg cagagccgaa aaagctttcc tatgagctga
 7321 cacagccacc ctccgtgtca gtgtcccccag gacaaaaggc caggatcacc tgctctggag
 7381 atgcattgcc agaaaaatat gtttatgtgt accagcagaa gtcaggccag gccctgtgtg
 10 7441 tggatcatcta tgaggacagc aaacgaccct cccggatccc tgagagattc tctggctcca
 7501 gctcagggac aatggccacc ttgactatca gtggggccca ggtggaagat gaagtgact
 7561 actactgtta ctcaactgac agcagtgggt atcataggga ggtgttcagc ggagggaacca
 7621 agctgaccgt cctaggtcag cccaaggctg cccctcgggt cactctgttc ccacctcct
 7681 ctgaggagct tcaagccaac aaggccacac tgggtgtgtc cataagtgac tectaccgg
 15 7741 gagcgtgac agtggcctgg aaggccagata gcagcccggt caaggccgga tgaggagaca
 7801 ccacaccctc caaacaaggc aacaacaagt acgcccagc cagctacctg agcctgacgc
 7861 ttgagcagtg gaagtccac aaaagctaca gctgcagggt caccgatgaa gggagcaccg
 7921 tggagaagac agtggccctc gcagaatgtt caccgcggag ggagggaagg gccctttttg
 7981 aagggggagg aaacttcgcg ccatgactcc tctcgtgcc cccgcacgga acactgatgt
 20 8041 gcagagggcc ctctgccatt gctgcttctt ctgcccttcc tgcctacttc gaatgtgggt
 8101 tctttgtctac tgccacagca agaaataaaa tctcaacatc taaatgggtt tcttgagatt
 8161 tttcaagagt cgttaagcac attccttccc cagcaccctt tgctgcaggc cagtgcagg
 8221 caccaacttg gttactgctg ccatgagag aaatccagtt caatattttc caaagcaaaa
 8281 tggattacat atgcccctga tccctgattaa cagggtgttt gtattatctg tgccttctg
 25 8341 tcaccacatc tatccattg cctccctcgg agggggggcc cggtacccaa ttcgccctat
 8401 agtgagtcgt attacgcgag ctactggcc gtcgttttac aacgtcgtga ctgggaaaaa
 8461 cctggcggtta ccaacttaa tgccttgca gcacatccc ctttcgccc ctggcgtaat
 8521 agcgaagagg ccgcaccca tgccttcc caacagttgc gcagcctgaa tggcgtaatg
 8581 aaattgtaag cgttaatat ttgttaaaat tgcgttaaa tttttgttaa atcagctcat
 30 8641 tttttaacca ataggccgaa atcgcaaaa tcccttataa atcaaaagaa tagacggaga
 8701 taggggtgag tgttgttcca gtttggaaca agagtccact attaaagaac gtggactcca
 8761 acgtcaaggc gcgaaaaacc gtctatcagg gcgatggccc actactccgg actcatatga
 8821 caagatgtgt atccacotta acttaatgat ttttaccaaa atcattaggg gattcatcag
 8881 tgctcagggt caacgagaat taacattccg tcaggaaagc ttatgatgat gatgtgctta
 35 8941 aaaacttact caatggctgg ttatgcatat cgcaatacat gcgaaaaacc taaaagagct
 9001 tgcgataaaa aaaggccaat ttattgctat ttaccgcggc tttttattga ttttgaaaga
 9061 taaataaaat agataggttt tatttgaagc taaatcttct ttatcgtaaa aaatgccctc
 9121 ttgggttatc aagagggtta ttatatctcg cggaataaca tcatttggtg acgaaataac
 9181 taagcacttg tctcctgttt actccctga gcttgagggg ttaacatgaa ggtcatcgat
 40 9241 agcaggataa taatacagta taacagctaaa ccaataatcc aaatccagc atcccaaat
 9301 ggtagtgaat gattataaat aacagcaaac agtaatgggc caataacacc ggttgcatg
 9361 gtaaggctca ccaataatcc ctgtaagaca ccttgctgat gactctttgt ttggatagac
 9421 atcactccct gtaatgcagg taagegatc ccaccaccag ccaataaaat taaaacaggg
 45 9481 aaaactaacc aaccttcaga tataacgctt aaaaaggcaa atgcactact atctgcaata
 9541 aatccgagca gtactgccgt tttttcgccc atttagtggc tattcttctt gccacaaagg
 9601 cttggaatac tgagtgtaaa agaccagac ccgtaatgaa aagccaacca tcatgctatt
 9661 catcatcacg atttctgtaa tagcaccaca ccgtgctgga ttggctatca atgctgtgaa
 9721 ataataatca acaaatggca tctgttaata agtgatgtat accgatcagc ttttgttccc
 50 9781 tttagttagg gtttaattgcg cgttgccgtt aatcatggtc atagctgttt cctgtgtgaa
 9841 attgttatcc gctcacaatt ccacacaaca tacgagccgg aagcataaag tgtaaaagct
 9901 ggggtgccta atgagtgage taactcacat taattgcgtt gcgctcactg cccgctttcc
 9961 agtcgggaaa cctgtcgtgc cagctgcatt aatgaatcgg ccaacgcggc gggagaggcg
 10021 gtttgcgat tgggcgctct tccgcttccc cgtcactga ctcgctgcgc tccgtgttcc
 55 10081 ggctgcggcg agcgggtatca gctcactcaa aggcggtaat accggttatcc acagaatcag
 10141 gggataacgc aggaagaac atgtgagcaa aaggccagca aaaggccagg aacgtaaaa
 10201 aggcgcggtt gctggcggtt ttccataggg tccgcccccc tgacgagcat cacaataatc
 10261 gacgctcaag tcagaggtgg cgaacccgca caggactata aagataccag gcgtttcccc
 10321 ctggaagctc cctcgtgcgc tctcctgttc cgaccctgcc gcttaccgga tacctgtccg
 10381 cctttctccc ttcgggaagc gtggcgcttt ctcatagctc acgctgtagg tatctcagt
 60 10441 cgggttaggt cgttcgctcc aagctgggt gtgtgcacga acccccgtt cagcccgacc
 10501 gctgcccctt atccggtaac tatcgtcttg agtccaaccc ggtaagacac gacttatcgc
 10561 cactggcagc agccactggt aacaggatta gcagagcgag gtatgtaggc ggtgctacag
 10621 agttcttgaa gtgggtggct aactacggct acactagaag gacagtattt ggtatctgcg
 10681 ctctgctgaa gccagttacc ttcggaaaaa gagggtgtag ctcttgatcc ggcaaacaaa
 65 10741 ccacgcgctg tagcgggtgt tttttgttt gcaagcagca gattacgcgc agaaaaaaag
 10801 gatctcaaga agatcctttg atcttttcta cggggtctga cgtcagtggt aacgaaaact
 10861 caggttaagg gattttgttc atgagattat caaaaaggat cttcacctag atccttttaa
 10921 attaaaaatg aagtttttaa tcaatctaaa gtatatatga gtaaaacttg tctgacagtt

	10981	acccaatgctt	aatcagtgag	gcacctatct	cagcgatctg	tctatttcgt	tcatccatag
	11041	ttgcctgact	ccccgtcgtg	tagataacta	cgatacggga	gggcttacca	tctggcccca
	11101	gtgctgcaat	gataccgcga	gacccacgct	cacccgctcc	agatttatcc	gcaataaaac
5	11161	agccagcccg	aaggggccgag	cgagaagtg	gtcctgcaac	tttatccgcc	tccatccagt
	11221	ctattaattg	ttgcgggaa	gctagagtaa	gtagttcgcc	agttaatagt	ttgcgcaacg
	11281	ttgttgccat	tgctacaggc	atcgtgggtg	cacgctcgtc	gtttggtagt	gcttcattca
	11341	gctcgggttc	ccaacgatca	aggcgagtta	catgatcccc	catgttggtg	aaaaaagcgg
	11401	ttagctcctt	cggctcctcg	atcgttgtea	gaagtaagtt	ggccgcagtg	ttatcactca
	11461	tggttatggc	agcactgcat	aattctctta	ctgtcatgcc	atccgttaaga	tgcttttctg
10	11521	tgactggtga	gtactcaacc	aagtcattct	gagaatagtg	tatgcccga	ccgagttgct
	11581	cttgcgccgc	gtcaatacgg	gataatacgg	cgccacatag	cagaacttta	aaagtgtcta
	11641	tcattggaaa	acgttctctg	ggcgaaaaac	tctcaaggat	cttaccgctg	ttgagatcca
	11701	gttcgatgta	accactcgt	gcacccaact	gatcttcagc	atcttttact	ttcaccagcg
15	11761	tttctgggtg	agcaaaaaa	ggaaggcaaa	atgccgcaaa	aaagggaata	agggcgacac
	11821	ggaaatgttg	aatactcata	ctcttccttt	ttcaatatta	ttgaagcatt	tatcagggtt
	11881	attgtctcat	gagcggtac	atatttgaat	gtatttagaa	aaataaaca	atagggggtt
	11941	cgcgacatt	tccccgaaaa	gtgccac			
20	SEQ ID NO:100 (pTnMCS (CMV-prepro-HCPro-CPA))	1	ctgacgcgcc	ctgtagcggc	gcattaagcg	cggcggtgtg	ggtggttacg
		61	ccgctacact	tgccagcgcc	ctagcgcgcc	ctcctttctg	tttcttccct
		121	ccacgttcgc	cggcatcaga	ttggctattg	gccattgcat	acgttgatc
		181	tatgtacatt	tatatggct	catgtccaac	attaccgcca	tggtgacatt
25		241	tagttattaa	tagtaatcaa	ttacggggtc	attagttcat	agcccatata
		301	cgttacataa	cttacggtaa	atggcccgcc	tggtgacgg	cccaacgacc
		361	gacgtcaata	atgacgtatg	ttcccatagt	aacgccata	gggactttcc
		421	atgggtggag	tatttacggt	aaactgcca	cttggcagta	catcaagtg
		481	aagtacggcc	cctattgacg	tcaatgacgg	taaatggccc	gcctggcatt
		541	catgacctta	tgggacttcc	ctacttgga	gtacatctac	gtattagtca
30		601	catggtgatg	cgtttttggc	agtacatcaa	tgggcgtgga	tagcggtttg
		661	atttccaagt	ctccaccca	tgacgtcaa	tgggagtgtg	ttttggcacc
		721	ggactttcca	aatgtcgtg	acaactccgc	cccattgacg	caaatggggc
		781	acgttgagg	gtctatataa	gcagagctcg	tttagtgaa	cgtcagatcg
35		841	ccatccacgc	tggtttgacc	tccatagaag	acacggggac	cgatccagcc
		901	ggaaacgggtg	attggaaacg	cgattcccg	tgccaagagt	gacgttaagt
		961	actctatagg	cacacccctt	tggtcttat	gcattgtata	ctgttttttg
		1021	atacaccccc	gcttccctat	gctataggtg	atgggtatag	ttagccatata
		1081	attgaccatt	attgaccact	cccctattgg	tgacgatact	ttccattact
40		1141	atggctcttt	gccacaacta	tctctattgg	ctatatgcca	atactctgtc
		1201	tgacacggac	tctgtatttt	tacaggatgg	gggtccattt	attattttaca
		1261	tacaacaacg	ccgtcccccg	tgcccgagtg	ttttattaaa	catagcgtgg
		1321	cgaatctcgg	gtacgtgttc	cggacatggg	ctcttctcgg	gtagcggcgg
45		1381	tccgagccct	gggtccatgc	ctccagcggc	tcattggtcgc	tcggcagctc
		1441	acagtggagg	ccagacttag	gcacagcaca	atgccacca	ccaccagtgt
		1501	gccgtggcgg	taggggtatg	gtctgaaaat	gagcgtggag	attgggtcgc
		1561	gcagatggaa	gacttaaggg	agcggcagaa	gaagatgcag	gcagctgagt
		1621	tgataagagt	cagaggtaac	tcccggtgcg	gtgctgttaa	cgggtggagg
		1681	tgagcagtag	tcgttgctgc	cgcgcgcgcc	accagacata	atagctgaca
50		1741	ctgttccttt	ccatgggtct	ttcttgagtg	caccgtcgga	ccatgtgcga
		1801	ttacacgact	ctctttacca	attctgcccc	gaattacact	taaaacgact
		1861	acgttggtct	gccacgcatt	acttgactgt	aaaactctca	ctcttaccga
		1921	aacctgccaa	ccaaagcgag	aacaaaacat	aacatcaaac	gaatcgacgc
		1981	aatcgtcacc	tccacaaaga	gcgactcgct	gtataccggt	ggcatgctag
55		2041	tcgggcaata	cgatgcccat	tgtacttggt	gactggtctg	atattcgtga
		2101	cttatgggtat	tgcgagcttc	agtgcacta	cacggtcgtt	ctgttactct
		2161	gcgttcccg	tttcagagca	atgttcaaa	aaagctcatg	accaatttct
		2221	gcgagcattc	taccgagtta	caccacaccg	ctcattgtca	gtgatgctgg
		2281	ccatgggtata	aatccggtga	gaagctgggt	tggtactggt	taagtgcagt
60		2341	gtacaatatg	cagacctagg	agcggaaaa	tggaacctta	tcagcaactt
		2401	tcactagtag	actcaaaagc	tttaggctat	aagaggctga	ctaaaagcaa
		2461	tgccaaattc	tattgtataa	atctcgctct	aaaggccgaa	aaaatcagcg
		2521	actcattgtc	accacccgct	acotaaaatc	tactcagcgt	cggcaaggga
		2581	ctagcaacta	acttacctgt	tgaatttcga	acacccaaac	aacttggtta
65		2641	aagcgaatgc	agattgaaga	actttccga	gacttgaaaa	gtcctgccta
		2701	ctacgccata	gccgaacgag	cagctcagag	cgttttgata	tcattgctgt
		2761	atgcttcaac	taacatgttg	gcttgccggc	gttcatgctc	agaaacaagg
		2821	cacttccagg	ctaacacagt	cagaaatcga	aacgtactct	caacagttcg
		2881	gaagtgttgc	ggcattctgg	ctacacaata	acaagggaag	acttactcgt

2941 ctactagctc aaaatttatt cacacatggg tacgctttgg ggaaattatg aggggatcgc
 3001 tctagagcga tccgggatct cgggaaaagc gttgggtgacc aaaggtgcct tttatcatca
 3061 ctttaaaaaat aaaaaacaat tactcagtgc ctgttataag cagcaattaa ttatgattga
 3121 tgcctacatc acaacaaaaa ctgatttaac aaatgggttg tctgccttag aaagtatatt
 3181 tgaacattat cttgattata ttattgataa taataaaaaa cttatcccta tccaagaagt
 3241 gatgcctatc attgggttga atgaacttga aaaaaattag ccttgaatac attactggta
 3301 aggtaaacgc cattgtcagc aaattgatcc aagagaacca acttaaagct ttctgacgg
 3361 aatgttaatt ctcggtgacc ctgagcactg atgaatcccc taatgatttt ggtaaaaaatc
 3421 attaaagttaa ggtggatata catcttgtca tatgatcccg gtaatgtgag ttactgcact
 3481 cattaggcac ccaggtctt acactttatg cttccggctc gtatgttggt tgggaattgtg
 3541 agcggataac aatttcacac aggaacacgc tatgacctg attacgcaa gcgcgcaatt
 3601 aacctcact aaagggaaca aaagctggag ctccaccgag gtggcgccg ccttagaact
 3661 agtggatccc cggggtgca ggaattcgat atcaagctta tgcataccgc tgacctcgag
 3721 catcagattg gctattggcc attgcatacg ttgtatccat atcataatat gtacatttat
 3781 attggctcat gtccaacatt acggccatgt tgacattgat tattgactag ttattaatag
 3841 taatcaatta cggggtcatt agttcatagc ccataatagg agttccgcgt tacataactt
 3901 acggtaaatg gcccgctgg ctgacgccc aacgaccccc gccattgac gtcaataatg
 3961 acgtatgttc ccatagtaac gccaataggg actttccatt gacgtcaatg ggtggagtat
 4021 ttacggtaaa ctgcccatc caagtgtatc atatgtcaag acgcccctc
 4081 attgacgtca atgacggtaa atggcccgcc tggcattatg cccagtcacat gaccttatgg
 4141 gacttttcta cttggcagta catctacgta ttagtcatcg ctattaccat ggtgatgcgg
 4201 ttttggcagt acatcaatgg gcgtggatag cggtttgact cacggggatt tccaagctct
 4261 caccocattg acgtcaatgg gagtttggtt tggcaccaaa atcaacggga ctttccaaa
 4321 tgtcgttaaca actccgcccc attgacgcaa atggcggtgta ggcggtgacg gtgggaggtc
 4381 tatataagca gagctcgttt agtgaaccgt cagatcgctt ggagacgcca tccacgctgt
 4441 tttgacctcc atagaagaca cgggaccca tccagcctcc gggcgggga acggtgcatt
 4501 ggaacgcgga ttccocgtgc caagagtgc ctaagtaccg cctatagct ctataggcac
 4561 acccctttgg ctcttatgca tgcatactg tttttggctt ggggcctata caccocgct
 4621 tctttatgct ataggtgatg gtatagctta gccataggt gtgggttatt gaccattatt
 4681 gaccactccc ctattgggtga cgatactttc cattactaat ccataacatg gctctttgcc
 4741 acaactatct ctattggcta tatgccaaata ctctgtcctt cagagactga caggactct
 4801 gtatttttac aggatggggg cccatttatt atttacaat tcacataac aacaacgctg
 4861 tcccccgctg ccgcagtttt tattaacat agcgtgggat ctccacgca atctcgggta
 4921 cgtgttcggg acatgggctc ttctccggta gggcgggagc ttccacatcc gagccctggg
 4981 cccatgcctc ccatggctca tggctcgctg gcagctcctt gctcctaaca gtggaggcca
 5041 gacttaggca cagcacaatg cccaccacca ccagtggtgc gcacaaggcc gtggcggtag
 5101 ggtatgtgtc tgaaaatgag cgtggagatt gggctcgac ggctgacgca gatggaagac
 5161 ttaaggcagc ggcagaagaa gatgcaggca gctgagttgt tgtattctga taagagtacg
 5221 aggtaaactc cgttgcggtg ctgttaacgg tggaggcgag tgtagctga gcagctactg
 5281 ttgctgccgc gcgcgccacc agacataata gctgacagac taacagactg ttctttcca
 5341 tgggtctttt ctgcagtcac cgtcggtatc atcattcacc tctgacttcc ttctgtgtg
 5401 gtgtttacct atatatctaa atttaatat tctgttatta aaatttaata tatttcgacg
 5461 atgaatttct caaggatatt ttcttcgtg ttctgtttg ttctggctt gtcaacagtt
 5521 tccgctgcgc cagagccgaa aggtaccacg gtgcagctgc aggagtcggg gggaggttg
 5581 gtaaacgcgg ggggtccct tagagtctcc tgtgcagcct ctggattcac tttcagaac
 5641 gcctggatga gctgggtccg ccaggctcca gggaaagggg tggagtggtt cggcgctatt
 5701 aaaagcaaaa ttgatggtg gacaacagac tatgtgcac ccgtgaaagg cagattcacc
 5761 atctcaagag atgattcaaa aaacacgtta tatctgcaaa tgaatagcct gaaagccgag
 5821 gacacagccg tatattactg taccacgggg attatgataa catttggggg agttatccct
 5881 ccccccgaatt ggggcccagg aacctggtc accgtctcct cagcctccac caagggccca
 5941 tgggtcttcc ccctggcacc ctctccaaag agcactctg ggggcacagc ggcctgggc
 6001 tgctgggtca aggaactact cccgaaccg gtgacgggtg cgtggaactc aggcgcctg
 6061 accagcggcg tgcacacctt tccggctgtc ctacagctct caggactcta cttccttagc
 6121 aacgtgggtga ccgtgccctc cagcagcttg ggcacccaga cctacatctg caacgtgaat
 6181 cacaagccca gcaacaccaa ggtggacaag aaagttgagc ccaaatcttg tgacaaaact
 6241 cacacatgcc caccgtgcc agcacctgaa ctctggggg gaccgtcagt cttctctctc
 6301 ccccaaaaac ccaaggacac cctcatgac tcccggaacc ctgaggtcac atgctggtg
 6361 gtggacgtga gccacgaaga cctgaggtc aagttcaact ggtacgtgga cggcgtggag
 6421 gtgcataatg ccaagacaaa gcccggggag gagcagtaac acagcagcta ccgtgtggtc
 6481 agcgtctctc ccgtctgca ccaggactgg ctgaatggca aggagtaaca gtgcaaggtc
 6541 tccaacaaag ccctcccagc ccccatcgag aaaaccatct ccaaaagccaa agggcagccc
 6601 cgagaaccac aggtgtacac cctgccccca tcccggtatg agctgaccaa gaaccaggtc
 6661 agcctgacct gcctgggtcaa aggttctat cccagcgaca tggcgtgga gtgggagagc
 6721 aatgggcagc cggagaacaa ctacaagacc acgctcccg tgcgtgactc cgaaggtctc
 6781 ttcttctctc acagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtctc
 6841 tcatgctccg tgatgcatga ggctctgcac aaccactaca cgcagaagag cctctccctg
 6901 tctccgggta aagcgccaga gccgaagctt tctatgagc tgacacagcc accctcggtg
 6961 tcagtgtccc caggacaaa ggcaggatc acctgctctg gagatgcatt gccagaaaa

	7021	tatgttttatt	ggtaccagca	gaagtcaggc	caggccctcg	tggtgggtcat	ctatgaggac
	7081	agcaaacgac	cctccgggat	ccctgagaga	ttctctggct	ccagctcagg	gacaatggcc
	7141	accttgacta	tcagtggggc	ccaggtggaa	gatgaagggtg	actactactg	ttactcaact
5	7201	gacagcagtg	gttatcatag	ggagggtgttc	agcggaggga	ccaagctgac	cgtccctaggt
	7261	cagcccaagg	ctgccccctc	ggtcactctg	ttcccacct	cctctgagga	gcttcaagcc
	7321	aacaaggcca	cactgggtgtg	tctcataagt	gactcctacc	cgggagccgt	gacagtggcc
	7381	tggaaggcag	atagcagccc	cgtcaaggcg	ggagtggaga	ccaccacacc	ctccaaacaa
	7441	agcaacaaca	agtacgcggc	cagcagctac	ctgagcctga	cgtttgagca	gtggaagtcc
10	7501	cacaaaagct	acagctgcca	ggtcacgcac	gaagggagca	cgtgggagaa	gacagtggcc
	7561	cctgcagaat	gttcaccgcg	gaggaggagg	agggcccttt	ttgaaggggg	aggaacttcc
	7621	gcgcatgac	tcctctcgtg	ccccccgcac	ggaacactga	tgtgcagagg	gccctctgcc
	7681	attgctgctt	cctctgccct	tctcgtcac	tctgaatgtg	gcttctttgc	tactgccaca
	7741	gcaagaaata	aaatctcaac	atctaaatgg	gtttcctgag	atttttcaag	agtctgtaag
15	7801	cacattcctt	ccccagcacc	ccttgctgca	ggccagtggc	aggcaccacc	ttggctactg
	7861	ctgcccata	gagaaatcca	gttcaatatt	ttccaaagca	aaatggatta	catatgccct
	7921	agatcctgat	taacagggtg	ttgtatttat	ctgtgcttcc	gcttcaccca	cattatccca
	7981	ttgctctccc	tgcagggggg	gcccgggtacc	caattcgccc	tatagttagt	cgtattacgc
20	8041	gcgctcagat	gcccgtcggt	tacaacgtcg	tgactgggaa	aacctggg	ttaccacttc
	8101	taatcgctt	gcagcacatc	cccttttcgc	cagctggcgt	aatagcgag	agggccgcac
	8161	cgatcgccct	tcccacagct	tgccagccct	gaatggcgaa	tggaattgt	aagcgttaat
	8221	atttgtttaa	aattcgcggt	aaatttttgt	taaatcagct	cattttttaa	ccaataggcc
	8281	gaaatcgcca	aaatccctta	taaatcaaaa	gaatagaccg	agatagggtt	gagtgttgtt
	8341	ccagtttggg	acaagagtcc	actattaaag	aacgtggact	ccaacgtcaa	agggcgaaaa
25	8401	accgtctatc	agggcgatgg	cccactactc	cgggatcata	tgacaagatg	tgtatccacc
	8461	ttaacttaat	gattttttacc	aaaatcatta	ggggattcat	cagtgtctag	ggtcaacgag
	8521	aatttaacatt	ccgtcaggaa	agcttatgat	gatgatgtgc	ttaaaaactt	actcaatggc
	8581	tggttatgca	tatcgcaata	catcgcaaaa	acctaataga	gcttgccgat	aaaaaaggcc
	8641	aattttattgc	tattttaccgc	ggctttttat	tgagcttgaa	agataaataa	gatagatagg
30	8701	ttttatttga	agctaaatct	tctttatcgt	aaaaaatgcc	ctcttgggtt	atcaagaggg
	8761	tcattatatt	tcgcggaata	acatcatttg	gtgacgaaat	aactaagcac	ttgtctcctg
	8821	tttactcccc	tgagcttgag	gggttaacat	gaaggtcatc	gatagcagga	taataataca
	8881	gtaaaacgct	aaaccaataa	tccaaatcca	gccatcccaa	attggtagtg	aatgattata
	8941	aataacagca	aacagtaatg	ggccaataac	accggttgca	ttggtaaggc	tcaccaataa
35	9001	tcctgttaaa	gcaccttgct	gatgactctt	tggttgata	gacatcactc	cctgtaatgc
	9061	aggtaaacgc	atcccacacc	aattcaataa	aaatcaataa	gggaaactca	accaactctc
	9121	agatataaac	gctaaaaagg	caaatgcact	actatctgca	ataaatccga	gcagtactgc
	9181	cgttttttcg	cccatttagt	ggctattctt	cctgccacaa	aggcttgga	tactgagtgt
	9241	aaaagaccaa	gaccgtaat	gaaaagccaa	ccatcatgct	attcatcatc	acgatttctg
40	9301	taatagcacc	acaccgtgct	ggattggcta	tcaatgcgct	gaaataataa	taaccaaatg
	9361	gcacgtttaa	ataagtgtg	tataccgac	agcttttgtt	cccttttagt	aggggttaatt
	9421	gcgcgcttgg	cgtaatcatg	gtcatagctg	tttcctgtgt	gaaattgtta	tccgctcaca
	9481	attccacaca	acatacagac	cggagcaca	aagtgtaaag	cctgggtgtc	ctaagtgtg
	9541	agctaaactc	cattaatg	gttcgctca	ctgcccgtt	tccagtccgg	aaactgtcg
45	9601	tgccagctgc	attaatgaat	cggccaacgc	gcggggagag	gcggtttgcg	tattggggcg
	9661	tcttccgctt	cctcgtcac	tgactcgtg	cgtcgtgctg	ttcgggtcgc	gcgagcggta
	9721	tcagctcact	caaaaggcgt	aatacgggtt	tccacagaat	caggggataa	cgcaggaaag
	9781	aacatgtgag	caaaaaggcca	aggaacggta	aaaaggccgc	ggtgtcggcg	gttgctggcg
	9841	tttttccata	ggctccgccc	ccctgacgag	catcacaaaa	atcgacgctc	aagtcagagg
50	9901	tgccgaaacc	cgacaggact	ataaagatac	caggcggttc	cccctggaag	ctccctcgtg
	9961	cgctctcctg	ttccgacct	gcccgttacc	ggatacctgt	ccgcctttct	cccttcggga
	10021	agcgtggcgc	tttctcatag	ctcacgctgt	aggtatctca	gttcggtgta	ggtcgttcgc
	10081	tccaagctgg	gctgtgtgca	cgaacccccc	gttcagcccg	accgctcgcg	cttatccggg
	10141	aactatcgtc	ttgagtccaa	cccggtaaga	cacgacttat	cgcactggc	agcagccact
55	10201	ggtaacagga	ttagcagagc	gagggtatgt	ggcgggtgta	cagagttctt	gaagtgggtg
	10261	cctaactacg	gctacactag	aaggacagta	tttgggtatc	gcgctctgct	gaagccaggt
	10321	accttcggaa	aaagagtgtg	tagctcttga	tccggcaaac	aaaccacgc	tggtagcggg
	10381	ggtttttttg	tttgcaagca	gcagattacg	cgcagaaaaa	aaggatctca	agaagatcct
	10441	ttgatctttt	ctacggggtc	tgacgctcag	tggaaacgaa	actcacgtta	agggattttg
60	10501	gtcatgagat	tatcaaaaag	gatcttcacc	tagatccttt	taaaataaaa	atgaagtttt
	10561	aaatcaatct	aaagtatata	tgagtaaact	tggtctgaca	gttaccatg	cttaatcagt
	10621	gaggcaccta	tctcagcgat	ctgtctattt	cgttcaccca	tagttgctg	actcccctgc
	10681	gtgtagataa	ctacgatacg	ggagggttca	ccatctggcc	ccagtgtcgc	aatgatccgc
	10741	cgagaccac	gctcaccggc	tccagattta	tcagcaataa	accagccagc	cggaaagggc
65	10801	gagcgcagaa	gtggctctgc	aactttatcc	gcctccatcc	agtctattaa	ttgttcggcg
	10861	gaagctagag	taagtgttcc	gccaagtta	agtttgccga	acgttggtgc	cattgtctaca
	10921	ggcatcgtgg	tgtaacgctc	gtcgttttgt	atggcttcat	tcagctccgg	ttcccaacga
	10981	tcaaggcgag	ttacatgatc	ccccatgttg	tgcaaaaaag	cgggttagctc	cttcggtcct
	11041	ccgatcgttg	tcagaagtaa	gttgcccgca	gtgttatcac	tcattggttat	ggcagcactg

11101 cataattctc ttactgtcat gccatccgta agatgctttt ctgtgactgg tgagtactca
 11161 accaagtcac tctgagaata gtgtatgctg cgaccgagtt gctctttgcc ggcgtcaata
 11221 cgggataata ccgcgccaca tagcagaact ttaaaagtgc tcatcattgg aaaaacgttct
 11281 tcggggcgaa aactctcaag gatcttaccg ctgttgagat ccagttcgat gtaacccact
 5 11341 cgtgcaccca actgatcttc agcatctttt actttcacca gcgtttctgg gtgagcaaaa
 11401 acaggaaggg aaaaatgcgc aaaaaagggg ataagggcga cacggaaatg ttgaatactc
 11461 atactcttcc tttttcaata ttattgaagc atttatcagg gttattgtct catgagcgga
 11521 tacatatttg aatgtattta gaaaaataaa caaatagggg ttccgcgcac atttccccga
 11581 aaagtgcac
 10
 SEQ ID NO:101 (pTnMCS (CMV-prepro-HCPro-Lys-CPA))
 1 ctgacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtgggtacg cgcagcgtga
 61 ccgctacact tgccagcgcc ctagecgccc ctccctttcgc tttcttccct tccctttctcg
 121 ccacgttcgc cggcatcaga ttgggtattg gccattgcat acgttgatc catatcataa
 15 181 tatgtacatt tatattggct catgtccaac attaccgcca tgttgacatt gattattgac
 241 tagttattaa tagtaataca ttacggggtc attagttcat agcccatata tggagttccg
 301 cgttacataa cttacggtaa atggcccgcc tggctgacgg cccaacgacc cccgcccatt
 361 gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca
 421 atgggtggag tatttacggg aaactgcccc cttggcagta catcaagtg atcatatgcc
 20 481 aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta
 541 catgacctta tgggactttc ctacttggca gtacatctac gtattagtc tgcctattac
 601 catgggtgatg cgggttttggc agtacctcaa tgggcgtgga tagcgggttg actcacgggg
 661 atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg
 721 ggactttcca aaatgtcgtg acaactccgc cccattgacg caaatgggcg gtaggcgtgt
 25 781 acgggtggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg cctggagacg
 841 ccatccacgc tgttttgacc tccatagaag acaccgggac cgatccagcc tccggggcgg
 901 ggaacggtgc attggaacgc ggaatccccg tgccaagagt gacgtaaatg cccgctatag
 961 actctatagg cacacccttt tggctcttat gcattgctata ctgtttttgg cttggggcct
 1021 atacaccccc gcttccctat gctatagggt atggtatagc ttagcctata ggtgtgggtt
 30 1081 attgaccatt attgaccact cccctattgg tgacgatact ttccattact aatccataac
 1141 atggctcttt gccacaacta tctctattgg ctatatgcca atactctgtc cttcagagac
 1201 tgacacggac tctgtatttt tacaggatgg ggtcccatat attatttaca aattcacata
 1261 tacaacaacg ccgtcccccg tgcccgcagt ttttattaaa catagcgtgg gatctccacg
 1321 cgaatctcgg gtacgtgttc cggacatggg ctcttctccg gtacggcgcg agcttccaca
 35 1381 tccgagccct ggtcccatgc tccagcggc tcatgggtcg tccgagctc cctgctccta
 1441 acagtggagg ccagacttag gcacagcaca atgcccacca ccaccagtgt gccgcacaag
 1501 gccgtggcgg taggggtatgt gtctgaaaat gagcgtggag attgggctcg caccgctgac
 1561 gcagatggaa gacttaaggc agcggcagaa gaagatgcag gcagctgagt tgttgtattc
 40 1621 tgataagagt cagaggtaac tccggttgcg gtgctgttaa cgggtggagg cagtgtatgc
 1681 tgagcagtag tctgtgtgc cgcgcgcgcc accagacata atagctgaca gactaacaga
 1741 ctgttccctt ccatgggtct tttctgcagt caccgtcgga ccatgtgcga actcgatatt
 1801 ttacacgact ctctttacca attctgcccc gaattacact taaaacgact caacagctta
 1861 acgttggtct gccacgcatt atttgactgt aaaactctca ctcttaacca acttggccgt
 45 1921 aacctgccaa ccaaagcgag aacaaaacat aacatcaaac gaatcgaccg attggttaggt
 1981 aatcgtcacc tccacaaaga gcgactcgct gtataccgtt ggcattgtag ctttatctgt
 2041 tcgggcaata cgatgcccc tgtacttgtt gactggctcg atattcgtga gcaaaaaaga
 2101 cttatgggtat tgcgagcttc atcgcgacta caccgtcgct ctgttactct ttatgagaaa
 2161 cgttccccgc tttcagagca atgttcaaag aaagctcatg accaatttct agccgacctt
 50 2221 gcgagcattc taccgagtaa caccacaccg ctcatgttca gtgatgctgg ctttaaagtg
 2281 ccatgggtata aatccgttga gaagctgggt tggactgggt taagtgcagt aagaggaaaa
 2341 gtacaatagc cagacctagg agcggaaaaa tggaaccta tcagcaactt acatgatag
 2401 tcatctagtc actcaagac tttaggctat aagaggctga ctaaaagcaa tccaatctca
 2461 tgccaaaattc tattgtataa atctcgctct aaaggccgaa aaaatcagcg ctgcacacgg
 55 2521 actcattgtc accacccgct acctaaaatc tactcagcgt cggcaaaagg gccatgggtt
 2581 ctagcaacta acttacctgt tgaatttoga acacccaaac aacttgtaa tatctattcg
 2641 aagcgaatgc agattgaaga aaccttccga gacttgaaaa gtccctgccta cggactaggg
 2701 ctacgccata gccgaacgag cagctcagag cgttttgata tcatgctgct aatcgccctg
 2761 atgcttcaac taacatgttg gcttgccggc gttcatgtc agaacaagg ttgggacaag
 60 2821 cacttccagg ctaacacagt cagaaatcga aacgtactct caacagttcg cttaggcatg
 2881 gaagttttgc ggcattcttg ctacacaata acaagggaag acttactcgt ggctgcaacc
 2941 ctactagctc aaaatttatt cacacatggt tacgctttgg ggaattatg aggggatcgc
 3001 tctagagcga tccgggatct cgggaaaaag gttgggtgacc aaagggtgct tttatcatca
 3061 ctttaaaaat aaaaaacaat tactcagtc ctgttataag cagcaattaa ttatgattga
 3121 tgcctacatc acaacaaaaa ctgtattaac aaatgggtgg tctgccttag aaagtattt
 65 3181 tgaacattat cttgattata ttattgataa taataaaaaa cttatcccta tccaagaagt
 3241 gatgcctatc attggttggg atgaacttga aaaaaattag cttgaatac attactggta
 3301 aggtaaaacg cattgtcagc aaattgatcc aagagaacca acttaaaagt ttocctgacg
 3361 aatgttaatt ctcgttgacc ctgagcactg atgaatcccc taatgatttt ggtaaaaaac

3421 attaatggttaa ggtggatata catcttgtca tatgatcccg gtaatgtgag ttagctcact
 3481 cattaggcac cccaggcttt acactttatg cttccggctc gtatgtgtg tggaaattgtg
 3541 agcggataac aatttcacac aggaaacagc tatgaccatg attacgcaa gcgcgcaatt
 3601 aaccctcact aaagggaaca aaagctggag ctccaccgag gtggcggcgc ctctagaact
 3661 agtggatccc cggggctgca ggaattcgat atcaagctta tcgataccgc tgacctcgag
 3721 catcagattg gctattggcc attgcatacg ttgtatccat atcataatat gtacatttat
 3781 attggctcat gtccaacatt accgccatgt tgacattgat tattgactag ttattaataag
 3841 taatcaatta cggggtcatt agttcatagc ccataatagg agttccgcgt tacataaactt
 3901 acggtaaatg gccgcgcctg ctgaccgccc aacgaccccc gccatttgac gtcaataatg
 3961 acgtatgttc ccatagtaac gccaataggg actttccatt gaogtcaatg ggtggagat
 4021 ttacggtaaa ctgcccactt ggagtagcat caagtgtatc atatgtcaag tacgccccct
 4081 attgacgtca atgacggtaa atggcccgcc tggcattatg cccagtagcat gaccttatgg
 4141 gactttcccta cttggcagta catctacgta ttagtcatcg ctattaccat ggtgatgcgg
 4201 ttttggcagt acatcaatgg gcgtggatag cggtttgact caccgggatt tccaagtctt
 4261 caccocattg acgtcaatgg gactttgttt tggcaccaaa atcaacggga ctttcaaaa
 4321 tggcgttaaca actccgcccc attgacgcaa atggggcggtta ggcgtgtacg gtgggaggtc
 4381 tatataagca gagctcgttt agtgaaccgt cagatcgccct ggagacgcca tccacgctgt
 4441 tttagacctcc atagaagaca cggggaccga tccagcctcc gcggcgggga acggtgcatt
 4501 ggaacgcgga ttccocgtgc caagagtacg gtaagtaccg cctatagact ctacggccac
 4561 acccctttgg ctcttatgca tgcatactg tttttggctt ggggectata caccoccgct
 4621 tcccttatgct ataggtgatg gtatagctta gcctatagggt gtgggttatt gaccatttatt
 4681 gaccactccc ctattggtag cgatactttc cattactaat ccataacatg gctctttgcc
 4741 acaactatct ctattggcta tatgcaata ctctgtcctt cagagactga caggactct
 4801 gtattttttac aggatgggggt cccatttatt atttacaat tcacatatac aacaacgcgc
 4861 tcccccgctgc ccgcagtttt tattaacat agcgtgggat ctccacgcca atctcgggta
 4921 cgtgttccgg acatgggctc ttctccggta gcggcggagc ttccacatcc gagccctggt
 4981 cccatgcctc cagcggctca tggctcgtcg gcagctcctt gctcctaaca gtggagggca
 5041 gacttaggca cagcacaatg cccaccacca ccagtggtgc gcacaaggcc gtggcggtag
 5101 ggtatgtgtc tgaatatgag cgtggagatt gggctcgcac ggctgacgca gatggaagac
 5161 ttaaggcagc ggcagaagaa gatgcaggca gctgagttgt tgtattctga taagagtacg
 5221 aggtaaactc cgttgcgggt cgtttaacgg tggaggcgag tgtagtctga cagtagctcg
 5281 ttgctgcccgc gcgcgcccac agacataata gctgacagac taacagactg ttcctttcca
 5341 tgggtctttt ctgcagtcac cgtcggatca atcattcatc tcgtgacttc ttcgtgtgtg
 5401 gtgtttacct atatatctaa atttaattt tgcgtttatta aaatttaata tatttogacg
 5461 atgaatttct caagtagatt ttcttcgtg ttcgctttgg ttctgacttc gtcaacgctt
 5521 tcggctgcgc cagagccgaa aggtaccagc gtgcagctgc aggagtcggg gggaggtctg
 5581 gtaaaagccg gggggctccct tagagctctc tgtgcagcct ctggattcac tttcagaaac
 5641 gcctggatga gctgggtccg ccaggctcca ggggaaggggc tggagtggtt cggccgtatt
 5701 aaaagcaaaa ttgatgttg gacaacagac tatgctgcac cctgtgaaag cagattcaac
 5761 atctcaagag atgattcaaa aaacacgtta tatctgcaa tgaatagcct gaaagccgag
 5821 gacacagccg tatattactg taccacgggg attatgataa catttggggg agttatccct
 5881 cccccgaatt gggggccaggg aaccctggtc accgtctcct cagcctccac caaggggcca
 5941 tccgtcttcc cctgggcacc ctctcccaag agcacctctg ggggcacagc ggcctggggc
 6001 tgcctggtca aggactactt cccgaaccgc gtgacggtgt cgtggaaact aggcgctctg
 6061 accagcggcg tgcacacctt tccggctgtc ctacagtcct caggactcta ctctcttagc
 6121 aacgtggtga ccgtgccctc cagcagcttg ggcacccaga cctacatctg caacgtgaat
 6181 cacaagccca gcaacaccaa ggtggacaag aaagttgagc ccaaatcttg tgacaaaact
 6241 cacacatgcc caccgtgccc agcacctgaa ctccctggggg gaccgtcagt ctctctcttc
 6301 ccccaaaaac ccaaggacac cctcatgac tcccggaccc ctgaggtcac atgctggtg
 6361 gtggacgtga gccacgaaga cctgaggtc aagttcaact ggtacgtgga cggcgtggag
 6421 gtgcataatg ccaagacaaa gccgcgggag gagcagtaca acagcacgta cctgtgtgtc
 6481 agcgtcctca ccgtcctgca ccaggactgg ctgaatggca aggagtacaa gtcgaaggct
 6541 tccaacaaag ccctcccagc ccccatcgag aaaaccatct ccaaagccaa agggcagccc
 6601 cgagaaccac aggtgtacac cctgccccca tcccgggatg agctgaccaa gaaccaggct
 6661 agcctgacct gcctggtcaa aggttctat cccagcgaca tcgcccgtgga gtgggagagc
 6721 aatgggcagc cggagaacaa ctacaagacc accgctcccg tgcgtgactc cgaaggctcc
 6781 ttcttctctc acagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc
 6841 tcatgctccg ttagtcatga ggctctgcac aaccactaca cgcagaagag cctctccctg
 6901 tctccgggta aagcgcacga gccgaaaaag ctttctctat agctgacaca gccacccctg
 6961 gtgtcagtgt cccagggaca aacggccagg atcacctgct ctggagatgc attgccaaga
 7021 aaatatgttt attggtacca gcagaagtca ggccaggccc ctgtgtgtgt catctatgag
 7081 gacagcaaac gacctccgg gatccctgag agattctctg gctccagctc agggacaatg
 7141 gccaccttga ctatcagtg ggcccagggt gaagatgaag gtgactacta ctgttactca
 7201 actgacagca gtgttatca ttcaggagtg ttcagcgag ggaccaaact gaccctcta
 7261 ggtcagccca aggtgcgcc ctccggtcact ctgttccac cctcctctga ggagctcaa
 7321 gccacaagg ccacactggt gtgtctcata agtgactcct acccgggagc cgtgacagt
 7381 gcctggaagg cagatagcag ccccgtaag gcgggagtg agaccaccac accctccaaa
 7441 caaagcaaca acaagtagc ggccagcagc taactgagcc tgacgttga gcagtggaag

7501 tcccacaaaa gctacagctg ccaggtcacg catgaaggga gcaccgtgga gaagacagtg
 7561 gccccctgcag aatgttcacc gcggaggagg ggaagggccc tttttgaagg gggaggaaac
 7621 ttgcgcgcat gactcctctc gtgccccccg cagggaaacac tgatgtgcag agggccctct
 7681 gccatttctg cttcctctgc cttcctctgt cactctgaat gtggtctctt tgctactgcc
 7741 acagcaagaa ataaaaatctc aacatctaaa tgggtttcct gagatttttc aagagtcggt
 7801 aagcacattc cttccccagc accccttgct gcaggccagt gccaggcacc aacttggcta
 7861 ctgctgcccc tgagagaaat ccagttcaat attttccaaa gcaaaatgga ttacatatgc
 7921 cctagatcct gattaacagg tgttttgtat tatctgtgct ttcgcttcac ccacattatc
 7981 ccattgcctc ccctcgaggg gggggcccggt acccaattcg ccctatagtg agtcgtatta
 8041 cgcgcgctca ctggccgtcg ttttacaacg tctgtactgg gaaaaccctg gcgttaccca
 8101 acttaatctc cttgcagcac atcccccttt cgccagctgg cgtaattagc aagaggcccg
 8161 caccgatcgc ctttcccaac agttgcgcag cctgaatggc gaatggaat tgtaagcggt
 8221 aatattttgt taaaattcgc gttaaaattt tgttaaatca gctcattttt taaccaatag
 8281 gcgaaatcg gcaaaatccc ttataaatca aaagaataga ccgagatagg gttgagtgtt
 8341 gttccagttt ggaacaagag ccactatta aagaacgtgg actccaaact caaaggcgga
 8401 aaaaccgtct atcagggcga tggccacta ctccgggac atatgacaag atgtgtatcc
 8461 accttaactt aatgattttt accaaaatca ttaggggatt catcagtgct cagggtcaac
 8521 gagaattaac attccgtcag gaaagcttat gatgatgatg tgcctaaaaa cttactcaat
 8581 ggttggttat gcataatgca atacatgcca aaaacctaaa agagcttggc gataaaaaag
 8641 gccattttat tgcattttac cgcggtttt tattgagctt gaaagataaa taaaatagat
 8701 aggtttttat tgaagctaaa tcttctttat cgtaaaaaat gccctcttgg gttatcaaga
 8761 ggttcattat atttcgcgga ataacatcat ttggtgacga aataactaag cacttgcttc
 8821 ctgtttactc ccctgagctt gagggtttaa catgaaggto atcgatagca ggaataaat
 8881 acagtaaaac gctaaaccaa taatccaaat ccagccatcc caaattggta gtgaatgatt
 8941 ataaataaca gcaaacagta atgggccaat aacaccggtt gcattggtaa ggctcaccaa
 9001 taatccctgt aaagcacctt gctgatgact ctttgtttgg atagacatca ctccctgtaa
 9061 tgcaggtaaa tgcattccac caccagccaa taaaattaaa acagggaata ctaaccaacc
 9121 ttcagatata aacgctaaaa aggcaaatgc actactatct gcaataaatc cgagcagtac
 9181 tgccgttttt tgcgccattt agtggctatt ctctctgcca caaaggcttg gaatactgag
 9241 tgtaaaagac caagaccctt aatgaaaagc caaccatcat gctattcatc atcacgattt
 9301 ctgtaatagc accacaccgt gctggattgg ctatcaatgc gctgaaataa taatcaacaa
 9361 atggcatcgt taaataagtg atgtatacog atcagctttt gttcccttta gtgagggtta
 9421 attgcgctct tggcgtaatc atggtcatag ctgtttctcg tgtgaaattg ttatccgctc
 9481 acaattccac acaacatacg agccggaagc ataaagtgtg aagccctggg tgccctaatga
 9541 gtgagctaac tcacattaat tagcttgccg tcactgcccg ctttccactg gggaaactcg
 9601 tgcgtgccagc tgcattaatg aatcggccaa cgcgcgggga gaggcggttt gcgtattggg
 9661 cgctcttccg cttcctcgtc cactgactcg ctgcgctcgg tgcgtccggt cgcggcagcg
 9721 gtatcagctc actcaaagcg ggtaatacgg ttatccacag aatcagggga taacgcagga
 9781 aagaacatgt gagcaaaaag gcagcaaaaag gccaggaaacc gtaaaaagcg cgcgttgctg
 9841 gcgttttttc ataggctcgg cccccctgac gagcatcaca aaaatcgacg ctcaagtcag
 9901 aggtggcgaa acccgacagg actataaaga taccaggcgt tccccctgg aagctccctc
 9961 gtgcgctctc ctgttccgac cctgcgctt aceggatacc tgtccgcctt tctccctctg
 10021 ggaagcggtg gcgtttctca tagctcacgc tgtaggatc tcagttcgtg gtgagtcgtt
 10081 cgctccaagc tgggctgtgt gcacgaaccc cccgttcagc ccgaccggtt gccttatcc
 10141 ggttaactatc gtcttgagtc caaccggtg agacacgact tatcgccact ggcagcagcc
 10201 actggttaaca ggattagcag agcagggatg gtaggcggtg ctacagagtt cttgaagtgg
 10261 tggcctaact acggtacac tagaaggaca gtatttggtg tctgcgctct gctgaagcca
 10321 gttaccttcg gaaaaagagt tggtagctct tgatccgga aacaaaccac cgctggttagc
 10381 ggttggtttt ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat
 10441 cctttgatct tttctacggg gtctgacgct cagtggaaacg aaaactcacg ttaagggaat
 10501 ttggtcatga gattatcaaa aaggatcttc acctagatcc ttttaaatc aaaaatgaat
 10561 tttaaatcaa tctaaagtat atatgagtaa acttggctcg acagttacca atgcttaatc
 10621 agtgaggcac ctatctcagc gatctgtcta tttcgttcat ccattagtgc ctgactcccc
 10681 gtcgtgtaga taactacgat acgggagggc ttaccatctg gcccagtgcc tgcaatgata
 10741 ccgcgagacc cacgctcacc ggctccagat ttatcagcaa taaaccagcc agccggaagg
 10801 ccgcgagcga gaagtggctc tgcaacttta tccgcctcca tccagctcat taattgttgc
 10861 cgggaagcta gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt tgccattgct
 10921 acaggcatcg tgggtgcacg ctgcgtcttt ggtatggctt cattcagctc cggttcccaa
 10981 cgatcaagcg gagttacatg atccccatg ttgtgcaaaa aagcggttag ctctctcggg
 11041 cctccgatcg ttgtcagaag ttgtttggcc gcagtggtat cactcatggt tatggcagca
 11101 ctgcataatt ctcttactgt catgccatcc gtaagatgct tttctgtgac tgggtgagta
 11161 tcaaccaagt cattctgaga atagtgtatg cggcgaccga gttgtctctg cccggcgctc
 11221 atacgggata ataccgcgcc acatagcaga actttaaaag tgcctcatcat tggaaaacgt
 11281 tcttcggggc gaaaactctc aagatcttta ccgctgttga gatccagttc gatgtaaccc
 11341 actcgtgcac ccaactgac ttcagcatct tttactttca ccagcgtttc tgggtgagca
 11401 aaaacaggaa ggcaaaatgc cgcataaaag ggaataaggg cgacacggaa atgttgaata
 11461 ctcatactct tcttttttca atattattga agcatttatc aggggtattg tctcatgagc
 11521 ggatacatat ttgaatgtat ttgaaaaaat aaacaaatag ggggtccgcg cacatttccc

11581 cgaaaagtgc cac

SEQ ID NO:102 (pTnMod (CHOvep-prepro-HCPro-CRA))

5 1 ctgacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga
61 ccgctacact tgcagcgcgc ctgacgcgcg ctccctttcgc tttcttccct tcccttctcg
121 ccacgttcgc cggcatcaga ttggtatttg gccattgcat acgttggtatc catatcataa
181 tatgtacatt tatattggct catgtccaac attaccgcca tgttgacatt gattattgac
241 tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata tggagttccg
10 301 cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgccatt
361 gacgtcaata atgacgtatg tcccatagat aacgccataa gggactttcc attgacgtca
421 atgggtggag tatttacggt aaactgccc aattggcagta catcaagtgt atcatatgcc
481 aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta
541 catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tgcctattac
15 601 catggtgatg cgggttttgc agtacatcaa tgggcgtgga tagcgggttg actcagggg
661 atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg
721 ggactttcca aaatgtcgta acaactccgc ccatttgacg caaatggcg gtaggcgtgt
781 acggtgggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg cctggagacg
841 ccattccacgc tggtttgacc tccatagaag acaccgggac cgtcccgccg cctgagcgtc
20 901 ggaacggtgc attggaacgc ggattccccg tgccaagagt gacgtaagta ccgcctatag
961 actctatagg cacacccctt tggctcttat gcatgctata ctgttttttg cttggggcct
1021 atacaccccc gcttccttat gctatagggt atgggtatagc ttagecctata ggtgtgggtt
1081 attgaccatt attgaccact cccctatttg tgacgatact ttccattact aatcacaac
1141 atggctcttt gccacaaacta tctctatttg ctatatgcca atactctgtc cttcagagac
25 1201 tgacacggac tctgtatttt tacaggatgg ggtcccattt attatttaca aattcacata
1261 tacaacaacg ccgtcccccg tgcccgagct ttttattaaa catagcgttg gatctccacg
1321 cgaatctcgg gtacgtgttc cggacatggg ctcttctccg tagcggcggt agcttccaca
1381 tccgagccct ggtcccatgc ctccagcggc tcatggtcgc tgggagctc cttgtccta
1441 acagtggagg ccagacttag gcacagcaca atgcccacca ccaccagtgt gccgcacaag
1501 gccgtggcgg tagggtatgt gtctgaaaa gacggtggag attgggctcg cacggctgac
30 1561 gcagatggaa gacttaaggc agcggcagaa gaagatgcag gcagctgagt tgttgtatc
1621 tgataagagt cagaggtaac tccggttgcg gtgctgttaa cgggtgaggg cagtgtagtc
1681 tgagcagtac tgcgtgctgc cgcgcgcgcc accagacata atagctgaca gactaacaga
1741 ctgttccctt ccatgggtct tttctgcagt caccgtcgga ccatgtgtga acttgatatt
35 1801 ttacatgatt ctctttacca attctgcccc gaattacact taaaacgact caacagctta
1861 acgttggtct gccacgcatt acttgactgt aaaactctca ctcttaccga acttggcgt
1921 aacctgccaa ccaaagcgag acaaaaacat aacatcaaac gaatcgaccg attgttaggt
1981 aatcgtcacc tccacaaaga gcgactcgct gtataccgtt ggcattgctag ctttatctgt
40 2041 tcgggcaata cgtatgccat gtacttgtt gactggtctg atattcgtga gcaaaaacga
2101 cttatgggtat tgcgagcttc agtcgcacta cacggtcgtt ctgttactct ttatgagaaa
2161 gcgttcccgc tttcagagca atgttcaaaag aaagctcatg accaatttct agccgacctt
2221 gcgagcattc taccagtagta caccacaccc ctccattgtca gtgatgctgg ctttaagtg
2281 ccattggata aatccgttga gaagctgggt tggtagtgggt taagtgcagt aagaggaaaa
2341 gtacaatatg cagacctagg agcggaaaaac tggaaaaccta tcagcaactt acatgatag
45 2401 tcatctagtc actcaaagac tttaggctat aagaggctga ctaaaagcaa tccaatctca
2461 tgccaaattc tattgtataa atctcgctct aaagggcgaa aaaatcagcg ctgcacacgg
2521 actcattgtc accacccgct acctaaaatc tactcagcgt cggcaaaagga gccatggggt
2581 ctagcaacta acttacctgt tgaattcga acacccaaac aacttgttaa tatctattcg
2641 aagcgaatgc agattgaaga aaccttccga gacttgaaaa gtccctgccta cggactaggc
50 2701 ctacgccata gccgaacgag cagctcagag cgttttgata tcatgctgct aatcgccctg
2761 atgcttcaac taacatgttg gcttgcgggc gttcatgctc agaaacaagg ttgggacaag
2821 cacttccagg ctaacacagt cagaaaatcga aacgtactct caacagttcg cttaggcatg
2881 gaagttttgc ggcattctgg ctacacaata acaagggaag acttactcgt ggctgcaacc
2941 ctactagctc aaaatttatt cacacatggt tacgcttttg ggaaattatg ataatgatcc
55 3001 agatcacttc tggctaataa aagatcagag ctctagagat ctgtgtgttg gttttttgtg
3061 gatctgctgt gccttctagt tgcagcccat ctgttgtttg cccctcccc gtgccttct
3121 tgacctgga aggtgccact cccactgtcc tttcctaata aaatgaggaa attgcatcgc
3181 attgtctgag taggtgtcat tctattcttg ggggtggggt ggggcagcac agcaaggggg
3241 aggattggga agacaatagc aggcattgct gggatcggtt gggctctatg ggtacctctc
60 3301 tctctctctc tctctctctc tctctctctc tctctctctc cctctctctc tctctctctc
3361 tctctctctc tctctctctc tctctctctc tctctctctc tctctctctc tctctctctc
3421 tgccttttat catcacttta aaaataaaaa acaattactc agtgctgtt ataagcagca
3481 attaatatg attgatgcct acatcacaac aaaaactgat ttaacaaatg gttggtctgc
3541 cttagaaagt atatttgaac attatcttga ttatattatt gataaataa aaaaccttat
65 3601 ccctatccaa gaagtgtatg ctatcatttg ttggaatgaa cttgaaaaaa attagccttg
3661 aatacattac tggtaaggta aacgccattg tcagcaaat gatccaagag aaccaactta
3721 aagctttcct gacggaatgt taattctcgt tgaccttgag cactgatgaa tccccgtaat
3781 attttggtaa aaatcattaa gttaagggtg atacacatct tgtcatatga tcccggtatg
3841 gtgaggttagc tcaactatta ggcacccag gctttactact ttatgcttcc ggtcgtgatg

5

10

15

20

25

30

35

40

45

50

55

60

65

```

3901 ttgtgtggaa ttgtgagcgg ataacaattt cacacaggaa acagctatga ccatgattac
3961 gccagcgcg caattaaccc tcaactaaagg gaacaaaagc tggagctcca ccgcggtggc
4021 ggccgctcta gaactagtgg atcccccggg ctgcaggaat tccgatataa gcttatcgat
4081 accgctgacc tcgagctgca gaaaaatgcc aggtggacta tgaactcaca tccaaaggag
4141 cttgacctga tacctgattt tcttcaaaaca ggggaaacaa cacaatccca caaaacagct
4201 cagagagaaa ccatcactga tggctacagc accaagggtat gcaatggcaa tccattcgac
4261 attcatctgt gacctgagca aaatgatttc tctctccatg aatggttgct tcttccctc
4321 atgaaaaggc aatttccaca ctccacaatat gcgacaaaaga caaacagaga acaattaatg
4381 tgctccttcc taatgtcaaa attgtagtgg caaagaggag aacaaaatct caagttctga
4441 gtagggttta gtgattggat aagaggcttt gacctgtgag ctccacctgga cttcatatcc
4501 ttttggataa aaagtgcctt tataactttc aggtctccga gtctttattc atgagactgt
4561 tgggttaggg acagaccac aatgaatgc ctggcatagg aaagggcagc agagccttag
4621 ctgacctttt cttgggacaa gcatgtgcaa acaatgtgtg acaaaaactat ttgtactgct
4681 ttgcacagct gtgctgggca gggcgatcca ttgccacctc tcccaggtaa ccttccaact
4741 gcaagaagat tggtgcttac tctctctaga aagcttctgc agactgtacat gcattccata
4801 ggtagagata acatttactg ggaagcacat ctatcatcac aaaaagcagg caagattttc
4861 agactttctt agtggctgaa atagaagcaa aagacgtaat taaaaacaaa atgaacaaa
4921 aaaaatcagt tgatacctgt ggtgtagaca tccagcaaaa aaatattatt tgcactacca
4981 tcttgtctta agtcctcaga cttaacagg agaattgata tttccacagt atatatgttt
5041 tcacaaaagg aaggagagaa acaaaagaaa atggcactga ctaaaactta gctagtgtta
5101 taggaaagta attctgctta acagagattg cagtgatctc tatgtatgtc ctgaagaatt
5161 atgttgtact tttttccccc atttttaaat caaacagtg cttacagagg tcagaatggt
5221 ttctttactg tttgtcaatt ctattatttc aatacagaac aatagcttct ataactgaaa
5281 tatatttgct attgtatatt atgattgtcc ctccaacct gaacactcct ccagctgaat
5341 ttcacaattc ctctgtcatc tgccaggcca ttaagttatt catggaagat ctttgaggaa
5401 cactgcaagt tcatatcata aacacatttg aaatttgata ttggtttgca ttgtatggag
5461 ctatgttttg ctgtatcttc agaaaaaaag tttgttataa agcattcaca cccataaaaa
5521 gatagattta aatattccag ctataggaaa gaaagtgcgt ctgctcttca ctctagtctc
5581 agttggctcc ttcacatgca tgcttcttta tttctcctat ttgtcaaga aaataatagg
5641 tcacgtcttg ttctcactta tgtcctgcct agcatggctc agatgcacgt tgtagatata
5701 agaaggatca aatgaacacg acttctggct tgttacctac aaccatagta ataagcacac
5761 taactaataa ttgctaatta tgttttccat ctctaagggt cccatatttt tctgtttctc
5821 taaagatccc attatctggt tghtaactgaa gctcaatgga acatgagcaa tatttcccag
5881 tcttctctcc catccaacag tcttgatgga ttacagaaac aggcagaaaa cacattgtta
5941 cccagaatta aaaactaata tttgtctctc attcaatcca aaatggacct attgaaacta
6001 aaatctaacc caatcccat aaatgatttc tatgggtgtc aagggtcaaac ttctgaaggg
6061 aacctgtggg tgggtcacaa ttcaggctat atattcccca gggctcagcc agtggatcaa
6121 tcattcatct cgtgacttct tctgtgtgtg tgtttaccta tatatctaaa tttaatattt
6181 cgttttattaa aatttaatat atttcagcga tgaatttctc aaggatattt ttcttctgtg
6241 tcgctttggg tctggctttg tcaacagttt cggctgcgcc agagccgaaa ggtaccagg
6301 tgcagctgca ggagtcgggg ggaggtctgg taaagccggg ggggtccctt agagtctcct
6361 gtgcagctcc tggattcact ttcagaaacg cctggatgag ctgggtccgc caggctccag
6421 ggaaggggct ggagtggggt gggcgattta aaagcaaat tgatgggtgg acaacagact
6481 atgctgcacc cgtgaaaggg agattcacca tctcaagaga tgattcaaaa aacacgttat
6541 atctgcaaat gaatagcctg aaagccgagg acacagccgt atattactgt accacgggga
6601 ttatgataac atttggggga gttatccctc ccccgaaattg gggccaggga accctggtca
6661 ccgtctctcc agcctccacc aagggcccat cgttcttccc cctggcacc ccttccaaga
6721 gcacctctgg gggcacagc gccctgggct gctgtgtcaa ggactacttc ccggaacgg
6781 tgacgggtgc gtggaactca ggcgcctga ccagcggcgt gcacaccttt ccggctgtcc
6841 tacagctctc aggaactctac ttcttagca acgtggtgac cgtgcctctc agcagcttgg
6901 gcaccagac ctacatctgc aacgtgaatc acaagccag caacaccaag gtggacaaga
6961 aagttgagcc caaatcttgt gacaaaactc acacatgcc accgtgccc gaacctgaac
7021 tcttgggggg accgtcagtc ttctcttctc ccccaaaacc caaggacacc ctcatgatct
7081 cccggacccc tgaggtcaca tgcgtgggtg tggacgtgag ccacgaagac cctgaggtca
7141 agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag ccgcgggagg
7201 agcagtacaa cagcacgtac cgtgtgttca cgtctctcac cgtcctgac caggactggc
7261 tgaatggcaa ggagtacaag tgcaaggctc ccaacaaagc cctcccagcc cccatcgaga
7321 aaacctatct caaagccaaa gggcagcccc gagaaccaca ggtgtacacc ctgcccccat
7381 cccgggatga gctgaccaag aaccaggctc gcctgacctg cctggtaaaa ggcttctatc
7441 ccagcgacat cgcgtggag cagggctcct tcttctctca cagcaagctc accgtggaca
7501 cgcctcccggt gctggaactc gaaggtctct catgctccgt gatgcatgag gctctgcaca
7561 agagcagggt gcagcagggg aacgtcttct ctccgggtaa agcgccagag ccgaagcttt
7621 accactacac gcagaagagc ctctccctgt ctccgggtta agcgccagag gccaggatca
7681 cctatgagct gacacagcca cctcgggtgt cagtgtcccc aggacaaacg gccaggatca
7741 cctgctctgg agatgcattg ccagaaaaat atgtttattg gtaccagcag aagtcaggcc
7801 agggccctgt ggtggtcatc tatgaggaca gcaaacgacc ctccgggatc cctgagagat
7861 tctctggctc cagctcaggg acaatggcca ccttgactat cagtggggcc caggtggaag
7921 atgaaggtga ctactactgt tactcaactg acagcagtggt ttatcatagg gaggtgtcca

```

7981 ggggagggac caagctgacc gtcctaggtc agcccaagggc tgccccctcg gtcactctgt
 8041 tcccaaccctc ctctgaggag cttcaagcca acaaggccac actggtgtgt ctcataagtg
 8101 actcctaccc gggagccgtg acagtggcct ggaaggcaga tagcagcccc gtcaaggcgg
 8161 gagtggagac caccacaccc tccaaacaaa gcaacaacaa gtacgcggcc agcagctacc
 8221 tgagcctgac gcttgagcag tgggaagtccc acaaaagcta cagctgccag gtcacgcatg
 8281 aaggggagcac cgtggagaag acagtggccc ctgcagaatg ttcaccggcg agggagggaa
 8341 gggccctttt tgaaggggga ggaaccttcg cgccatgact cctctcgtgc cccccgcacg
 8401 gaacactgat gtgcagaggg ccctctgcca ttgctgcttc ctctgccctt cctcgtcact
 8461 ctgaatgtgg cttctttgct actgccacag caagaaataa aatctcaaca totaaatggg
 8521 tttcctgaga tttttcaaga gtcgttaagc acattccttc cccagcacc cttgctgcag
 8581 gccagtggca ggcaccaact tggctactgc tgcccatgag agaaatccag ttcaatattt
 8641 tccaaagcaa aatggattac atatgcccta gatcctgatt aacagggtgt ttgtattatc
 8701 tgtgctttcg cttcacccac attatcccat tgccctccct cgaggggggg cccggtaccc
 8761 aattcgccct atagtgaagc gtattacggc cgctcactgg ccgtcgtttt acaacgtcgt
 8821 gactgggaaa accctggcgt taccacaactt aatcgccctg cagcacatcc cctcttcgcc
 8881 agctggcgta atagcgaaga ggcccgaccc gatcgccctt cccaacagtt gcgcagcctg
 8941 aatggcgaat ggaatttga agcgttaata ttttgttaaa attcgcgtaa aatttttgtt
 9001 aaatcagctc attttttaac caataggccg aaatcggcaa aatcccttat aaatcaaaag
 9061 aatagaccga gatagggttg aggtgtgttc cagtttgtaa caagagtcca ctataaaga
 9121 acgtggactc caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactactcc
 9181 gggatcatat gacaagatgt gtatccacct taacttaatg atttttacca aaatcattag
 9241 gggattcatc agtgctcagg gtcaacgaga attaacattc cgtcaggaaa gcttatgatg
 9301 atgatgtgct taaaactta tcaatggct gggtatgcat atcgcaatac atgcgaaaaa
 9361 cctaaaagag cttgccgata aaaaaggcca atttattgct atttaccgag gctttttatt
 9421 gagcttgaaa gataaataaa atagataggt tttatttgaa gctaaatcct ctttatcgta
 9481 aaaaatgccc tcttgggtta tcaagagggc cattatattt cgcggaataa catcatttgg
 9541 tgacgaaata actaagcact tgcctcctgt ttactccctt gagcttgagg gggttaacatg
 9601 aaggctcatc atagcaggat aataatacag taaaacgcta aaccaataat ccaaatccag
 9661 ccatcccaaa ttggtagtga atgattataa ataacagcaa acagtaatgg gccaataaca
 9721 ccggttgcat tggtaaggct caccataat cctgttaaag caccttgcgt atgactcttt
 9781 gtttgatag acatcactcc ctgtaatgca ggtaaaagca tccaccacc agccaataaa
 9841 attaaaacag ggaactta ccaacctca gatataaacg ctaaaaggcc aatgcaacta
 9901 ctatctgcaa taaatccgag cagtactgcc gttttttcgc ccatttagtg gctattcttc
 9961 ctgccacaaa ggcttggaa actgagtga aaagaccaag acccgtaatg aaaagccaac
 10021 catcatgcta ttcacatca cgtattctgt aatagacca caccgtgctg gattggctat
 10081 caatgcgctg aaataataat caadaaatgg catcgtaaa taagtgtatg ataccgatca
 10141 gcttttgttc cctttagtga gggtaattg cgcgcttggc gtaatcatgg tcatagctgt
 10201 ttcctgtgtg aaattgttat ccgctcacaa ttccacacaa catagcagcc ggaagcataa
 10261 agtgtaaaagc ctgggggtgc taatagtga gctaactcac attaatgagc ttgcgctcac
 10321 tgcccgcttt ccagtcggga aacctgtcgt gccagctgca ttaatgaatc ggccacggcg
 10381 cggggagagg cggtttgctg attgggcgct ctcccgcttc ctcgctcact gactcgtgc
 10441 gctcggctgt tcgctgctgg cgagcggtat cagctcactc aaaggcggtg atacgggtat
 10501 ccacagaatc aggggataac gcaggaaaga acatgtgagc aaaaggccac caaaaggcca
 10561 ggaacgtaaa aaaggccgct ttctggcgt ttttccatag gctccgccc cctgacgagc
 10621 atcacaaaaa tcgacgctca agtcagaggt ggcaaaacc gacaggacta taaagatacc
 10681 aggcgttttc ccctggaaagc tcctcgtgc gctctcctgt tccgacctg ccgcttacog
 10741 gatacctgtc cgcctttctc ccttcgggaa cgtggtgct ttctcatagc tcacgctgta
 10801 ggtatctcag ttccgtgtag ttcggttcgt ccaagctggg ctggtgtcac gaacccccg
 10861 ttcagcccgca ccgctgcgac ttatccggtg actatcgtct tgagtcacac ccggttaagac
 10921 acgacttatc gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgtag
 10981 gcggtgctac agagtctctg aagtgtggc ctaactacgg ctacactaga aggacagat
 11041 ttggtatctg cgctcgtcgt aagccagtta ccttcggaaa aagagtgtgt agctcttgat
 11101 ccggcaaaaca aaccaccgct ggtagcgggt gtttttttgt ttgcaagcag cagattacgc
 11161 gcagaaaaaa aggatctcaa gaagatcctt tgatcttttc tacggggtct gacgctcagt
 11221 ggaacgaaaa ctcacgttaa gggatttttg tcatgagatt atcaaaaagg atcttcacct
 11281 agatcctttt aaattaaaaa tgaagtttta aatcaatcta aagtatatat gagtaaacct
 11341 ggtctgacag ttaccaatgc ttaatcagt aggcacctat ctcagcgatc tgcctatttc
 11401 gttcatccat agttgcctga ctccccgtcg ttagataaac tacgatacgg gagggttac
 11461 catctggccc cagtgtgca atgataccgc gagaccacg ctcaccggct ccagatttat
 11521 cagcaataaa ccagccagcg ggaaggggcg agcgagaag tggctctgca actttatccg
 11581 cctccatcca gtctattaat tgttgcgggg aagctagagt aagtagttcg ccagttaata
 11641 gtttgcgcaa cgttgttgcc attgctacag gcactgtggt gtcacgctcg tctgttgta
 11701 tggcttcatt cagctccggt tcccaacgat caaggcgagt tacatgatcc cccatgttgt
 11761 gcaaaaaagc ggttagctcc ttcggctcct cgatcgttgt cagaagtaag ttggccgcag
 11821 tgttatcact catgggttatg gcagcactgc ataattctct tactgtcatg ccatcgtaa
 11881 gatgcttttc tgtgactggt gactactcaa ccaagtcatt ctgagaatag tgtatcgggc
 11941 gaccgagttg ctcttgcccg gcgtcaatac gggataatac cgcgccacat agcagaactt
 12001 taaaagtgcct catcattgga aaacgttctt cggggcgaaa actctcaagg atcttacccg

12061 tgttgagatc cagttcagatg taaccactc gtgcacccaa ctgatcttca gcattcttcta
 12121 ctttaccag cgtttctggg tgagcaaaaa caggaaaggca aaatggccga aaaaaggga
 12181 taaggggcag acggaaatgt tgaataactca tactcttctt ttttcaatat tattgaagca
 12241 tttatcaggg ttattgtctc atgagcgga acatatttga atgtatttag aaaaataaac
 5 12301 aaataggggt tccgcgcaca tttccccgaa aagtgccac

SEQ ID NO:103 (pTnMod (CHOvep-prepro-HCPro-LYS-CPA))

1 ctgacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga
 61 ccgctacact tgccagcgcc ctacgcggcg ctcccttctc tttcttccct tccttctctg
 10 121 ccacgttcgc cggcatcaga ttggctattg gccattgcat acgttgatc catatcataa
 181 tatgtacatt tatattggct catgtccaac attacgcga tgttgacatt gattattgac
 241 tagttattaa tagtaataca ttacggggtc attagtctat agcccatata tggagttccg
 301 cgttacataa cttacggtaa atggcccgcc tggctgacgg cccaacgacc ccgcgccatt
 361 gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca
 15 421 atgggtggag tattttcggg aaactgcccc cttggcagta catcaagtgt atcatatgcc
 481 aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta
 541 catgacctta tgggactttc ctacttggca gtacatctac gtatttagta tcgctattac
 601 catggtgatg cggttttggc agtacaataa tgggcgttga tagcggtttg actcacgggg
 661 atttccaagt tccaccccca ttgacgtcaa tgggagtttg ttttggcacc aaaaataaac
 20 721 ggactttcca aaatgtccta acaactccgc cccattgacg caaatgggag gtaggcgtgt
 781 acgggtggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg cctggagacg
 841 ccacccagcg tgttttgacc tccatagaag acacggggac cgtacccagc tccgcggcgg
 901 ggaacgggtg attggaacgc ggattccccc tgccaagagt gacgtaagta ccgcctatag
 961 actctatagg cacacccctt tggctcttat gcatgctata ctgtttttgg cttggggcct
 25 1021 atacaccccc gcttccctat gctatagggt atgggtatagc ttacgctata ggtgtgggtt
 1081 attgaccatt attgaccatt cccctattgg tgacgatact ttccattact aatccataac
 1141 atggctcttt gccacaacta tctctattgg ctatattgcca atactctgtc cttcagagac
 1201 tgacacggac tctgtatttt tacaggatgg ggtcccatct attatttaca aattcacata
 1261 tacaacaacg ccgtcccccg tgcccgagct tttattataa catagcgttg gatctccacg
 30 1321 cgaatctcgg gtacgtgttc cggacatggg ctcttctctc gtacggcgcg agcttccaca
 1381 tccgagccct gggtcccatg ctcacggcgg tcactggtcg tcggcagctc cctgctccta
 1441 acagtggagg ccagacttag gcacagcaca atgcccacca ccaccagtgt gccgcacaag
 1501 gccgtggcgg tagggatagt gtctgaaaat gagcgtggag attgggctcg caccgctgac
 1561 gcagatggaa gacttaaggg agcggcagaa gaagatgcag gcagctgagt tgttgtatc
 35 1621 tgataaagat cagaggtaac tccggttgcg gtgctgttaa cgggtggagtg cagtgtatc
 1681 tgagcagtag tctgtctctc cgcgcgcggc accagacata atagctgaca gactaacaga
 1741 ctgttctctt ccatgggtct tttctgcagt caccgtcgga ccatgtgtga acttgatatt
 1801 ttacatgatt ctctttacca attctgcccc gaattacact taaaacgact caacagctta
 1861 acgttggctt gccacgactt acttgactgt aaaactctca ctcttaccga acttggcgt
 40 1921 aacctgcca ccaaaagcag aacaaaacat aacatcaaac gaatcgaccg attgttaggt
 1981 aatcgtcacc tccacaaga gcgactcgct gtataccgtt ggcatgctag ctttatctgt
 2041 tcgggcaata cgtgcccatt tgtacttgtt gactggtctg atattctgta gcaaaaacga
 2101 cttatgggat tgccagcttc agtcgacta caccgctctt ctgttactct ttatgagaaa
 45 2161 gcgttccccg tttcagagca atgttcaaag aaagctcatg accaatttct agccgacctt
 2221 gcgagcattc taccgagtaa caccacaccg ctcatgtgca gtgatgctgg ctttaaagtg
 2281 ccatgggtata aatccgttga gaagctgggt tggtagctgt taagttagt aagaggaaaa
 2341 gtacaatatg cagacatagg agcggaatac tggaaacctc tcagcaactt acatgatag
 2401 tcatctagtc actcaaaagc tttaggctat aagaggctga ctaaaagcaa tccaatctca
 2461 tgccaaattc tattgtataa atctcgctct aaaggccgaa aaatcagcg ctgcacacgg
 50 2521 actcattgtc accacccgct acctaaaatc tactcagcgt cggcaaaagg gccatgggtt
 2581 ctagcaacta acttacctgt tgaatttcga acacccaaac aacttgtaa tatctattcg
 2641 aagcgaatgc agattgaaga aaccttccga gacttgaaaa gtctgctc cggactaggc
 2701 ctacgcataa gccgaacgag cagctcagag cgttttgata tcatgctgct aatcgccctg
 55 2761 atgcttcaac taacatgttg gcttgcgggc gttcatgctc agaacaagg ttgggacaag
 2821 cacttccagg ctaacacagt cagaatacga aacgtactct caacagttcg cttaggcag
 2881 gaagttttgc ggcattcttg ctacacataa acaagggaag acttactcgt ggcgtgcaac
 2941 ctactagctc aaaatttatt cacacatggt tacgctttgg ggaattatg ataattatcc
 3001 agatcacttc tggctaataa aagatcagag ctctagagat ctgtgtgttg gttttttgtg
 3061 gatctgctgt gccttctagt tgcagccat ctgttgtttg cccctccccg gtgcttctct
 60 3121 tgaccctgga aggtgccact cccactgtcc tttcctaata aaatgaggaa attgcatcgc
 3181 attgtctgag taggtgtcat tctattctgg ggggtggggg ggggcagcac agcaaggggg
 3241 aggtattgga agacaatagc aggcattgct gggatgcggt gggctctatg ggtacctctc
 3301 tctctctctc tctctctctc tctctctctc tctctcggtc cctctctctc tctctctctc
 3361 tctctctctc tctctctctc tctctctctc tctctctctc tctctctctc tctctctctc
 65 3421 tgctttttat catcacttta aaaaataaaa acaattactc agtgctgtgt ataagcagca
 3481 attaatattg attgatgcct acatcacac aaaaactgat ttaacaaatg gttggctctg
 3541 cttagaagat atatttgaac attatcttga ttatattatt gataataata aaaactctat
 3601 cctatccaa gaagtgtatg ctatcattgg ttggaatgaa cttgaaaaaa attagccttg

3661 aatacattac tggtaaggta aacgccattg tcagcaaatt gatccaagag aaccaactta
 3721 aagctttcct gacggaatgt taattctcgt tgacctgag cactgatgaa tccctaatg
 3781 attttggtaa aaatcattaa gttaagggtg atacacatct tgtcatatga tcccggtaat
 3841 gtgagttagc tcaactcatta ggcaccccag gctttacact ttatgcttcc ggctcgtatg
 3901 ttgtgtggaa ttgtgagcgg ataacaattt cacacaggaa acagctatga ccatgattac
 3961 gccaaagcgcg caattaaccc tcagctaaagg gaacaaaagc tggagctcca ccgcggtggc
 4021 ggccgctcta gaactagtgg atcccccggt ctgcaggaaat tgcatatcaa gcttatcgat
 4081 accgctgacc tgcagctgca gaaaaatgcc aggtggacta tgaactcaca tccaaaggag
 4141 cttgacctga tacctgattt tcttcaaaca ggggaaacaa cacaatccca caaaacagct
 4201 cagagagaaa ccatcactga tggctacagc accaagggtat gcaatggcaa tccattcgac
 4261 attcatctgt gacctgagca aaatgatttc tctctccatg aatgggttget tctttccctc
 4321 atgaaaaggc aattttccaca ctcacaatat gcgacaaaaga caaacagaga acaattaatg
 4381 tgctccttcc taatgtcaaa attgtagtgg caaagaggag aacaaaatct caagttctga
 4441 gtagggtttta gtgattggat agaggccttt gacctgtgag ctacactcca tctcatcc
 4501 ttttggataa aaagtgcctt tataactttc aggtctccga gtctttattc atgagactgt
 4561 tgggttaggg acagaccac aatgaaatgc ctggcatagg aaagggcagc agagccttag
 4621 ctgacctttt cttgggacaa gcattgtcaa acaatgtgtg aaaaaactat ttgtactgct
 4681 ttgcacagat gtgctgggca gggcgatcca ttgccaccta tccaggttaa tcttccact
 4741 gcaagaagat tgggtcttac tctctctaga aagcttctgc agactgacat gcaattcata
 4801 ggtagagata acatttactg ggaagcacat ctatcatcac aaaaagcagg caagattttc
 4861 agactttcct agtggtgtaa atagaagcaa aagacgtaat taaaaacaaa atgaaacaaa
 4921 aaaaatcagt tgatacctgt ggtgtagaca tccagcaaaa aaatatattt tgcactacca
 4981 tcttgtctta agtcctcaga ctttagcaagg agaattgtaga tttccacagt atatatgttt
 5041 tcacaaaagg aaggagagaa acaaaagaaa atggcactga ctaaacttca gctagtggta
 5101 taggaaagta attctgctta acagagattg cagtgtatctc tatgtatgtc ctgaagaatt
 5161 atgtttgact tttttccccc atttttaaat caaacagtcg tttacagagg tcagaatggg
 5221 ttctttactg tttgtcaatt ctattatttc aatacagaa aatagcttct ataactgaaa
 5281 tatatttgct attgtatatt atgattgtcc ctggaacct gaacactcct ccagctgaat
 5341 ttcacaattc ctctgtcctc tgcaggcca ttaagttatt catggaagat ctttgaggaa
 5401 cactgcaagt tcatatcata aacacatttg aaattgagta ttggtttgca ttgtatggag
 5461 ctatgttttg ctgtatcctc agaaaaaaag tttgttataa agcattcaca cccataaaaa
 5521 gatagattta aatattccag ctataggaaa gaaagtgcgt ctgctcttca ctctagtctc
 5581 agttggctcc ttcacatgca tgcctcttca tttctcctat tttgtcaaga aaataatagg
 5641 tcacgtcttg tctcactta tgcctgctc agcatggctc agatgcacgt tgtagatata
 5701 agaaggatca aatgaaacag actctgggtc tgttacctac aacctatgta ataagcacac
 5761 taactaataa ttgctaatta tgttttccat ctctaagggt cccatatttt tctgttttct
 5821 taaagatccc attatctggt tgaactgaa gctcaatgga acatgagcaa tatttccag
 5881 tcttctctcc catccaacag tctgatgga ttagcagaac aggcagaaaa cacattgta
 5941 cccagaatta aaaaactaata tttgctctcc attcaatcca aaatggacct tcttcaacta
 6001 aaatctaacc caatccatt aaatgatttc tatggtgtca aaggtcaaac tctgaagggt
 6061 aacctgtggg tgggtcacia ttcaggctat atattcccca gggctcagcc agtggatcaa
 6121 tcattcatct cgtgacttct tegtgtgtgg tgtttaccta tatatctaaa tttaatattt
 6181 cgtttattaa aatttaatat atttcgacga tgaatttctc aaggatattt tcttctgtgt
 6241 tcgctttggt tctggctttg tcaacagttt cggctgcgcc agagccgaaa ggtaccaggt
 6301 tgcagctgca ggagtcgggt ggaggttggg taaagccggg ggggtccctt agagtctcct
 6361 gtgcagcctc tggattcact ttcagaaacg cctggatgag ctgggtccgc cagggtccag
 6421 ggaagggtgt ggagtggtgt ggcgttatta aaagcaaaat tgatgggtgg acaacagact
 6481 atgctgcacc cgtgaaaggc agattcacca tctcaagaga tgattcaaaa aacacgttat
 6541 atctgcaaat gaatagcctg aaagccgagg acacagccgt atattactgt accacgggga
 6601 ttatgataac atttggggga gttatccctc ccccgaaattg gggccaggga accctggtca
 6661 ccgtctcctc agcctccacc aaggggccat cgtctctccc cctggcacc tctccaaga
 6721 gcacctctgg gggcacagcg gccctgggtc gctgggtcaa ggactacttc cccgaaccgg
 6781 tgacggtgtc gtggaactca ggcgccttga ccagcggcgt gcacacctt cgggtgtcc
 6841 tacagtcctc aggaactctac ttccttagca acgtgggtgac cgtgccctcc agcagcttgg
 6901 gcaccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag gtggacaaga
 6961 aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgcccc gcacctgaac
 7021 tcttgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc ctcatgtct
 7081 cccggacccc tgaggtcaca tgcgtgggtg tggacgtgag ccacgaagac cctgaggtca
 7141 agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag ccgcggtggg
 7201 agcagtaaaa gacacgtac cgtgtgggtc gegtccctc cgtcctgcac caggactggc
 7261 tgaatggcaa ggagtacaag tgcaagggtc ccaacaaaag cctcccagcc cccatcgaga
 7321 aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc ctgcccccat
 7381 cccgggatga gctgaccaag aaccagggtc gctgacctg cctgggtcaa ggttctatc
 7441 ccagcgacat gcgcgtggag tgggagagca atggggagcc ggagaacac tacaagacca
 7501 cgctcccggt gctggactcc gacgggtcct tcttctctca cagcaagctc accgtggaca
 7561 agagcagggt gcagcagggg aacgtcttct catgctccgt gatgcatgag gctctgcaca
 7621 accactacac gcagaagagc ctctccctgt ctccgggtta agcgccagag ccgaaaaagc
 7681 tttcctatga gctgacacag ccacctcgg tgtcagtgct cccaggacaa accggcaggga

5 7741 tcacctgctc tggagatgca ttgccagaaa aatatgttta ttggtaccag cagaagtcag
 7801 gccaggcccc tgtggtgggc atctatgagg acagcaaacg accctccggg atccctgaga
 7861 gattctctgg ctccagctca gggacaatgg ccaccttgac tatcagtggg gcccgagtg
 7921 aagatgaagg tgactactac tgttactcaa ctgacagcag ttggttatcat agggaggtgt
 7981 tcagcggagg gaccaagctg accgtcttag gtcagcccaa ggctgcccc tcggctcactc
 8041 tgttccccacc ctctcttgag agagcttcaag ccaacaaggc cacactgggtg tgtctcataa
 8101 gtgactccta cccgggagcc gtgacagtgg cctggaaggc agatagcagc cccgtcaagg
 8161 cgggagtgga gaccaccaca cctccaaaac aaagcaacaa caagtacgcy gccagcagct
 10 8221 acctgagcct gacgcttgag cagtggaaagt ccacaaaaag ctacagctgc caggctcacgc
 8281 atgaaggagg caccgtggag aagacagtgg ccctgcaga atgttcaccg cggaggagg
 8341 gaaggggcct ttttgaagg ggaggaaact tcgcgccatg actcctctcg tgccccccgc
 8401 acggaacact gatgtgcaga gggccctctg ccattgtctg ttctctctg
 8461 actctgaatg tggcttcttt gctactgcca cagcaagaaa taaaatctca acatctaat
 15 8521 ggggttccctg agatttttca agcactcgta tcccccagca cccctgtctg
 8581 caggccagtg ccaggcacca acttggctac tgcgtcccat gagagaaatc cagttcaata
 8641 ttttccaaag caaaatggat tacatatgcc ctgatctctg attaacagggt gttttgtatt
 8701 atctgtgctt tcgcttcacc cacattatcc cattgctctc cctcgagggg gggcccggt
 8761 cccaattcgc cctatagtga gtctgtattac gcgcgtcac ttgacagcgt
 20 8821 cgtgactggg aaaacccctg cgttacccaa cttaatcgcc ttgcagcaca tcccccttc
 8881 gccagctggc gtaatagcga agaggcccgcc accgatcgcc ctcccaaca gttgcgcagc
 8941 ctgaatggcg aatggaaatt gtaagcggtta atattttgtt aaaattcgcy ttaattttt
 9001 gttaaatcag ctcatTTTTT aaccaatagg ccgaaatcgg caaaatccct ttaaatcaa
 9061 aagaatagac cgagataggg ttgagtgttg ttccagtttg gaacaagagt ccactattaa
 25 9121 agaactggga ctccaacgctc aaaggggcgaa aaaccgtcta tcaggcgat gggccactac
 9181 tcgggatc caatgacaaga tgtgtatcca ccttaactta atgattttta ccaaaatcat
 9241 taggggatc ttactgctc agggctcaacg agaattaaca ttccgtcagg aaagcttatg
 9301 atgatgatgt gcttaaaaac ttactcaatg gctggttatg catatcgcaa tacatcgcaa
 9361 aaacctaata gagcttgccg ataaaaaagg ccaatttatt gctatttacc gcggctttt
 9421 attgagcttg aaagataaat aaaatagata ggttttattt gaagctaata cttctttatc
 30 9481 gtaaaaaatg ccctcttggtg ttatcaagag ggtcattata ttccgaggaa taacatcatt
 9541 tggtagcga ataaactaagc acttgtctcc tgtttactcc cctgagcttg aggggttaac
 9601 atgaagggtc tcgatagcag gataataata cagtaaaacg ctaaaaccaat aatccaaatc
 9661 cagccatccc aaattggtag tgaatgatta taaataacag caaacagtaa tgggccaata
 35 9721 acaccgggtg cattggtaag gtcaccaat aatccctgta aagcaccttg ctgatgactc
 9781 tttgtttgga tagacatcac tccctgtaat gcaggtaaag cgatccaccc accagccaat
 9841 aaaattaaaa cagggaatac taaccaacct tcagatataa acgctaataa ggcaaatgca
 9901 ctactatctg caataaatcc gagcagtagt gcggtttttt cgccatttta gtggctatc
 9961 ttcttgccac aaaggcttgg aatactgagt gtaaaagacc aagaccgta atgaaaagcc
 40 10021 aaccatcatg ctattcatca tcacgatttc tghtaatgca ccacaccgtg ctggattggc
 10081 tatcaatgcy ctgaaataat aatcaacaaa tggcatcggt aaataagtga tgtataccga
 10141 tcagcttttg ttcccttttag tgagggttaa ttgcgcgctt ggcgtaatac tggctatagc
 10201 tgtttctctg ttgaaattgt tatccgctca caattccaca caacatacga gccggaagca
 10261 taaagtgtaa agcctggggg gctaatgag tgagctaaat cacattaagt gcgttgctg
 45 10321 cactgcccgc tttccagtcg ggaacccgtg cgtgccagct gcattaatga atcgcccaac
 10381 gcgcggggag agggcggttg cgtattgggc gctcttccgc ttctctgctc actgactcgc
 10441 tgcgctcggt cgctcgctg cggcgagcgg tatcagctca ctcaaaaggc cagcaaaaag
 10501 tatccacaga atcaggggat aacgcaggaa agaactgtg agcaaaaagg cagcaaaaag
 10561 ccaggaaaccg taaaaaggcc gcgttgctgg cgtttttcca taggctccgc cccctgacg
 10621 agcatcacaa aaatcgagcgc tcaagtcaaa ggtggcgaaa ccgcagagga ctataaagat
 50 10681 accaggcggt tcccctgga agctccctcg tgcgctctcc tgttccgacc ctgcccgtta
 10741 ccggatacct gtcgcctttt ctccctcggg gaagcggtggc gctttctcat agctcacgct
 10801 gtaggtatct cagttcggtg taggtcgttc gctccaagct gggctgtgtg cagcaacccc
 10861 ccgttcagcc cgaccgctgc gccttatccg gtaactatcg tcttgagtc aaccgggtta
 55 10921 gacacgactt atcgccactg gcagcagcca ctggtaacag gattagcaga gcgaggtatg
 10981 taggcgggtg tacagagttc ttgaagtggg ggcctaacta cggctacact agaaggacag
 11041 tatttggtat ctgcgctctg ctgaagccag ttacctcggg aaaaagaggt ggtagctctt
 11101 gatccggcaa acaaacaccg gctggtagcg gtgggttttt tgtttgcaag cagcagatta
 11161 cgcgagaaa aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc
 60 11221 agtggaaacga aaactcagct taagggtatt tggctatgag attatcaaaa aggatcttca
 11281 cctagatcct tttaaattaa aaatgaagtt ttaaatcaat ctaaagtata tatgagtaaa
 11341 cttggtctga cagttacca tgcctaatca gtgaggcacc tatctcagcg atctgtctat
 11401 ttctgtctat catagttgcc tgactccccg tcgtgtagat aactacgata cgggaggggt
 11461 taccatctgg cccagtgct gcaatgatac cgcgagacc acgctcacgc gctccagctt
 11521 tatcagcaat aaaccagcca gccggaaggc ccgagcgag aagtggtctc gcaactttat
 11581 ccgctcccat ccagttctatt aattgttgcc gggaagctag agtaagtagt tcgccaagta
 65 11641 atagtttgcg caacgttgtt gccattgcta caggcatcgt ggtgtcacgc tcgtctgtt
 11701 gtatggcttc attcagctcc ggttcccaac gatcaaggcg agttacatga tccccatgt
 11761 tgtgcaaaaa agcgggttagc tccttcgggt ctcgatcgt tgtcagaagt aagttggcgc

11821 cagtgttatac actcatgggtt atggcagcac tgcataattc tcttactgtc atgccatccg
 11881 taagatgctt ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc
 11941 ggcgaccgag ttgctcttgc ccggcggtcaa tacgggataa taccgcgcca catagcagaa
 12001 ctttaaaagt gctcatcatt ggaataacgtt cttcggggcg aaaaactctca aggatcttac
 12061 cgctgttgag atccagttcg atgtaaccca ctctgtgcacc caactgatct tcagcatctt
 12121 ttactttcac cagcgtttct ggttgagcaa aaacaggaag gcaaaaatgcc gcaaaaaagg
 12181 gaataagggc gacacggaaa tgttgaatac tcatactctt cctttttcaa tattattgaa
 12241 gcatttatca ggggtattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata
 12301 aacaaatagg ggttcgcgcg acatttcccc gaaaagtgcc ac
 10
 SEQ ID NO:104 (pTnMOD (CMV-prepro-HCPro-CPA))
 1 ctgacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtggttaog cgcagcgtga
 61 ccgtacact tgcagcgcc ctacgcccc ctcttttcgc tttcttccct tcctttctcg
 121 ccacgttcgc cggcatcaga ttgctattg gccattgcat acgtttgtac catatcataa
 181 tatgtacatt tatattggct catgtccaac attaccgcca tgttgacatt gattattgac
 241 tagttattaa tagtaataca ttacgggggtc attagtctat agcccatata tggagttccg
 301 cgttacataa cttacggtaa atggcccgcc tggctgacgg cccaacgacc cccgccatt
 361 gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca
 421 atgggtggag tatttacggc aaactgcccc cttggcagta catcaagtgt atcatatgcc
 481 aagtacggcc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta
 541 catgacctta tgggaacttc ctacttggca gtacatctac gtattagtca tcgctattac
 601 catgggtgat cgggttttgc agtacatcaa tgggcgtgga tagcggtttg aatcacgggg
 661 atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg
 721 ggactttcca aaatgtcgta acaactccgc cccattgacg caaatggcg gttaggcgtgt
 781 acgggtgggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg cctggagacg
 841 ccatccaagc tgttttgacc tccatagaag acaccgggac cgtaccagcc tcgcgcgcg
 901 ggaacggtgc attggaacgc ggattccccg tgccaagagt gacgtaagta ccgcctatag
 961 actctatagg cacacccctt tggctcttat gcatgctata ctgtttttgg ctggggcct
 1021 atacaccccc gcttccctat gctatagggt atggtatagc ttagcctata ggtgtgggtt
 1081 attgaccatt attgaccact cccctattgg tgacgatact ttccattact aatccataac
 1141 atggetcttt gccacaacta tctctattgg ctatatgcca atactctgtc cttcagagac
 1201 tgacacggac tctgtatttt tacaggatgg ggtcccat tttatttaca aattcacata
 1261 tacaacaacg ccgtcccccg tgcccgcagt ttttattaaa catagcgtgg gatctccacg
 1321 cgaatctcgg gtacgttggc cggacatggg ctcttctccg gtacggcgcc agcttcaca
 1381 tccgagccct ggtcccatgc ctccagcgcc tcatggctcg tcggcagctc cttgtctcta
 1441 acagtgaggc ccagacttag gcacagcaca atgcccacca ccaccagtgt gcgcacaaag
 1501 gccgtggcgg taggggtatgt gtctgaaaaat gagcgtggag attgggctcg cacggctgac
 1561 gcagatggaa gacttaaggc agcggcagaa gaagatgcag gcagctgagt tgttgtattc
 1621 tgataagagt cagaggtaac tcccggttgc gtgctgttaa cgggtggaggg cagtgtatgc
 1681 tgagcagtag tcgttgctgc cgcgcgcgcc accagacata atagctgaca gactaacaga
 1741 ctgttccctt ccattgggtct tttctgcagt caccgtcgga ccatgtgtga acttgatatt
 1801 ttacatgatt ctctttacca attctgcccc gaattacact taaaacgact caacagctta
 1861 acgttggett gccacgcatt acttgactgt aaaactctca ctcttacga acttgccgt
 1921 aacctgccaa ccaaacgcag aacaaaacat aacatcaaac gaatcgacgg attgttaggt
 1981 aatcgctacc tccacaaaga gcgactcgct gtataccggt ggcatgctag ctttatctgt
 2041 tggggcaata cgtatcccat tgtacttgtt gactggtctg atattctga gcaaaaacga
 2101 cttatggtat tgcgagcttc agtgcacta cacggctcgt ctgttactct tatagagaaa
 2161 cgtttccgcg tttcagagca atgttcaaag aaagctcatg accaattctc agccgacctt
 2221 gcgagcattc taccgagtaa caccacaccg ctcatgttca gtgatgctgg ctttaaagt
 2281 ccattggtata aatccgttga gaagctgggt tggtagctgt taagtgcagt aagaggaaa
 2341 gtacaatatg cagacatagg agcggaaaaac tggaaacctc tcagcaactt acatgatag
 2401 tcatctagtc actcaaagac tttaggctat aagaggctga ctaaaagcaa tccaatctca
 2461 tgccaaattc tattgtataa atctcgctct aaaggccgaa aaaatcagcg ctgcacacgg
 2521 actcattgtc accaccgctc acctaaaate tactcagcgt cggcaaaagg gccatgggtt
 2581 cttagcaacta acttacctgt tgaatttga acacccaaac aacttgttaa tatctattcg
 2641 aagcgaatgc agattgaaga aaccttccga gacttgaaaa gtctgccta cggactaggc
 2701 ctacgccata gccgaacgag cagctcagag cgttttgata tcatgtgctt aatcgccctg
 2761 atgcttcaac taacatgttg gcttgccggc gttcatgctc agaacaagg ttgggacaag
 2821 cacttccagg ctaacacagt cagaaaatga aacgtactct caacagttcg cttagcgatg
 2881 gaagttttgc ggcattcttg ctacacaata acaagggaag acttactcgt ggctgcaacc
 2941 ctactagctc aaaatttatt cacacatggt tacgcttttg ggaaattatg ataattgatc
 3001 agatcacttc tggctaataa aagatcagag ctctagagat ctgtgtgttg gttttttgtg
 3061 gatctgctgt ggcctctagt tgcagcccat ctgttgtttg cccctccccc cctctctcct
 3121 tgaccctgga aggtgccact cccactgtcc tttcttaata aaatgaggaa attgcatcgc
 3181 attgtctgag taggtgtcat tctattctgg ggggtggggg ggggcagcac agcaaggggg
 3241 aggattggga agacaatagc aggcagctgt gggatggcgt gggctctatg ggtacctctc
 3301 tctctctctc tctctctctc tctctctctc tctctcgta cctctctctc tctctctc
 3361 tctctctctc tctctctctc tccgtaccag gtgctgaaga attgaccggg tgaccaaaag

3421 tgccttttat catcacttta aaaaataaaa acaattactc agtgccctgtt ataagcagca
 3481 attaatatg attgatgcct acatcacaaac aaaaactgat ttaacaaatg gttgggtctgc
 3541 cttagaaagt atatttgaac attatcttga ttatattatt gataataata aaaaccttat
 3601 ccctatccaa gaagtgtatgc ctatcattgg ttggaatgaa cttgaaaaaa attagccttg
 5 3661 aatacattac tggtaaggta aacgccattg tcagcaaat gatccaagag aaccaactta
 3721 aagctttcct gacggaatgt taattctcgt tgacctgag cactgatgaa tcccctaattg
 3781 attttggtaa aaatcattaa gtttaagggtg atacacatct tgtcatatga tcccggtaat
 3841 gtgagtttagc tcaactcatta ggcaccccag gctttacact ttatgcttcc ggctcgtatg
 10 3901 ttgtgtggaa ttgtgagcgg ataacaattt cacacaggaa acagctatga ccatgattac
 3961 gccaaagcgg caattaaccc tcactaaagg gaacaaaagc tggagctcca ccgcggtggc
 4021 ggccgctcta gaactagtgg atcccccggt ctgcaggaa tcgatatcaa gcttatcgat
 4081 accgctgacc tcgagcatca gattggctat tggccattgc atacgttgta tccatcatat
 4141 aatatgtaca tttatattgg ctcatgtcca acattaccgc catgttgaca ttgattattg
 4201 actagttatt aatagtaatc taattcgggg tcattagtcc atagccata ttggagttc
 15 4261 cgcgttacat aacttacggt aaatggcccg cctggctgac cgcccaacga ccccgccca
 4321 ttgacgtcaa taatgacgta tgttcccata gtaacgcaa tagggacttt ccattgacgt
 4381 caatgggtgg agtatttacg gtaaaactgcc cacttggcag tacatcaagt gtatcatatg
 4441 tcaagtacgc cccctattga cctcaatgac ggtaaatggc cgcctggcag ttatgcccag
 20 4501 tacatgacct tatgggactt tccacttgg cagtacatct acgtattagt catcgctatt
 4561 accatgggtga tgcggttttg gcagtacatc aatgggctg gatagcgtt tgactcacgg
 4621 ggatttccaa gtcttcaccc cattgacgtc aatgggagtt tgttttggca ccaaaatcaa
 4681 cgggactttc caaaatgtcg taacaactcc gccccattga cgcaaatggg cgttaggctg
 4741 gtacggtggg aggtctatat aagcagagct cgtttagtga accgtcagat cgcctggaga
 25 4801 cgccatccac gctgttttga cctccataga agacaccggg accgatccag cctccgctgc
 4861 cgggaacggg gcattggaac ggcgattccc cgtgccaa ga gtgacgtaag taccgctat
 4921 agactctata ggcacacccc ttgtgctctt atgcatgcta tactgttggg
 4981 ctatacaccc ccgcttccct atgctatagg tgatggtata gcttagccta taggttggg
 5041 ttattgacca ttattgacca ctcccctatt ggtgacgata ctttccatta ctaatccata
 30 5101 acatggctct ttgccacaac tatctctatt ggtatattgc caatactctg tccctcagag
 5161 actgacacgg actctgtatt ttacaggat ggggtcccat ttattattta caaattacaa
 5221 tatacaacaa cgcgcgtccc cgtgcccga gtttttatta aacatagcgt gggatctcca
 5281 cgcgaatctc ggttacgtgt tccggacatg ggtctctctc cgttagcggc ggagcttcca
 5341 catcogagcc ctggtcccat gccccagcg gctcatggtc gctcggcagc tccctgctcc
 35 5401 taacagtggg gccagactt aggcacagca caatgccac caccaccgt gtcgcgaca
 5461 aggcggtggc ggtagggtat gtgtctgaaa atgagcgtgg agattgggct cgcacgctg
 5521 acgcagatgg aagacttaag gcagcggcag aagaagatgc aggcagctga gttgtgtgat
 5581 tctgataaga gtcagaggta actcccgttg cgtgtctgtt aacgggtggg ggcaggtgat
 5641 tctgagcagt actcgttgc tccgcgcgcg ccaccagaca taatagctga cagactaaca
 40 5701 gactgttcc tccatgggt cttttctgca gtcaccgtcg gatcaatcat tcatctctg
 5761 acttcttctg gtgtggtgtt tactatata tctaaattta atatttctgt tattaaaaat
 5821 taatatattt cgacgatgaa tttctcaagg atatttttct tegtgttctg tttggttctg
 5881 gctttgtcaa cagtctcggc tgcgccagag ccgaaaggta cccaggtgag gctgcaggag
 5941 tcgggggggag gcttggtaaa gccggggggg tcccttagag tctcctgtgc agcctctgga
 45 6001 ttacttttca gaaacgcctg gatgagctgg gtcgccagg ctcagggaag ggggctggag
 6061 tgggtcggcc gtattaaaag caaaattgat ggtgggacaa cagactatgc tgcaccgtg
 6121 aaaggcagat tcaccatctc aagagatgat tcaaaaaaca cgttatatct gcaaatgaat
 6181 agcctgaaag ccgaggacac agcgtatat tactgtacca cggggattat gataacattt
 6241 gggggagtta tccctcccc gaattggggc cagggaaccc tggtcaccgt ctctcagcc
 50 6301 tccaccaagg gcccatcggt ctccccctg gcaccctcct ccaagagcac ctctgggggc
 6361 acagcggccc tgggctgcct ggtcaaggac tacttccccg aaccggtgac ggtgtcgtgg
 6421 aactcaggeg cctgaccag cggcgtgcac accttccgg ctgtcttaca gtcctcagga
 6481 ctctacttcc ttagcaacgt ggtgaccgtg ccctccagca gcttgggac ccagacctac
 6541 atctgcaacg tgaatcaca gccagcaac accaagggtg acaagaaagt tgagcccaaa
 55 6601 tottgtgaca aaactcacac atgcccaccg tgcaccagc ctgaactcct ggggggagcc
 6661 tcagtcttcc tcttcccccc aaaacccaag gacacctca tgatctccc gaccctgag
 6721 gtcacatgag tgggtgtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac
 6781 gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacaacagc
 6841 acgtaccgtg tggtcagcgt cctcacctgc ctgcaccagg actgggtgaa tggcaaggag
 60 6901 tacaagtgca aggtctccaa caaagccctc ccagcccca tcgagaaaaac catctccaaa
 6961 gccaaagggc agccccgaga accacagggtg tacacctgc ccccatccc ggatgagctg
 7021 accaagaacc aggtcagcct gacctgcctg gtcaaaggct tctatcccag cgacatcgcc
 7081 gtggagtgag agagcaatgg gcagccggag aacaactaca agaccacgac tcccgtgctg
 7141 gactcagag gctccttct cctctacagc aagctcaccc tggacaagag cagggtggcag
 65 7201 cagggaacg tcttctcatg ctccgtgatg catgagctc tgcacaacca ctacacgag
 7261 aagagcctct ccctgtctcc gggtaaaagc ccagagccga agctttccta tgagctgaca
 7321 cagccaccct cgggtgcagt gtccccagga caaacggcca ggatcacctg ctctggagat
 7381 gcattgccag aaaaatatgt ttattggtac cagcagaagt caggccagcc cctgtggtg
 7441 gtcactctatg aggcagcaac acgacctcc gggatccctg agagattctc tggctccagc

5 7501 tcagggacaa tggccacett gactatcagt ggggcccagg tgggaagtga aggtgactac
 7561 tactgttact caactgacag cagtgggttat catagggagg tgttcagcgg agggaccaag
 7621 ctgaccgtcc taggtcagcc caaggtcgcc ccctcggtca ctctgttccc accctcctct
 7681 gaggagcttc aagccaacaa ggccacactg gtgtgtctca taagtgactc ctaccoggga
 7741 gccgtgacag tggcctggaa ggcagatagc agccccgtca aggcgggagt ggagaccacc
 7801 acaccctcca aacaaagcaa caacaagtac gcggccagca gctacctgag cctgacgctt
 7861 gagcagtggg agtcccacaa aagctacagc tgccagggtca cgcataaagg gagcaccgtg
 7921 gagaagacag tggccctcgc agaattgttca ccgcggaggg agggaaaggc cctttttgaa
 10 7981 gggggaggaa acttcgcgcc atgactcctc tcgtgcccccc cgcacggaaac actgatgtgc
 8041 agagggccct ctgccattgc tgcttccctc gcccttccctc gtcactctga atgtggcttc
 8101 tttgctactg ccacagcaag aaataaaatc tcaacatcta aatgggtttc ctgagatttt
 8161 tcaagagtgc ttaagcacat tccttcccca gcacctcttg ctgcaggcca gtgccaggca
 8221 ccaacttggc tactgctgcc cagtagagaa atccagttca atattttcca aagcaaaatg
 15 8281 gattacatat gccctagatc ctgattaaca ggtgttttgt attatctgtg ctttcgcttc
 8341 accacattta tccattgccc tccctcgac tcgagggggg gcccggtacc caatcgccc
 8401 tatagttagt cgtattacgc gcgtcactg gccgtcgttt tacaacgtgc tgactgggaa
 8461 aacctggcg ttaccaact taatgcctt gcagcacatc cccctttcgc cagctggcgt
 8521 aatagcgaag aggcgcgac cgatcgccct tcccaacagt tgcgcagcct gaatggcgaa
 8581 tggaaattgt aagcgttaat attttgttaa aattcgctt aaatttttgt taaatcagct
 20 8641 cattttttaa ccaataggcc gaaatcgcca aaatccctta taaatcaaaa gaatagaccg
 8701 agataggggt gagtgttgtt ccagtttggg acaagagtcc actattaaag aactgtgact
 8761 ccaacgtcaa agggcgaaaa accgtctatc agggcgatgg cccactactc cgggatcata
 8821 tgacaagatg tgtatccacc ttaacttaat gatttttacc aaaatcatta ggggatctat
 25 8881 cagtgtcag ggtcaacgag aattaacatt ccgtcaggaa agcttatgat gatgatgtgc
 8941 ttaaaaaact actcaatggc tggttatgca tatcgcaata catcgcaata acctaaaaga
 9001 gcttgccgat aaaaaaggcc aatttattgc tatttaccgc ggctttttat tgagcttgaa
 9061 agataaataa aatagatagg ttttatttga agctaaatct totttatcgt aaaaaatgcc
 9121 ctcttgggtt atcaagaggg tcattatatt tcgcggaata acatcatttg gtgacgaaat
 30 9181 aactaagcac ttgtctctgc ttactcccc tgagcttgag ggggttaaac gaaggtcatc
 9241 gatagcagga taataatata gtaaaacgct aaaccaataa tccaaatcca gccatcccaa
 9301 attggttagt aatgattata aataacagca aacagtaatg ggccaataac accggttgca
 9361 ttggttaagg tcaccaataa tccctgtaaa gcaccttgct gatgactctt tgtttggata
 9421 gacatcactc cctgtaatgc aggtaaagcg atocaccac cagccaataa aattaaaaca
 35 9481 gggaaaacta accaaccttc agatataaac gctaaaaagg caaatgcact actatctgca
 9541 ataaatccga gcagtactgc cgttttttgc cccatttagt ggctattctt cctgccacaa
 9601 aggttgggaa tactgagtgt aaaagacca gacctgtaat gaaaagccaa ccatcatgct
 9661 attcatcacc acgatttctg taatagcacc acaccgtgct ggatttggct tcaattgcgt
 9721 gaaataataa tcaacaaatg gcatcgtaa ataagttagt tatacogac agcttttgtt
 40 9781 cccttttagt aggttattt gcgcgcttg cgtaatcatg gtcatactg tttcctgtgt
 9841 gaaattgtta tccgtcaca attccacaca acatacagc cggaagcata aagtgtaaag
 9901 cctgggggtg ctaatgagt agctaactca cattaattgc gttgcgctca ctgccgctt
 9961 tccagtcggg aaacctgtgc tgccagctgc attaatgaat cggccaacgc gcggggagag
 10021 gcggtttgcg tattggggcg tcttcgctt cctcgctcac tgactcgctg cgctcggtcg
 45 10081 ttccggtcgc gcgagcggta tcagctcact caaaggcggg aatacgggta tccacagaat
 10141 caggggataa cgcaggaaag aacatgtgag caaaaaggcc gcaaaaaggc aggaaccgta
 10201 aaaaaggcgc gttgctggcg tttttccata ggctcggccc cctgacgag catcacaana
 10261 atcgacgctc aatgcagagg tggcgaaacc cgacaggact ataaagatac caggcggttc
 10321 cccctggaag ctccctcgct cgctctctgc ttcgaccct gccgcttacc ggatacctgt
 50 10381 ccgcttttct ccttcggga agcgtggcgc tttctcatag ctacogctgt aggtatctca
 10441 gttcgggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaaccccc gttcagcccg
 10501 accgctgcgc ctatccggt aactatcgtc ttgagccaa cccggtaaag cagcacttat
 10561 cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta ggcgttgcta
 10621 cagagtctt gaagtgttg cctaactac gctacactag aaggacagta tttggtactt
 55 10681 gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga tccggcaaac
 10741 aaaccaccgc tggtagcggg ggtttttttg tttgcaagca gcagattacg cgcagaaaaa
 10801 aaggatctca agaagatcct ttgatcttt ctacgggggc tgacgctcag tggaaacgaa
 10861 actcacgta agggattttg gtcataagat tatcaaaaag gatcttcacc tagatccttt
 10921 taaattaaaa atgaagtttt aatcaatct aaagtatata tgagtataa tggctcgaca
 60 10981 gttaccaatg cttaatcagt gaggaccta tctcagcgat ctgtctattt cgttcatcca
 11041 tagttgctg actccccgtc gtgtagataa ctacgatacg ggagggttta ccatctggcc
 11101 ccagtgtgc aatgataccg cgagaccac gctcaccggc tccagattta tcagcaataa
 11161 accagccagc cggaaggccc gagcgcagaa gtggtcctgc aactttatcc cctccatcc
 11221 agtctattaa ttgttgccgg gaagctagag taagtgttc gccagttaat agtttgccga
 65 11281 acgttggttc cattgtctaca ggcatcgtgg tgcacgctc gtcggttgg atggcttcat
 11341 tcagctccgg ttcccaacga tcaaggcgag ttacatgac ccccatgtt tgcaaaaaag
 11401 cggttagctc cttcggtcct ccatcgtttg tcagaagtaa gttggcgca gttgttatcc
 11461 tcatggttat ggcagcactg cataattctc ttactgtcat gccatccgta agatgctttt
 11521 ctgtgactgg tgagtactca accaagtcac tctgagaata gtgtatgcgg cgaccgagtt

5

```
11581 gctcttgccc ggcgtaata cgggataata ccgcgccaca tagcagaact ttaaaagtgc
11641 tcatcattgg aaaacgttct tcggggcgaa aactctcaag gatcttaccg ctgttgagat
11701 ccagttcgat gtaaccact cgtgcacca actgatcttc agcatctttt actttcacca
11761 gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc aaaaaggga ataaggcgga
11821 cacggaaatg ttgaatactc atactcttc ttttcaata ttattgaagc atttatcagg
11881 gttattgtct catgagcgga tacatatftg aatgtattta gaaaaataaa caaatagggg
11941 ttccgcgcac atttcccga aaagtgccac
```